{"ctNumber":"2023-506686-66-01","ctStatus":"Authorised","startDateEU":"2024-10-09","decisionDate":"2024-08-09T11:19:58.047","publishDate":"2026-11-14T02:40:35.060400961","ctPublicStatusCode":5,"authorizedApplication":{"authorizedPartI":{"id":148302,"rowSubjectCount":266,"rowCountriesInfo":[{"eutctId":100000000536,"name":"Switzerland","isoNumber":756,"isoAlpha2Code":"CH","isoAlpha3Code":"CHE","current":true},{"eutctId":100000000557,"name":"United States","isoNumber":840,"isoAlpha2Code":"US","isoAlpha3Code":"USA","current":true},{"eutctId":100000000429,"name":"Israel","isoNumber":376,"isoAlpha2Code":"IL","isoAlpha3Code":"ISR","current":true},{"eutctId":100000000556,"name":"United Kingdom","isoNumber":826,"isoAlpha2Code":"GB","isoAlpha3Code":"GBR","current":true},{"eutctId":100000000354,"name":"Canada","isoNumber":124,"isoAlpha2Code":"CA","isoAlpha3Code":"CAN","current":true},{"eutctId":100000000329,"name":"Australia","isoNumber":36,"isoAlpha2Code":"AU","isoAlpha3Code":"AUS","current":true}],"products":[{"id":620443,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB06882MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"DACARBAZINE","pharmForm":"POWDER FOR SOLUTION FOR INFUSION","activeSubstanceName":"DACARBAZINE","euSubstNumber":"SUB06882MIG","productSubstances":[{"substancePk":"174830","actSubstOrigin":"Chemical","actSubstName":"DACARBAZINE","substanceEvCode":"SUB06882MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":"DACARBAZINE 1000 mg powder for solution for infusion"},"isPaediatricFormulation":false,"mpRoleInTrial":"2","orphanDrugEdit":false,"doseUom":"mg/m2 milligram(s)/sq. meter","maxDailyDoseAmount":"1000","doseUomTotal":"mg/m2 milligram(s)/square meter","maxTotalDoseAmount":"8670","productChangedRelationMA":false,"maxTreatmentPeriod":6,"timeUnitCode":"3","otherMedicinalProduct":"Chemical","sponsorProductCodeEdit":"DACARBAZINE 1000 mg powder for solution for infusion","miaNumber":"DE_BB_01_MIA_2021_0008","scientificProductEvCode":"SUB06882MIG","devices":[],"characteristics":["11"],"routes":["INTRAVENIOUS INFUSION"],"allSubstancesChemicals":false,"productName":"DACARBAZINE","jsonActiveSubstanceNames":"dacarbazine"},{"id":620449,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"10390878","productPharmForm":"TABLET","euMpNumber":"PRD10390878","prodAuthStatus":1,"prodName":"IDE196 (LXS196)","pharmForm":"TABLET","activeSubstanceName":"DAROVASERTIB","euSubstNumber":"SUB218613","nameOrg":"IDEAYA BIOSCIENCES INC.","productSubstances":[{"productPk":"10390878","substancePk":"320865","nameOrg":"IDEAYA BIOSCIENCES INC.","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"DAROVASERTIB","substanceEvCode":"SUB218613"}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"600","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"219","maxTreatmentPeriod":12,"timeUnitCode":"3","otherMedicinalProduct":"Chemical","evCode":"PRD10390878","sponsorProductCodeEdit":"IDE196","miaNumber":"IMP11566/00001","devices":[],"characteristics":["11"],"routes":["ORAL"],"allSubstancesChemicals":true,"productName":"IDE196 (LXS196)","jsonActiveSubstanceNames":"darovasertib","pharmaceuticalFormDisplay":"TABLET"},{"id":620445,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB167136","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"PEMBROLIZUMAB","pharmForm":"CONCENTRATE FOR SOLUTION FOR INJECTION","activeSubstanceName":"PEMBROLIZUMAB","euSubstNumber":"SUB167136","productSubstances":[{"substancePk":"288763","actSubstOrigin":"Protein - Other","actSubstName":"PEMBROLIZUMAB","substanceEvCode":"SUB167136"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":"Pembrolizumab 100 mg concentrate for solution for injection; One vial of 4 mL of concentrate contains 100 mg of pembrolizumab;"},"isPaediatricFormulation":false,"mpRoleInTrial":"2","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"200","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"1.74","productChangedRelationMA":false,"maxTreatmentPeriod":6,"timeUnitCode":"3","miaNumber":"DE_BB_01_MIA_2021_0008","scientificProductEvCode":"SUB167136","devices":[],"characteristics":["7"],"routes":["INFUSION"],"allSubstancesChemicals":false,"productName":"PEMBROLIZUMAB","jsonActiveSubstanceNames":"pembrolizumab"},{"id":620444,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB122750","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"NIVOLUMAB","pharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","activeSubstanceName":"NIVOLUMAB","euSubstNumber":"SUB122750","productSubstances":[{"substancePk":"147067","actSubstOrigin":"Chemical","actSubstName":"NIVOLUMAB","substanceEvCode":"SUB122750"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":"Nivolumab 100mg/10 ml concentrate for solution for infusion"},"isPaediatricFormulation":false,"mpRoleInTrial":"2","orphanDrugEdit":false,"doseUom":"mg/Kg milligram(s)/kilogram","maxDailyDoseAmount":"1","doseUomTotal":"mg/Kg milligram(s)/kilogram","maxTotalDoseAmount":"4","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","miaNumber":"DE_BB_01_MIA_2021_0008","scientificProductEvCode":"SUB122750","devices":[],"characteristics":["7"],"routes":["INFUSION"],"allSubstancesChemicals":false,"productName":"NIVOLUMAB","jsonActiveSubstanceNames":"nivolumab"},{"id":620446,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB32267","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"CRIZOTINIB","pharmForm":"CAPSULE, HARD","activeSubstanceName":"CRIZOTINIB","euSubstNumber":"SUB32267","productSubstances":[{"substancePk":"232804","actSubstOrigin":"Chemical","actSubstName":"CRIZOTINIB","substanceEvCode":"SUB32267"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":"Crizotinib 200mg hard capsules"},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"400","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"146","productChangedRelationMA":false,"maxTreatmentPeriod":12,"timeUnitCode":"3","otherMedicinalProduct":"Chemical","miaNumber":"76364","scientificProductEvCode":"SUB32267","devices":[],"characteristics":["11"],"routes":["ORAL"],"allSubstancesChemicals":false,"productName":"CRIZOTINIB","jsonActiveSubstanceNames":"crizotinib"},{"id":620448,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"10390877","productPharmForm":"TABLET","euMpNumber":"PRD10390877","prodAuthStatus":1,"prodName":"IDE196 (LXS196)","pharmForm":"TABLET","activeSubstanceName":"DAROVASERTIB","euSubstNumber":"SUB218613","nameOrg":"IDEAYA BIOSCIENCES INC.","productSubstances":[{"productPk":"10390877","substancePk":"320865","nameOrg":"IDEAYA BIOSCIENCES INC.","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"DAROVASERTIB","substanceEvCode":"SUB218613"}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"400","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"146","maxTreatmentPeriod":12,"timeUnitCode":"3","otherMedicinalProduct":"Chemical","evCode":"PRD10390877","sponsorProductCodeEdit":"IDE196","miaNumber":"IMP11566/00001","devices":[],"characteristics":["11"],"routes":["ORAL"],"allSubstancesChemicals":true,"productName":"IDE196 (LXS196)","jsonActiveSubstanceNames":"darovasertib","pharmaceuticalFormDisplay":"TABLET"},{"id":620450,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB29397","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"IPILIMUMAB","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"IPILIMUMAB","euSubstNumber":"SUB29397","productSubstances":[{"substancePk":"287482","actSubstOrigin":"Protein - Other","actSubstName":"IPILIMUMAB","substanceEvCode":"SUB29397"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":"YERVOY 5 mg/ml concentrate for solution for infusion"},"isPaediatricFormulation":false,"mpRoleInTrial":"2","orphanDrugEdit":false,"doseUom":"mg/kg milligram(s)/kilogram","maxDailyDoseAmount":"3","doseUomTotal":"mg/kg milligram(s)/kilogram","maxTotalDoseAmount":"12","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","miaNumber":"DE_BB_01_MIA_2021_0008","scientificProductEvCode":"SUB29397","devices":[],"characteristics":["7"],"routes":["INFUSION"],"allSubstancesChemicals":false,"productName":"IPILIMUMAB","jsonActiveSubstanceNames":"ipilimumab"},{"id":620447,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB32267","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"CRIZOTINIB","pharmForm":"CAPSULE, HARD","activeSubstanceName":"CRIZOTINIB","euSubstNumber":"SUB32267","productSubstances":[{"substancePk":"209620","actSubstOrigin":"Chemical","actSubstName":"CRIZOTINIB","substanceEvCode":"SUB32267"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":"Crizotinib 250 mg hard capsules"},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"250","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"91.25","productChangedRelationMA":false,"maxTreatmentPeriod":12,"timeUnitCode":"3","otherMedicinalProduct":"Chemical","miaNumber":"76364","scientificProductEvCode":"SUB32267","devices":[],"characteristics":["11"],"routes":["ORAL"],"allSubstancesChemicals":false,"productName":"CRIZOTINIB","jsonActiveSubstanceNames":"crizotinib"}],"trialDetails":{"clinicalTrialIdentifiers":{"fullTitle":"IDE196 (Darovasertib) in Combination with Crizotinib Versus Investigator’s Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma","fullTitleTranslations":[{"id":12676487,"uuid":"841f61cb-014c-4521-a916-6e607cdb5ae0","attributeTranslation":"IDE196 (Darovasertib) en association avec le Crizotinib en traitement de première intention du mélanome métastatique de l'uvée","language":34,"languageDescription":"French (France)"},{"id":12676485,"uuid":"841f61cb-014c-4521-a916-6e607cdb5ae0","attributeTranslation":"IDE196 (darovasertib) in combinazione con crizotinib verso un trattamento a scelta dello sperimentatore come terapia di prima linea nel melanoma uveale metastatico HLA-A2 negativo","language":14,"languageDescription":"Italian"},{"id":12676488,"uuid":"841f61cb-014c-4521-a916-6e607cdb5ae0","attributeTranslation":"IDE196 (Darovasertib) in Kombination mit Crizotinib im Vergleich zur Behandlungswahl als Erstlinientherapie bei HLA-A2-negativem metastasiertem Aderhautmelanom","language":29,"languageDescription":"German (Germany)"},{"id":12676486,"uuid":"841f61cb-014c-4521-a916-6e607cdb5ae0","attributeTranslation":"IDE196 (darovasertib) w skojarzeniu z kryzotynibem w porównaniu z wyborem leczenia przez badacza jako terapia pierwszego rzutu w HLA-A2-ujemnym przerzutowym czerniaku błony naczyniowej oka","language":19,"languageDescription":"Polish"},{"id":12676490,"uuid":"841f61cb-014c-4521-a916-6e607cdb5ae0","attributeTranslation":"IDE196 (Darovasertib) in Kombination mit Crizotinib im Vergleich zur Behandlungswahl als Erstlinientherapie bei HLA-A2-negativem metastasiertem Aderhautmelanom","language":28,"languageDescription":"German (Belgium)"},{"id":12676489,"uuid":"841f61cb-014c-4521-a916-6e607cdb5ae0","attributeTranslation":"IDE196 (darovasertib) in combinatie met crizotinib versus behandeling naar keuze van de onderzoeker als eerstelijnsbehandeling bij HLA-A2-negatief metastatisch uveamelanoom","language":36,"languageDescription":"Dutch (Belgium)"},{"id":12676482,"uuid":"841f61cb-014c-4521-a916-6e607cdb5ae0","attributeTranslation":"IDE196 (darovasertib) in combinatie met crizotinib versus door de onderzoeker gekozen behandeling als eerstelijnsbehandeling bij HLA-A2-negatief gemetastaseerd uveaal melanoom","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12676483,"uuid":"841f61cb-014c-4521-a916-6e607cdb5ae0","attributeTranslation":"IDE196 (darovasertib) en combinación con crizotinib frente a la elección del investigador como tratamiento de primera línea en el melanoma maligno uveal metastásico con HLA-A2 negativo","language":7,"languageDescription":"Spanish"},{"id":12676484,"uuid":"841f61cb-014c-4521-a916-6e607cdb5ae0","attributeTranslation":"IDE196 (darovasertib) en association avec le crizotinib par rapport au traitement de première intention choisi par l’investigateur dans le mélanome uvéal métastatique HLA-A2 négatif","language":33,"languageDescription":"French (Belgium)"}],"publicTitle":"IDE196 (Darovasertib) in Combination with Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","publicTitleTranslations":[{"id":12676580,"uuid":"01116577-d2f3-42ed-a42d-df56c7174886","attributeTranslation":"IDE196 (Darovasertib) en association avec le Crizotinib en traitement de première intention du mélanome métastatique de l'uvée","language":34,"languageDescription":"French (France)"},{"id":12676577,"uuid":"01116577-d2f3-42ed-a42d-df56c7174886","attributeTranslation":"IDE196 (Darovasertib) in combinatie met Crizotinib als eerstelijnstherapie bij gemetastaseerd uveaal melanoom","language":36,"languageDescription":"Dutch (Belgium)"},{"id":12676583,"uuid":"01116577-d2f3-42ed-a42d-df56c7174886","attributeTranslation":"IDE196 (Darovasertib) w skojarzeniu z Crizotinibem jako terapia pierwszego rzutu w przerzutowym czerniaku błony naczyniowej oka","language":19,"languageDescription":"Polish"},{"id":12676579,"uuid":"01116577-d2f3-42ed-a42d-df56c7174886","attributeTranslation":"IDE196 (Darovasertib) in combinazione con Crizotinib come terapia di prima linea nel melanoma Uveale Metastatico","language":14,"languageDescription":"Italian"},{"id":12676576,"uuid":"01116577-d2f3-42ed-a42d-df56c7174886","attributeTranslation":"IDE196 (Darovasertib) in Kombination mit Crizotinib als Erstlinientherapie bei metastasiertem Aderhautmelanom","language":29,"languageDescription":"German (Germany)"},{"id":12676575,"uuid":"01116577-d2f3-42ed-a42d-df56c7174886","attributeTranslation":"IDE196 (Darovasertib) in combinatie met Crizotinib als eerstelijnstherapie bij gemetastaseerd uveaal melanoom","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12676582,"uuid":"01116577-d2f3-42ed-a42d-df56c7174886","attributeTranslation":"IDE196 (Darovasertib) en association avec le Crizotinib en traitement de première intention du mélanome métastatique de l'uvée","language":33,"languageDescription":"French (Belgium)"},{"id":12676581,"uuid":"01116577-d2f3-42ed-a42d-df56c7174886","attributeTranslation":"IDE196 (Darovasertib) en combinación con crizotinib como terapia de primera línea en melanoma uveal metastásico","language":7,"languageDescription":"Spanish"},{"id":12676578,"uuid":"01116577-d2f3-42ed-a42d-df56c7174886","attributeTranslation":"IDE196 (Darovasertib) in Kombination mit Crizotinib als Erstlinientherapie bei metastasiertem Aderhautmelanom","language":28,"languageDescription":"German (Belgium)"}],"shortTitle":"IDE196-002","secondaryIdentifyingNumbers":{"nctNumber":{"id":590635,"number":"NCT05987332"},"additionalRegistries":[]}},"trialInformation":{"trialCategory":{"isLowIntervention":false,"trialPhase":"10","trialCategory":"2","justificationForTrialCategory":"Phase 2/3 clinical trial, IDE196 (darovasertib) in combination with crizotinib versus investigator’s choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma. In line with EMA Guidance on Disclosure Rules, the study meets the criteria of a Category 2 trial.","trialCategoryId":137496},"medicalCondition":{"partIMedicalConditions":[{"id":155726,"medicalCondition":"HLA-A2 negative metastatic uveal melanoma","medicalConditionTranslations":[{"id":12676302,"uuid":"4ee5f861-ab62-40d9-822e-ffabecdbc536","attributeTranslation":"HLA-A2-ujemnym przerzutowym czerniaku błony naczyniowej oka","language":19,"languageDescription":"Polish"},{"id":12676305,"uuid":"4ee5f861-ab62-40d9-822e-ffabecdbc536","attributeTranslation":"melanoma maligno uveal metastásico con HLA-A2 negativo","language":7,"languageDescription":"Spanish"},{"id":12676304,"uuid":"4ee5f861-ab62-40d9-822e-ffabecdbc536","attributeTranslation":"mélanome uvéal métastatique HLA-A2 négatif","language":10,"languageDescription":"French"},{"id":12676303,"uuid":"4ee5f861-ab62-40d9-822e-ffabecdbc536","attributeTranslation":"HLA-A2-ujemnym przerzutowym czerniaku błony naczyniowej oka","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12676307,"uuid":"4ee5f861-ab62-40d9-822e-ffabecdbc536","attributeTranslation":"HLA-A2-negativem metastasiertem Aderhautmelanom","language":18,"languageDescription":"Dutch"},{"id":12676306,"uuid":"4ee5f861-ab62-40d9-822e-ffabecdbc536","attributeTranslation":"melanoma uveale metastatico HLA-A2 negativo","language":14,"languageDescription":"Italian"}],"isConditionRareDisease":true}],"meddraConditionTerms":[{"termId":200000009517,"version":"21.1","level":"PT","termName":"Uveal melanoma","classificationCode":"10081431","organClass":100000004864,"active":false}]},"trialObjective":{"trialScopes":[{"code":"6","trialScopeId":451956},{"code":"3","trialScopeId":451955},{"code":"5","trialScopeId":451960},{"code":"4","trialScopeId":451958},{"code":"7","trialScopeId":451957},{"code":"13","otherDescription":"biomarkers, Quality of Life (QoL),","trialScopeId":451959},{"code":"9","trialScopeId":451954}],"mainObjective":"Phase 2a: To determine the optimal dose of IDE196 + crizotinib combination in Phase 2a in order to establish the recommended dose for Phase 2b and Phase 3\nPhase 2b: To compare IDE196 + crizotinib to investigator’s choice of treatment with respect to PFS per RECIST 1.1 as assessed by blinded independent central review (BICR)\nPhase 3:To compare IDE196 + crizotinib to investigator’s choice of treatment with respect to OS","mainObjectiveTranslations":[{"id":12676573,"uuid":"7e598017-b32f-4371-a725-2d15697a674d","attributeTranslation":"• Phase 2a : Déterminer la dose optimale de l’association IDE196 + crizotinib dans la phase 2a afin de définir la dose recommandée pour la phase 2b et la phase 3\n• Phase 2 : Comparer IDE196 + crizotinib au traitement choisi par l’investigateur en ce qui concerne la SSP selon les critères RECIST v.1.1 tels qu’évalués par l’ECIA\n• Phase 3 :Comparer IDE196 + crizotinib au traitement choisi par l’investigateur en ce qui concerne la SG","language":10,"languageDescription":"French"},{"id":12676570,"uuid":"7e598017-b32f-4371-a725-2d15697a674d","attributeTranslation":"• Faza IIa: Określenie optymalnej dawki IDE196 w skojarzeniu z kryzotynibem w badaniu fazy IIa w celu określenia dawki zalecanej do badania fazy IIb i fazy III\n• Faza II: Porównanie IDE196 + kryzotynib z leczeniem wybranym przez badacza w odniesieniu do PFS według kryteriów RECIST w wer. 1.1 na podstawie oceny BICR\n• Faza III: Porównanie IDE196 +\nkryzotynib z leczeniem\nwybranym przez badacza\nw odniesieniu do OS","language":19,"languageDescription":"Polish"},{"id":12676574,"uuid":"7e598017-b32f-4371-a725-2d15697a674d","attributeTranslation":"• Phase IIa: Bestimmung der optimalen Dosis der Kombination von IDE196 + Crizotinib in Phase IIa, um die empfohlene Dosis für Phase IIb und Phase III zu etablieren\n• Phase II: Vergleich von IDE196 + Crizotinib mit der vom Prüfarzt ausgewählten Behandlung hinsichtlich PFS per RECIST Version 1.1, beurteilt durch BICR\n• Phase III: Vergleich von IDE196 + Crizotinib mit der vom Prüfarzt ausgewählten Behandlung hinsichtlich des Gesamtüberlebens","language":4,"languageDescription":"German"},{"id":12676571,"uuid":"7e598017-b32f-4371-a725-2d15697a674d","attributeTranslation":"• Fase 2a: het bepalen van de optimale dosiscombinatie IDE196 + crizotinib in fase 2a om de aanbevolen dosis voor fase 2b en fase 3 vast te stellen\n• Fase 2: het vergelijken van IDE196 + crizotinib met de behandeling naar keuze van de onderzoeker met betrekking tot PFS volgens RECIST v1.1 zoals beoordeeld door BICR\n• Fase 3: het vergelijken van IDE196 + crizotinib met de behandeling naar keuze van de onderzoeker met betrekking tot OS","language":18,"languageDescription":"Dutch"},{"id":12676572,"uuid":"7e598017-b32f-4371-a725-2d15697a674d","attributeTranslation":"• Fase 2a: determinare la dose ottimale della combinazione IDE196 + crizotinib nella fase 2a per stabilire la dose raccomandata per la fase 2b e la fase 3.\n• Fase 2: confrontare IDE196 + crizotinib rispetto al trattamento scelto dallo sperimentatore in relazione alla PFS secondo i criteri RECIST v1.1 valutata mediante BICR\n• Fase 3: confrontare IDE196 + crizotinib rispetto al trattamento scelto dallo sperimentatore in relazione all’OS","language":14,"languageDescription":"Italian"},{"id":12676569,"uuid":"7e598017-b32f-4371-a725-2d15697a674d","attributeTranslation":"• Fase 2a: Determinar la dosis óptima de la combinación de IDE196 + crizotinib en la fase 2a para establecer la dosis recomendada para la fase 2b y la fase 3.\n• Fase 2: comparar IDE196 + crizotinib con el tratamiento de elección del investigador con respecto a la SSP según RECIST v1.1, evaluada mediante RCIE\n• Fase 3: comparar IDE196 + crizotinib con el tratamiento de elección del investigador con respecto a la SG","language":7,"languageDescription":"Spanish"}],"secondaryObjectives":[{"id":533869,"number":1,"secondaryObjective":"Phase 3, Options 1 and 2: To compare IDE196 + crizotinib to investigator’s choice of treatment with respect to objective response rate (ORR) per RECIST v1.1 as assessed by BICR","secondaryObjectiveTranslations":[{"id":12676589,"uuid":"26567bec-4015-4d72-8898-c15414da6f83","attributeTranslation":"• Fase 3, opties 1 en 2: het vergelijken van IDE196 + crizotinib met de behandeling naar keuze van de onderzoeker met betrekking tot het objectieve responspercentage (ORR) volgens RECIST v1.1 zoals beoordeeld door BICR","language":18,"languageDescription":"Dutch"},{"id":12676586,"uuid":"26567bec-4015-4d72-8898-c15414da6f83","attributeTranslation":"• Faza III, Opcje 1 i 2: Porównanie IDE196 + kryzotynib z leczeniem wybranym przez badacza w odniesieniu do wskaźnika obiektywnej odpowiedzi (ORR) według kryteriów RECIST 1.1 na podstawie niezależnej zaślepionej oceny centralnej (BICR)","language":19,"languageDescription":"Polish"},{"id":12676588,"uuid":"26567bec-4015-4d72-8898-c15414da6f83","attributeTranslation":"• Fase 3, opciones 1 y 2: comparar\nIDE196 + crizotinib con el\ntratamiento de elección Del\ninvestigador con respecto a la tasa\nde respuesta objetiva (TRO) según\nRECIST v1.1 evaluada mediante\nRCIE.","language":7,"languageDescription":"Spanish"},{"id":12676587,"uuid":"26567bec-4015-4d72-8898-c15414da6f83","attributeTranslation":"• Phase 3, Options 1 et 2 : Comparer l’association IDE196 + crizotinib au traitement choisi par l’investigateur en ce qui concerne le taux de réponse objective (TRO) selon les critères RECIST v.1.1","language":10,"languageDescription":"French"},{"id":12676584,"uuid":"26567bec-4015-4d72-8898-c15414da6f83","attributeTranslation":"• Phase 3, Optionen 1 und 2: Vergleich von IDE196 + Crizotinib mit der vom Prüfer gewählten Behandlung im Hinblick auf die objektive Ansprechrate (ORR) gemäß RECIST v1.1, bewertet durch BICR","language":4,"languageDescription":"German"},{"id":12676585,"uuid":"26567bec-4015-4d72-8898-c15414da6f83","attributeTranslation":"• Fase 3, Opzioni 1e 2:\nconfrontare IDE196 +\ncrizotinib rispetto al\ntrattamento scelto dallo\nsperimentatore in relazione\nalla PFS secondo i criteri\nRECIST v1.1 valutata\nmediante BICR","language":14,"languageDescription":"Italian"}]},{"id":533870,"number":2,"secondaryObjective":"Phase 3, Option 3: To compare IDE196 + crizotinib to investigator’s choice of treatment with respect to PFS and ORR per RECIST v1.1 as assessed by BICR","secondaryObjectiveTranslations":[{"id":12676595,"uuid":"a34692b1-01aa-4077-9c38-29dba8a8faaa","attributeTranslation":"• Faza III, Opcja 3: Porównanie IDE196 + kryzotynib z leczeniem wybranym przez badacza w odniesieniu do PFS i ORR według kryteriów RECIST 1.1 na podstawie oceny BICR","language":19,"languageDescription":"Polish"},{"id":12676593,"uuid":"a34692b1-01aa-4077-9c38-29dba8a8faaa","attributeTranslation":"• Fase 3, optie 3: het vergelijken van IDE196 + crizotinib met de behandeling naar keuze van de onderzoeker met betrekking tot PFS en ORR volgens RECIST v1.1 zoals beoordeeld door BICR","language":18,"languageDescription":"Dutch"},{"id":12676591,"uuid":"a34692b1-01aa-4077-9c38-29dba8a8faaa","attributeTranslation":"• Fase 3, opción 3: comparar\nIDE196 + crizotinib con el\ntratamiento de elección del\ninvestigador en cuanto a SSP y\nTRO según RECIST v1.1\nevaluadas mediante RCIE.","language":7,"languageDescription":"Spanish"},{"id":12676592,"uuid":"a34692b1-01aa-4077-9c38-29dba8a8faaa","attributeTranslation":"Fase 3, Opzione 3:\nconfrontare IDE196 +\ncrizotinib rispetto al\ntrattamento scelto dallo\nsperimentatore in relazione\nalla PFS e all’ORR secondo i\ncriteri RECIST v1.1 valutati\nmediante BICR","language":14,"languageDescription":"Italian"},{"id":12676594,"uuid":"a34692b1-01aa-4077-9c38-29dba8a8faaa","attributeTranslation":"• Phase 3, Option 3: Vergleich von IDE196 + Crizotinib mit der vom Prüfer gewählten Behandlung im Hinblick auf PFS und ORR gemäß RECIST v1.1, bewertet durch BICR","language":4,"languageDescription":"German"},{"id":12676590,"uuid":"a34692b1-01aa-4077-9c38-29dba8a8faaa","attributeTranslation":"• Phase 3, Option 3 : Comparer l’association IDE196 + crizotinib au traitement choisi par l’investigateur en ce qui concerne la SSP et le TRO selon les critères RECIST v1.1 tels qu’évalués par ECIA","language":10,"languageDescription":"French"}]},{"id":533871,"number":3,"secondaryObjective":"To evaluate the safety and tolerability of IDE196 in combination with crizotinib","secondaryObjectiveTranslations":[{"id":12676596,"uuid":"c1546d7a-4dc1-4d35-9e39-34c41c794872","attributeTranslation":"• Het beoordelen van de veiligheid en verdraagbaarheid van IDE196 in combinatie met crizotinib","language":18,"languageDescription":"Dutch"},{"id":12676600,"uuid":"c1546d7a-4dc1-4d35-9e39-34c41c794872","attributeTranslation":"• Évaluer la sécurité d’emploi et la tolérance de l’association IDE196 et du crizotinib","language":10,"languageDescription":"French"},{"id":12676599,"uuid":"c1546d7a-4dc1-4d35-9e39-34c41c794872","attributeTranslation":"• Bewertung der Sicherheit und Verträglichkeit von IDE196 in Kombination mit Crizotinib","language":4,"languageDescription":"German"},{"id":12676597,"uuid":"c1546d7a-4dc1-4d35-9e39-34c41c794872","attributeTranslation":"• Ocena bezpieczeństwa stosowania i tolerancji IDE196 w skojarzeniu z kryzotynibem","language":19,"languageDescription":"Polish"},{"id":12676598,"uuid":"c1546d7a-4dc1-4d35-9e39-34c41c794872","attributeTranslation":"• Evaluar la seguridad y tolerabilidad\nde IDE196 en combinación con\ncrizotinib.","language":7,"languageDescription":"Spanish"},{"id":12676601,"uuid":"c1546d7a-4dc1-4d35-9e39-34c41c794872","attributeTranslation":"• Valutare la sicurezza e la\ntollerabilità di IDE196 in\ncombinazione con crizotinib","language":14,"languageDescription":"Italian"}]},{"id":533872,"number":4,"secondaryObjective":"To compare IDE196 + crizotinib to investigator’s choice of treatment with respect to objective response and duration of response (DOR) per RECIST v1.1 as assessed by BICR for any options of Phase 3","secondaryObjectiveTranslations":[{"id":12676607,"uuid":"2f8d37ec-542a-4acc-9c1a-815bacfa51d1","attributeTranslation":"• Comparer l’association IDE196 + crizotinib au traitement choisi par l’investigateur en ce qui concerne la réponse objective et la durée de la réponse (DR) selon les critères RECIST v1.1 tels qu’évalués par ECIA pour toute option de la Phase 3.","language":10,"languageDescription":"French"},{"id":12676606,"uuid":"2f8d37ec-542a-4acc-9c1a-815bacfa51d1","attributeTranslation":"• Het vergelijken van IDE196 + crizotinib met de behandeling naar keuze van de onderzoeker met betrekking tot objectieve respons en duur van respons (DOR) volgens RECIST v1.1 zoals beoordeeld door BICR voor alle opties van fase 3","language":18,"languageDescription":"Dutch"},{"id":12676605,"uuid":"2f8d37ec-542a-4acc-9c1a-815bacfa51d1","attributeTranslation":"• Comparar IDE196 + crizotinib con\nel tratamiento de elección del\ninvestigador con respecto a la\nrespuesta objetiva y la duración de\nla respuesta (DR) según RECIST\nv1.1 evaluadas mediante BICR para\ncualquiera de las opciones de la fase 3","language":7,"languageDescription":"Spanish"},{"id":12676602,"uuid":"2f8d37ec-542a-4acc-9c1a-815bacfa51d1","attributeTranslation":"• Vergleich von IDE196 + Crizotinib mit der vom Prüfer gewählten Behandlung im Hinblick auf objektives Ansprechen und Ansprechdauer (DOR) gemäß RECIST v1.1, bewertet durch BICR für alle Optionen der Phase 3","language":4,"languageDescription":"German"},{"id":12676603,"uuid":"2f8d37ec-542a-4acc-9c1a-815bacfa51d1","attributeTranslation":"• Porównanie IDE196 + kryzotynib z leczeniem wybranym przez badacza w odniesieniu do obiektywnej odpowiedzi i czasu trwania odpowiedzi (duration of response, DOR) według kryteriów RECIST 1.1 na podstawie oceny BICR w przypadku dowolnej z opcji w ramach badania fazy III","language":19,"languageDescription":"Polish"},{"id":12676604,"uuid":"2f8d37ec-542a-4acc-9c1a-815bacfa51d1","attributeTranslation":"• Confrontare IDE196 + crizotinib\nrispetto al trattamento scelto dallo\nsperimentatore in relazione alla\nrisposta oggettiva e alla durata\ndella risposta secondo i criteri\nRECIST 1.1 mediante BICR per\ntutte le opzioni nella fase 3","language":14,"languageDescription":"Italian"}]},{"id":533873,"number":5,"secondaryObjective":"To compare IDE196 + crizotinib to investigator’s choice of treatment with respect to PFS per RECIST v1.1 as assessed by investigator","secondaryObjectiveTranslations":[{"id":12676609,"uuid":"67fc4d66-3417-443c-9518-89fc7968ef15","attributeTranslation":"• Comparer l’association IDE196 + crizotinib au traitement choisi par l’investigateur en ce qui concerne la SSP selon les critères RECIST v1.1 tels qu’évalués par l’investigateur","language":10,"languageDescription":"French"},{"id":12676611,"uuid":"67fc4d66-3417-443c-9518-89fc7968ef15","attributeTranslation":"• Confrontare IDE196 + crizotinib\nrispetto al trattamento scelto dallo\nsperimentatore in relazione alla\nPFS secondo i criteri RECIST 1.1\nin base alla valutazione dello\nsperimentatore","language":14,"languageDescription":"Italian"},{"id":12676613,"uuid":"67fc4d66-3417-443c-9518-89fc7968ef15","attributeTranslation":"• Porównanie IDE196 + kryzotynib z leczeniem wybranym przez badacza w odniesieniu do PFS według kryteriów RECIST 1.1 na podstawie oceny badacza","language":19,"languageDescription":"Polish"},{"id":12676610,"uuid":"67fc4d66-3417-443c-9518-89fc7968ef15","attributeTranslation":"• Vergleich von IDE196 + Crizotinib mit der vom Prüfer gewählten Behandlung im Hinblick auf das vom Prüfer beurteilte PFS gemäß RECIST v1.1","language":4,"languageDescription":"German"},{"id":12676612,"uuid":"67fc4d66-3417-443c-9518-89fc7968ef15","attributeTranslation":"Comparar IDE196 + crizotinib con\nel tratamiento de elección del\ninvestigador con respecto a la SSP\nsegún RECIST v1.1, evaluada por\nel investigador","language":7,"languageDescription":"Spanish"},{"id":12676608,"uuid":"67fc4d66-3417-443c-9518-89fc7968ef15","attributeTranslation":"• Het vergelijken van IDE196 + crizotinib met de behandeling naar keuze van de onderzoeker met betrekking tot PFS volgens RECIST v1.1 zoals beoordeeld door de onderzoeker","language":18,"languageDescription":"Dutch"}]},{"id":533874,"number":6,"secondaryObjective":"To compare IDE196 + crizotinib to investigator’s choice of treatment with respect to objective response and DOR per RECIST v1.1 as assessed by investigator","secondaryObjectiveTranslations":[{"id":12676617,"uuid":"dd6fe571-22bb-4c93-9ae4-1139c15d882e","attributeTranslation":"• Comparar IDE196 + crizotinib con\nel tratamiento de elección del\ninvestigador con respecto a la\nrespuesta objetiva y la DR según\nRECIST v1.1, evaluada por el\ninvestigador","language":7,"languageDescription":"Spanish"},{"id":12676618,"uuid":"dd6fe571-22bb-4c93-9ae4-1139c15d882e","attributeTranslation":"•\nPorównanie IDE196 + kryzotynib z leczeniem wybranym przez badacza w odniesieniu do obiektywnej odpowiedzi i DOR według kryteriów RECIST 1.1 na podstawie oceny badacza","language":19,"languageDescription":"Polish"},{"id":12676619,"uuid":"dd6fe571-22bb-4c93-9ae4-1139c15d882e","attributeTranslation":"• Vergleich von IDE196 + Crizotinib mit der vom Prüfer gewählten Behandlung im Hinblick auf objektives Ansprechen und DOR gemäß RECIST v1.1, wie vom Prüfer beurteilt","language":4,"languageDescription":"German"},{"id":12676614,"uuid":"dd6fe571-22bb-4c93-9ae4-1139c15d882e","attributeTranslation":"• Comparer l’association IDE196 + crizotinib au traitement choisi par l’investigateur en ce qui concerne la réponse objective et la DR selon les critères RECIST v1.1 tels qu’évalués par l’investigateur","language":10,"languageDescription":"French"},{"id":12676615,"uuid":"dd6fe571-22bb-4c93-9ae4-1139c15d882e","attributeTranslation":"• Confrontare IDE196 + crizotinib\nrispetto al trattamento scelto dallo\nsperimentatore in relazione alla\nrisposta obiettiva e alla durata\ndella risposta secondo i criteri\nRECIST v1.1 in base alla\nvalutazione dello sperimentatore","language":14,"languageDescription":"Italian"},{"id":12676616,"uuid":"dd6fe571-22bb-4c93-9ae4-1139c15d882e","attributeTranslation":"• Het vergelijken van IDE196 + crizotinib met de behandeling naar keuze van de onderzoeker met betrekking tot objectieve respons en DOR volgens RECIST v1.1 zoals beoordeeld door de onderzoeker","language":18,"languageDescription":"Dutch"}]},{"id":533875,"number":7,"secondaryObjective":"To compare IDE196 + crizotinib to investigator’s choice of treatment with respect to quality-of-life scores.","secondaryObjectiveTranslations":[{"id":12676623,"uuid":"c8a1cbf8-d1f2-4754-9916-d5397f4ac684","attributeTranslation":"•\tVergleich von IDE196 + Crizotinib mit der vom Prüfer gewählten Behandlung hinsichtlich der Werte zur Lebensqualität","language":4,"languageDescription":"German"},{"id":12676625,"uuid":"c8a1cbf8-d1f2-4754-9916-d5397f4ac684","attributeTranslation":"•\tComparer l’association IDE196 + crizotinib au traitement choisi par l’investigateur en ce qui concerne les scores de qualité de vie","language":10,"languageDescription":"French"},{"id":12676620,"uuid":"c8a1cbf8-d1f2-4754-9916-d5397f4ac684","attributeTranslation":"•\tConfrontare IDE196 + crizotinib rispetto al trattamento scelto dallo sperimentatore in relazione ai punteggi sulla qualità della vita.","language":14,"languageDescription":"Italian"},{"id":12676624,"uuid":"c8a1cbf8-d1f2-4754-9916-d5397f4ac684","attributeTranslation":"•\tComparar IDE196 + crizotinib con el tratamiento de elección del investigador con respecto a las puntuaciones de calidad de vida.","language":7,"languageDescription":"Spanish"},{"id":12676622,"uuid":"c8a1cbf8-d1f2-4754-9916-d5397f4ac684","attributeTranslation":"•\tPorównanie IDE196 + kryzotynib z leczeniem wybranym przez badacza w odniesieniu do wyników oceny jakości życia.","language":19,"languageDescription":"Polish"},{"id":12676621,"uuid":"c8a1cbf8-d1f2-4754-9916-d5397f4ac684","attributeTranslation":"•\tHet vergelijken van IDE196 + crizotinib met de behandeling naar keuze van de onderzoeker met betrekking tot kwaliteit-van-levenscores","language":18,"languageDescription":"Dutch"}]}]},"eligibilityCriteria":{"principalInclusionCriteria":[{"id":1013258,"number":1,"principalInclusionCriteria":"Must be at least 18 years of age.","principalInclusionCriteriaTranslations":[{"id":12676492,"uuid":"1af66468-a934-46c2-aeeb-2fed57df4cde","attributeTranslation":"1.\tSie müssen mindestens 18 Jahre alt sein.","language":4,"languageDescription":"German"},{"id":12676494,"uuid":"1af66468-a934-46c2-aeeb-2fed57df4cde","attributeTranslation":"1.\tÊtre âgé d’au moins 18 ans.","language":10,"languageDescription":"French"},{"id":12676491,"uuid":"1af66468-a934-46c2-aeeb-2fed57df4cde","attributeTranslation":"1.\tEtà pari almeno a 18 anni.","language":14,"languageDescription":"Italian"},{"id":12676493,"uuid":"1af66468-a934-46c2-aeeb-2fed57df4cde","attributeTranslation":"1.\tTener al menos 18 años de edad.","language":7,"languageDescription":"Spanish"},{"id":12676495,"uuid":"1af66468-a934-46c2-aeeb-2fed57df4cde","attributeTranslation":"1.\tWiek co najmniej 18 lat","language":19,"languageDescription":"Polish"},{"id":12676496,"uuid":"1af66468-a934-46c2-aeeb-2fed57df4cde","attributeTranslation":"1.\tMoeten ten minste 18 jaar oud zijn","language":18,"languageDescription":"Dutch"}]},{"id":1013259,"number":10,"principalInclusionCriteria":"Has a life expectancy of ≥3 months.","principalInclusionCriteriaTranslations":[{"id":12676499,"uuid":"28b75c38-f134-4c69-8e48-f27e729deb9d","attributeTranslation":"10.\tAvoir une espérance de vie de >= 3 mois.","language":10,"languageDescription":"French"},{"id":12676498,"uuid":"28b75c38-f134-4c69-8e48-f27e729deb9d","attributeTranslation":"10.\tPrzewidywana długość życia wynosi >=3 miesiące","language":19,"languageDescription":"Polish"},{"id":12676497,"uuid":"28b75c38-f134-4c69-8e48-f27e729deb9d","attributeTranslation":"10.\tTener una esperanza de vida >=3 meses.","language":7,"languageDescription":"Spanish"},{"id":12676501,"uuid":"28b75c38-f134-4c69-8e48-f27e729deb9d","attributeTranslation":"10.\tAspettativa di vita >=3 mesi.","language":14,"languageDescription":"Italian"},{"id":12676502,"uuid":"28b75c38-f134-4c69-8e48-f27e729deb9d","attributeTranslation":"10.\tHebben een levensverwachting van >=3 maanden.","language":18,"languageDescription":"Dutch"},{"id":12676500,"uuid":"28b75c38-f134-4c69-8e48-f27e729deb9d","attributeTranslation":"10.\tSie haben eine Lebenserwartung von >= 3 Monaten","language":4,"languageDescription":"German"}]},{"id":1013260,"number":11,"principalInclusionCriteria":"Has adequate organ function (screening assessment must be obtained within 14 days of C1D1): • Absolute neutrophil count (ANC) ≥ 1500/mm3 without the use of hematopoietic growth factors • Platelet count ≥ 100,000/mm3 (must be at least 2 weeks post-platelet transfusion and not receiving platelet-stimulating agents) • Hemoglobin ≥ 9.0 g/dL (must be at least 2 weeks post-red blood cell transfusion) • AST and ALT ≤ 3 × ULN in the absence of documented liver metastases; ≤ 5 × ULN in the presence of liver metastases • Total and direct bilirubin ≤ 1.5 × the upper limit of normal (ULN). o\tIf total bilirubin is > 1.5 × ULN, and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are within normal limits, direct bilirubin must be ≤ 1.5 × ULN. o\tFor participants with documented Gilbert’s disease, total bilirubin ≤ 3.0 mg/dL is allowed. • Serum albumin ≥ 3.0 g/dL. • Creatinine clearance ≥ 45 mL/min by Cockcroft-Gault equation (see Appendix 1, Section 14.1). Participants with creatinine clearance between 30 and 45 mL/min can be considered for trial enrollment, contingent upon consultation with the Medical Monitor to assess the need for dose modification, ensuring safe administration of the investigational agent. • Prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time test results at screening ≤ 1.5 × ULN (this applies only to participants who do not receive therapeutic anticoagulation; participants receiving therapeutic anticoagulation should be on a stable dose for at least 2 weeks prior to the first dose of study drug).","principalInclusionCriteriaTranslations":[{"id":12676508,"uuid":"912c7a0c-184e-4a4b-9556-f1cda5ee8210","attributeTranslation":"11.\tOdpowiednia czynność narządów (ocena przesiewowa musi zostać przeprowadzona w ciągu 14 dni od C1D1):\n•\tBezwzględna liczba neutrofili (ANC) ≥ 1500/mm3 bez stosowania hematopoetycznych czynników wzrostu\n•\tLiczba płytek ≥krwi 100 000/mm3 (musi być co najmniej 2 tygodnie po przetoczeniu płytek krwi i uczestnik nie może przyjmować środków stymulujących płytki krwi)\n•\tHemoglobina ≥9,0 g/dl (musi być co najmniej 2 tygodnie po przetoczeniu krwinek czerwonych)\n•\tAST i ALT ≤3 × GGN przy braku udokumentowanych przerzutów do wątroby; ≤5 × GGN przy obecności przerzutów do wątroby.\n•\tBilirubina całkowita i bezpośrednia ≤1,5 × górna granica normy (GGN).\no\tJeżeli stężenie bilirubiny całkowitej wynosi >1,5 × GGN, a aktywność aminotransferazy asparaginianowej (AST) i aminotransferazy alaninowej (ALT) mieści się w zakresie wartości prawidłowych, stężenie bilirubiny bezpośredniej musi wynosić ≤1,5 × GGN.\no\tW przypadku uczestników z udokumentowaną chorobą Gilberta dozwolone jest stężenie bilirubiny całkowitej na poziomie ≤3,0 mg/dl.\n•\tAlbumina w surowicy ≥3.0 g/dl.\n•\tKlirens kreatyniny ≥45 ml/min według wzoru Cockcrofta-Gaulta (patrz Załącznik 1, punkt 14.1). Można rozważyć włączenie do badania uczestników z klirensem kreatyniny w zakresie od 30 do 45 ml/min warunkowo po konsultacji przypadku z monitorem medycznym w celu oceny potrzeby modyfikacji dawki, aby zapewnić bezpieczne podanie leku eksperymentalnego.\n•\tCzas protrombinowy (PT)/międzynarodowy współczynnik znormalizowany (INR) lub wyniki częściowego badania czasu tromboplastyny podczas badań przesiewowych ≤1,5 × GGN (dotyczy to tylko uczestników, którzy nie otrzymują terapeutycznych leków przeciwzakrzepowych; uczestnicy otrzymujący terapeutyczne leki przeciwzakrzepowe powinni przyjmować stałą dawkę przez co najmniej 2 tygodnie przed podaniem pierwszej dawki badanego leku).","language":19,"languageDescription":"Polish"},{"id":12676503,"uuid":"912c7a0c-184e-4a4b-9556-f1cda5ee8210","attributeTranslation":"11.\tPrésenter une fonction organique satisfaisante (l’évaluation de sélec-tion devra être réalisée dans les 14 jours précédant le J1C1) :\n•\tNumération absolue des neutrophiles (NAN) ≥ 1 500/mm3 sans re-cours à des facteurs de croissance hématopoïétiques.\n•\tNumération plaquettaire ≥ 100 000/mm3 (au moins 2 semaines après la transfusion de plaquettes et sans recevoir d’agents stimulateurs de plaquettes).\n•\tHémoglobine ≥ 9,0 g/dl (au moins 2 semaines après la transfusion de globules rouges).\n•\tASAT et ALAT ≤ 3 x LSN en l’absence de métastases hépa-tiques documentées ; ≤ 5 x LSN en présence de métastases hépatiques.\n•\tBilirubine totale et directe ≤ 1,5 x la limite supérieure de la normale (LSN).\no\tSi la bilirubine totale est > 1,5 x LSN, et que l’aspartate aminotransférase (ASAT) et l’alanine aminotransférase (ALAT) sont dans les limites de la normale, la bilirubine directe doit être ≤ 1,5 x LSN.\no\tEn ce qui concerne les participants atteints d’une maladie de Gilbert documentée, une bilirubine totale ≤ 3,0 mg/dl est admise.\n•\tTaux d’albumine sérique ≥ 3,0 g/dl.\n•\tClairance de la créatinine ≥ 45 ml/min selon l’équation de Cock-croft- Gault (voir Annexe 1, Section 14.1). Les participants ayant une clairance de la créatinine comprise entre 30 et 45 ml/min peu-vent être envisagés pour l’inclusion dans l’essai après une discussion avec le moniteur médical pour évaluer le besoin d’une modification de la dose, en garantissant une administration sûre de l’agent expé-rimental.\n•\tTemps de prothrombine (TP)/Rapport normalisé international (Inter-national Normalized Ratio, INR) ou résultats de l’analyse du temps de céphaline à la sélection ≤ 1,5 x LSN (cela s’applique uniquement aux participants ne recevant pas d’anticoagulation thérapeutique ; les participants recevant une anticoagulation thérapeutique doivent être sous dose stable depuis au moins 2 semaines avant la première dose du médicament à l’étude).","language":10,"languageDescription":"French"},{"id":12676507,"uuid":"912c7a0c-184e-4a4b-9556-f1cda5ee8210","attributeTranslation":"11.\tSie haben eine ausreichende Organfunktion (die Voruntersuchung muss innerhalb von 14 Tagen C1D1 erfolgen):\n•\tAbsolute Neutrophilenzahl (ANC) von ≥ 1500/mm3 ohne Einsatz hämatopoetischer Wachstumsfaktoren\n•\tThrombozytenzahl von ≥ 100.000/mm3 (nach einer Thrombozytentransfusion müssen mindestens 2 Wochen ohne thrombozytenstimulierende Wirkstoffe vergangen sein)\n•\tHämoglobin ≥ 9,0 g/dl (nach einer Erythrozytentransfusion müssen mindestens 2 Wochen vergangen sein)\n•\t(AST) und (ALT) ≤ als das 3- Fache der ONG und keine dokumentierte Lebermetastasen; ≤ als das\n%-Fache der ONG bei Vorhandensein von Lebermetastasen\n•\tGesamt- und direktes Bilirubin ≤ das 1,5-Fache der oberen Normgrenze (ONG). \no\tWenn das Gesamtbilirubin > 1,5 × ONG ist und Aspartataminotransferase (AST) und Alaninaminotransferase (ALT) innerhalb normaler Grenzen liegen, muss das direkte Bilirubin ≤ 1,5 × ONG sein. \no\tFür Teilnehmer mit dokumentiertem Gilbert- Meulengracht-Syndrom ist ein Gesamtbilirubinwert von ≤ 3,0 mg/dl zulässig\n•\tAlbumin im Serum ≥ 3,0 g/dl\n•\tKreatinin-Clearance ≥ 45 ml/min nach Cockcroft-Gault-Gleichung (siehe Anhang 1, Abschnitt 14.1). Teilnehmer mit einer Kreatinin-Clearance zwischen 30 und 45 ml/min können nach Rücksprache mit dem Medical Monitor für die Aufnahme in die Studie in Betracht gezogen werden, um die Notwendigkeit einer Dosismodifizierung zu beurteilen. So wird die sichere Verabreichung der Prüfsubstanz gewährleistet.\n•\tTestergebnisse zu Prothrombinzeit (PT) / International Normalized Ratio (INR) oder partieller Thromboplastinzeit bei der Voruntersuchung ≤ das 1,5-Fache der ONG (dies gilt nur für Teilnehmer, die keine therapeutische Antikoagulation erhalten; Teilnehmer, die eine therapeutische Antikoagulation erhalten, sollten vor der ersten Studienbehandlung seit mindestens 2 Wochen eine stabile Dosis erhalten haben)","language":4,"languageDescription":"German"},{"id":12676504,"uuid":"912c7a0c-184e-4a4b-9556-f1cda5ee8210","attributeTranslation":"11.\tFunzionalità d’organo adeguata (con valutazione di screening obbligatoriamente ottenuta entro 14 giorni dal C1G1):\n•\tConta assoluta dei neutrofili (ANC) ≥1500/mm3 senza l’uso di fattori di crescita ematopoietici.\n•\tConta piastrinica ≥100.000/mm3 (valutata a distanza di almeno 2 settimane da un’eventuale trasfusione di piastrine e in assenza di terapia con agenti stimolanti le piastrine).\n•\tEmoglobina ≥9,0 g/dl (valutata a distanza di almeno 2 settimane da un’eventuale trasfusione di globuli rossi).\n•\tAST e ALT ≤3 x l’ULN in assenza di metastasi epatiche documentate; ≤5 x l’ULN in presenza di metastasi epatiche.\n•\tBilirubina totale e diretta ≤1,5 x il limite superiore della norma (ULN).\no\tSe la bilirubina totale è > 1,5 × ULN e l’aspartato aminotransferasi (AST) e l’alanina aminotransferasi (ALT) rientrano nei limiti normali, la bilirubina diretta deve essere ≤ 1,5 × ULN.\no\tPer i partecipanti con malattia di Gilbert documentata, è consentito un valore di bilirubina totale ≤3,0 mg/dl.\n•\tAlbumina sierica ≥3,0 g/dl.\n•\tClearance della creatinina ≥45 ml/min in base all’equazione di Cockcroft-Gault (vedere Appendice 1, Sezione 14.1). I partecipanti con clearance della creatinina compresa tra 30 e 45 ml/min possono essere considerati per l’arruolamento nello studio, in seguito alla consultazione con il medical monitor per valutare la necessità di modifica della dose, garantendo la somministrazione sicura dell’agente sperimentale.\n•\tRisultati dei test del tempo di protrombina (PT)/rapporto internazionale normalizzato (INR) o del tempo di tromboplastina parziale allo screening ≤1,5 x l’ULN (vale solo per i partecipanti non sottoposti ad anticoagulazione terapeutica; i partecipanti sottoposti ad anticoagulazione terapeutica devono ricevere una dose stabile per almeno 2 settimane prima della prima dose di farmaco dello studio).","language":14,"languageDescription":"Italian"},{"id":12676505,"uuid":"912c7a0c-184e-4a4b-9556-f1cda5ee8210","attributeTranslation":"11.\tBeschikken over adequate orgaanfunctie (de screeningsbeoordeling moet binnen 14 dagen vanaf C1D1 worden verkregen):\n•\tAbsoluut aantal neutrofielen (ANC) ≥1500/mm3 zonder gebruik van hematopoëtische groeifactoren\n•\tAantal bloedplaatjes ≥100.000/mm3 (moet ten minste 2 weken na een bloedplaatjestransfusie zijn en geen bloedplaatjesstimulerende middelen krijgen)\n•\tHemoglobine ≥9,0 g/dl (moet ten minste 2 weken na transfusie van rode bloedcellen zijn)\n•\tAST en ALT ≤3 × ULN in afwezigheid van gedocumenteerde levermetastasen; ≤5 × ULN in aanwezigheid van levermetastasen\n•\tTotaal en direct bilirubine ≤1,5 × de bovengrens van normaal (ULN).\no\tAls het totaal bilirubine ≤1,5 × ULN is en de gehaltes aspartaat-aminotransferase (AST) en alanine-aminotransferase (ALT) liggen binnen de normale grenzen, moet het bilirubine ≤1,5 × ULN zijn.\no\tVoor deelnemers met gedocumenteerde ziekte van Gilbert is totaal bilirubine ≤3,0 mg/dl toegestaan.\n•\tSerumalbumine ≥3,0 g/dl\n•\tCreatinineklaring ≥45 ml/min volgens de Cockcroft-Gault-vergelijking (zie bijlage 1, sectie 14.1). Deelnemers met een creatinineklaring tussen 30 en 45 ml/min kunnen in aanmerking komen voor deelname aan het onderzoek, afhankelijk van overleg met de medische monitor om de noodzaak van dosisaanpassing te beoordelen, zodat een veilige toediening van het onderzoeksmiddel wordt gegarandeerd.\n•\tTestresultaten voor protrombinetijd (PT)/internationaal genormaliseerd ratio (INR) of partiële tromboplastinetijd bij screening ≤1,5 × ULN (dit geldt alleen voor deelnemers die geen therapeutische anticoagulatie krijgen; deelnemers die therapeutische anticoagulatie krijgen, moeten een stabiele dosis krijgen gedurende ten minste 2 weken voorafgaand aan de eerste dosis van het onderzoeksgeneesmiddel).","language":18,"languageDescription":"Dutch"},{"id":12676506,"uuid":"912c7a0c-184e-4a4b-9556-f1cda5ee8210","attributeTranslation":"11.\tPresentar una funcionalidad orgánica adecuada (debe obtenerse una evaluación de selección en los 14 días previos a D1C1):\n•\tRecuento absoluto de neutrófilos (RAN) ≥ 1500/mm3 sin el uso de factores de crecimiento hematopoyéticos.\n•\tRecuento de plaquetas ≥100 000/mm3 (obtenido al menos 2 semanas después de una transfusión de plaquetas y sin recibir estimulantes plaquetarios).\n•\tHemoglobina ≥9,0 g/dl (deben haber transcurrido al menos 2 semanas desde una transfusión de eritrocitos).\n•\tAST ALT ≤ 3 × LSN en ausencia de metástasis hepáticas documentadas; ≤ 5 × LSN en presencia de metástasis hepáticas.\n•\tBilirrubina total y directa ≤1,5 × el límite superior de la normalidad (LSN). \no\tSi la bilirrubina total es > 1,5 × LSN, y la aspartato aminotransferasa (AST) y la alanina aminotransferasa (ALT) están dentro de los límites normales, la bilirrubina directa debe ser ≤ 1,5 × LSN. \no\tPara los participantes con enfermedad de Gilbert documentada se permiten valores de bilirrubina total ≤3,0 mg/dl.\n•\tAlbúmina en suero ≥3,0 g/dl.\n•\tAclaramiento de creatinina ≥45 ml/min calculado mediante la ecuación de Cockcroft-Gault (véase el Apéndice 1, Sección 14.1). Los participantes con un aclaramiento de creatinina entre 30 y 45 ml/min pueden ser considerados para ser incluidos en el ensayo tras consulta con el monitor clínico, garantizando así la administración segura del producto en investigación.\n•\tResultados de las pruebas de tiempo de protrombina/ (TP)/índice internacional normalizado (International Normalized Ratio, INR) o de tiempo de tromboplastina parcial en la selección ≤1,5 × LSN (esto solo se aplica a los participantes que no reciban anticoagulación terapéutica; los que sí la reciban deben haber mantenido una dosis estable durante al menos 2 semanas antes de la primera dosis del fármaco del estudio).","language":7,"languageDescription":"Spanish"}]},{"id":1013261,"number":12,"principalInclusionCriteria":"Women of child-bearing potential (WOCBP) who are sexually active with a non-sterilized male partner, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective contraception during study treatment (see Appendix 5, Section 14.5), and must agree to continue using such precautions for 6 months after the final dose of study treatment; cessation of birth control after this point should be discussed with a responsible physician. Highly effective methods of contraception are described in Appendix 5, Section 14.5. Systemically-acting hormonal contraceptives should always be combined with a barrier method (preferably male condom).","principalInclusionCriteriaTranslations":[{"id":12676514,"uuid":"544ad64a-3750-45ba-bb3e-617380b9a10e","attributeTranslation":"12.\tLe donne in età fertile (WOCBP) sessualmente attive con un partner maschile non sterilizzato, definite come tutte le donne fisiologicamente in grado di avviare una gravidanza, devono utilizzare un metodo contraccettivo altamente efficace durante il trattamento dello studio (vedere Appendice 5, Sezione 14.5) e devono acconsentire a continuare a utilizzare tali precauzioni per 6 mesi dopo l’ultima dose di trattamento dello studio; la cessazione della contraccezione dopo tale data dovrà essere discussa con un medico responsabile. I metodi contraccettivi altamente efficaci sono descritti nell’Appendice 5, Sezione 14.5. I contraccettivi ormonali ad azione sistemica devono essere sempre combinati con un metodo barriera (preferibilmente preservativo maschile).","language":14,"languageDescription":"Italian"},{"id":12676513,"uuid":"544ad64a-3750-45ba-bb3e-617380b9a10e","attributeTranslation":"12.\tMujeres con capacidad de concebir (MCC) sexualmente activas con una pareja masculina no esterilizada, definido como todas las mujeres fisiológicamente capaces de quedarse embarazadas, a menos que estén utilizando un método anticonceptivo de gran eficacia durante el tratamiento del estudio (véase el Apéndice 5, Sección 14.5), y deben comprometerse a seguir adoptando dichas precauciones durante 6 meses después de la última dosis del tratamiento del estudio; el cese de los anticonceptivos después de este punto debe comentarse con un médico responsable. Los métodos anticonceptivos de gran eficacia se describen en el Apéndice 5,\nSección 14.5. Los anticonceptivos hormonales de acción sistémica deben combinarse siempre con un método de barrera (preferiblemente, preservativo masculino).","language":7,"languageDescription":"Spanish"},{"id":12676509,"uuid":"544ad64a-3750-45ba-bb3e-617380b9a10e","attributeTranslation":"12.\tVruchtbare vrouwen die seksueel actief zijn met een niet- gesteriliseerde mannelijke partner, gedefinieerd als alle vrouwen die fysiologisch in staat zijn om zwanger te worden, tenzij ze zeer effectieve anticonceptie gebruiken tijdens de onderzoeksbehandeling (zie bijlage 5, sectie 14.5), moeten ermee instemmen om dergelijke voorzorgsmaatregelen te blijven gebruiken gedurende 6 maanden na de laatste dosis onderzoeksbehandeling; het stopzetten van anticonceptie na dit punt moet worden besproken met een verantwoordelijke arts. Zeer effectieve anticonceptiemethoden worden beschreven in bijlage 5, sectie 14.5. Systemische hormonale anticonceptiemiddelen moeten altijd worden gecombineerd met een barrièremethode (bij voorkeur mannencondoom).","language":18,"languageDescription":"Dutch"},{"id":12676510,"uuid":"544ad64a-3750-45ba-bb3e-617380b9a10e","attributeTranslation":"12.\tLes femmes en âge de procréer (FAP) qui sont sexuellement actives avec un partenaire masculin non stérilisé, c’est-à-dire toutes les femmes en mesure de débuter une grossesse sur le plan physiologique, sauf si elles utilisent une méthode de contraception hautement efficace pendant le traitement à l’étude (voir Annexe 5, Section 14.5), doivent accepter de continuer à suivre ces précautions pendant 6 mois après la dernière dose du traitement à l’étude ; l’arrêt de la contraception après ce moment-là doit faire l’objet d’une discussion avec un médecin responsable. Les méthodes de contraception hautement efficaces sont décrites à l’Annexe 5, Section 14.5. Des contraceptifs hormonaux à action systémique doivent toujours être associés à une méthode barrière (de préférence un préservatif masculin).","language":10,"languageDescription":"French"},{"id":12676511,"uuid":"544ad64a-3750-45ba-bb3e-617380b9a10e","attributeTranslation":"12.\tGebärfähige Frauen, die mit einem nicht sterilisierten männlichen Partner sexuell aktiv sind, definiert als alle Frauen, die körperlich in der Lage sind, schwanger zu werden, müssen während der Studienbehandlung eine hochwirksame Empfängnisverhütung anwenden (siehe Anhang 5, Abschnitt 14.5) und müssen zustimmen, diese Vorsichtsmaßnahmen über 6 Monate nach der letzten Studienbehandlung weiterhin anzuwenden; das Absetzen der Empfängnisverhütung nach diesem Zeitpunkt sollte mit dem\nzuständigen Arzt besprochen werden. Hochwirksame Verhütungsmethoden sind in Anhang 5, Abschnitt 14.5, beschrieben. Systemisch wirkende hormonelle Kontrazeptiva sollten immer mit einer Barrieremethode (vorzugsweise Männerkondom) kombiniert werden.","language":4,"languageDescription":"German"},{"id":12676512,"uuid":"544ad64a-3750-45ba-bb3e-617380b9a10e","attributeTranslation":"12.\tKobiety zdolne do posiadania potomstwa (WOCBP), które są aktywne seksualnie z partnerem niepoddanym sterylizacji, definiowane jako wszystkie kobiety fizjologicznie zdolne do zajścia w ciążę, chyba że stosują wysoce skuteczną antykoncepcję podczas leczenia w ramach badania (patrz Załącznik 5 punkt 14.5) i które wyraziły zgodę na dalsze stosowanie takich środków ostrożności przez 6 miesięcy po przyjęciu ostatniej dawki badanego leku; zaprzestanie stosowania antykoncepcji po tym czasie należy omówić z lekarzem prowadzącym. Wysoce skuteczne metody antykoncepcji opisano w Załączniku 5 punkt 14.5. Hormonalne środki antykoncepcyjne o działaniu ogólnoustrojowym należy zawsze stosować wraz z metodą barierową (najlepiej prezerwatywą dla mężczyzn).","language":19,"languageDescription":"Polish"}]},{"id":1013262,"number":13,"principalInclusionCriteria":"Male participants must be surgically sterile or must agree to use double-barrier contraception methods from enrollment through treatment and for 3 months following administration of the last dose of study treatment.","principalInclusionCriteriaTranslations":[{"id":12676519,"uuid":"4dcf872d-64c2-4918-8e2f-11385477e676","attributeTranslation":"13.\tMężczyźni uczestniczący w badaniu muszą być po zabiegu sterylizacji chirurgicznej lub wyrazić zgodę na stosowanie podwójnych barierowych metod antykoncepcji od włączenia do badania do leczenia i przez 3 miesiące po podaniu ostatniej dawki badanego leku.","language":19,"languageDescription":"Polish"},{"id":12676515,"uuid":"4dcf872d-64c2-4918-8e2f-11385477e676","attributeTranslation":"13.\tLes participants de sexe masculin doivent avoir été stérilisés par voie chirurgicale ou doivent accepter d’utiliser des méthodes de contraception à double barrière à partir de leur inclusion, tout au long du traitement, et pendant 3 mois après l’administration de la dernière dose du traitement à l’étude.","language":10,"languageDescription":"French"},{"id":12676518,"uuid":"4dcf872d-64c2-4918-8e2f-11385477e676","attributeTranslation":"13.\tI partecipanti di sesso maschile devono essere chirurgicamente sterili o devono acconsentire all’uso di metodi contraccettivi a doppia barriera a partire dall’arruolamento, per tutta la durata del trattamento e per 3 mesi dopo la somministrazione dell’ultima dose di trattamento dello studio.","language":14,"languageDescription":"Italian"},{"id":12676516,"uuid":"4dcf872d-64c2-4918-8e2f-11385477e676","attributeTranslation":"13.\tMännliche Teilnehmer müssen chirurgisch sterilisiert sein oder zustimmen, ab der Aufnahme und bis zu 3 Monate nach der letzten Studienbehandlung doppelte Barrieremethoden als Empfängnisverhütung anzuwenden.","language":4,"languageDescription":"German"},{"id":12676517,"uuid":"4dcf872d-64c2-4918-8e2f-11385477e676","attributeTranslation":"13.\tLos participantes varones deben estar esterilizados quirúrgicamente o aceptar el uso de métodos anticonceptivos de doble barrera desde la inclusión hasta el tratamiento y durante 3 meses después de la administración de la última dosis del tratamiento del estudio.","language":7,"languageDescription":"Spanish"},{"id":12676520,"uuid":"4dcf872d-64c2-4918-8e2f-11385477e676","attributeTranslation":"13.\tMannelijke deelnemers moeten chirurgisch steriel zijn of moeten instemmen met het gebruik van anticonceptiemethoden met dubbele barrière vanaf de inschrijving tot en met de behandeling en gedurende 3 maanden na toediening van de laatste dosis onderzoeksbehandeling.","language":18,"languageDescription":"Dutch"}]},{"id":1013263,"number":2,"principalInclusionCriteria":"Written, informed consent has been obtained before initiation of any study related-procedures, and the participant is able, in the opinion of the investigator, to comply with all the requirements of the study.","principalInclusionCriteriaTranslations":[{"id":12676522,"uuid":"d02b8322-c97c-41da-adbf-91a9df0e8e64","attributeTranslation":"2.\tIl consenso informato scritto è stato ottenuto prima dell’avvio di qualsiasi procedura correlata allo studio e il partecipante è in grado, secondo il giudizio dello sperimentatore, di rispettare tutti i requisiti dello studio.","language":14,"languageDescription":"Italian"},{"id":12676526,"uuid":"d02b8322-c97c-41da-adbf-91a9df0e8e64","attributeTranslation":"2.\tSe ha obtenido un consentimiento informado por escrito antes del inicio de cualquier procedimiento relacionado con el estudio y, en opinión del investigador, el participante es capaz de cumplir con todos los requisitos del estudio.","language":7,"languageDescription":"Spanish"},{"id":12676524,"uuid":"d02b8322-c97c-41da-adbf-91a9df0e8e64","attributeTranslation":"2.\tUzyskanie pisemnej, świadomej zgody przed poddaniem się jakimkolwiek procedurom związanym z badaniem i zdolność uczestnika (w opinii badacza) do przestrzegania wszystkich wymogów badania.","language":19,"languageDescription":"Polish"},{"id":12676521,"uuid":"d02b8322-c97c-41da-adbf-91a9df0e8e64","attributeTranslation":"2.\tVor Beginn von Studienverfahren wurde eine schriftliche Einwilligungserklärung eingeholt, und der Teilnehmer ist nach Ansicht des Prüfarztes in der Lage, alle Anforderungen der Studie einzuhalten.","language":4,"languageDescription":"German"},{"id":12676525,"uuid":"d02b8322-c97c-41da-adbf-91a9df0e8e64","attributeTranslation":"2.\tUn consentement éclairé a été obtenu par écrit avant le début de toute procédure liée à l’étude et, de l’avis de l’investigateur, le participant est en mesure de se conformer à toutes les exigences de l’étude.","language":10,"languageDescription":"French"},{"id":12676523,"uuid":"d02b8322-c97c-41da-adbf-91a9df0e8e64","attributeTranslation":"2.\tSchriftelijke geïnformeerde toestemming is verkregen vóór aanvang van onderzoeksgerelateerde procedures, en de deelnemer is in staat om, naar het oordeel van de onderzoeker, te voldoen aan alle vereisten van het onderzoek.","language":18,"languageDescription":"Dutch"}]},{"id":1013264,"number":3,"principalInclusionCriteria":"Has histological or cytological confirmed UM with metastatic disease","principalInclusionCriteriaTranslations":[{"id":12676529,"uuid":"2ded7c08-9276-4c75-a0d6-98ce9f074da6","attributeTranslation":"3.\tUM istologicamente o citologicamente confermato con presenza di malattia metastatica","language":14,"languageDescription":"Italian"},{"id":12676532,"uuid":"2ded7c08-9276-4c75-a0d6-98ce9f074da6","attributeTranslation":"3.\tHebben histologisch of cytologisch bevestigde UM met gemetastaseerde ziekte","language":18,"languageDescription":"Dutch"},{"id":12676528,"uuid":"2ded7c08-9276-4c75-a0d6-98ce9f074da6","attributeTranslation":"3.\tPotwierdzona histologicznie lub cytologicznie UM z przerzutami","language":19,"languageDescription":"Polish"},{"id":12676527,"uuid":"2ded7c08-9276-4c75-a0d6-98ce9f074da6","attributeTranslation":"3.\tSie haben ein histologisch oder zytologisch bestätigtes Aderhautmelanom mit metastasierter Erkrankung.","language":4,"languageDescription":"German"},{"id":12676531,"uuid":"2ded7c08-9276-4c75-a0d6-98ce9f074da6","attributeTranslation":"3.\tPrésenter un MU histologique ou cytologique confirmé avec une maladie métastatique.","language":10,"languageDescription":"French"},{"id":12676530,"uuid":"2ded7c08-9276-4c75-a0d6-98ce9f074da6","attributeTranslation":"3.\tPadecer MMU confirmado histológica o citológicamente con metástasis.","language":7,"languageDescription":"Spanish"}]},{"id":1013265,"number":4,"principalInclusionCriteria":"HLA-A*02:01 negative","principalInclusionCriteriaTranslations":[{"id":12676533,"uuid":"fb1b928f-3f1b-48ce-a4ea-1965512bbef2","attributeTranslation":"4.\tHLA-A*02:01 negativo.","language":7,"languageDescription":"Spanish"},{"id":12676536,"uuid":"fb1b928f-3f1b-48ce-a4ea-1965512bbef2","attributeTranslation":"4.\tSie sind HLA-A*02:01-negativ","language":4,"languageDescription":"German"},{"id":12676538,"uuid":"fb1b928f-3f1b-48ce-a4ea-1965512bbef2","attributeTranslation":"4.\tHLA-A*02:01 négatif","language":10,"languageDescription":"French"},{"id":12676535,"uuid":"fb1b928f-3f1b-48ce-a4ea-1965512bbef2","attributeTranslation":"4.\tNegatività per l’antigene HLA-A*02:01.","language":14,"languageDescription":"Italian"},{"id":12676537,"uuid":"fb1b928f-3f1b-48ce-a4ea-1965512bbef2","attributeTranslation":"4.\tHLA-A*02:01 ujemny","language":19,"languageDescription":"Polish"},{"id":12676534,"uuid":"fb1b928f-3f1b-48ce-a4ea-1965512bbef2","attributeTranslation":"4.\tHLA-A*02:01 negatief","language":18,"languageDescription":"Dutch"}]},{"id":1013266,"number":5,"principalInclusionCriteria":"Must meet the following criteria related to prior treatment: • No prior systemic therapy in the metastatic or advanced setting including chemotherapy, immunotherapy, or targeted therapy • No prior regional, liver-directed therapy including chemotherapy, radiotherapy, or embolization • Prior ablations or surgical resection of oligometastatic disease are allowed • Prior neoadjuvant or adjuvant therapy is allowed provided administered in the curative setting in participants with localized disease and a minimum of 4 weeks (28 days) has elapsed since the end of neoadjuvant/adjuvant treatment and the start of study treatment o Participants who have received a combination of anti-programmed cell death ligand 1 (PD-L1) plus anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) as prior neoadjuvant/adjuvant treatment should not receive ipilimumab + nivolumab as investigator’s choice therapy o Participants who have received an anti-PD-L1 agent as prior neoadjuvant/adjuvant treatment should not receive pembrolizumab as investigator’s choice therapy o Participants who have received a dacarbazine-containing regimen as prior neoadjuvant/adjuvant treatment should not receive dacarbazine as investigator’s choice therapy","principalInclusionCriteriaTranslations":[{"id":12676539,"uuid":"e9bf2b48-15f1-44bd-9d4f-5e5747fb3eba","attributeTranslation":"5.\tSie müssen die folgenden Kriterien in Bezug auf Vorbehandlungen erfüllen:\n•\tKeine vorherige systemische Therapie im metastasierten oder fortgeschrittenen Setting, einschließlich Chemotherapie, Immuntherapie oder zielgerichteter Therapie\n•\tKeine vorherige regionale, auf die Leber gerichtete Therapie, einschließlich Chemotherapie, Strahlentherapie oder Embolisation\n•\tFrühere Ablationen oder chirurgische Resektion einer oligometastatischen Erkrankung sind zulässig\n•\tEine vorherige neoadjuvante oder adjuvante Therapie ist zulässig, wenn sie Teilnehmern mit lokalisierter Erkrankung im kurativen Setting verabreicht wurde und mindestens 4 Wochen (28 Tage) zwischen dem Ende der neoadjuvanten/adjuvanten Behandlung und dem Beginn der Studienbehandlung vergangen sind\no\tTeilnehmer, die als vorherige neoadjuvante/adjuvante Behandlung eine Kombination aus anti-programmiertem Zelltodligand 1 (PD-L1) plus antizytotoxischem T-Lymphozyten-assoziiertem Protein 4 (CTLA-4) erhalten haben, sollten die Ipilimumab + Nivolumab-Therapie nach Wahl des Prüfarztes nicht erhalten \no\tTeilnehmer, die einen Anti-PD-L1-Wirkstoff als vorherige neoadjuvante/adjuvante Behandlung erhalten haben, sollten Pembrolizumab nicht als Therapie nach Wahl des Prüfarztes erhalten\no\tTeilnehmer, die ein Behandlungsschema mit Dacarbazin als vorherige neoadjuvante/adjuvante Behandlung erhalten haben, sollten Dacarbazin nicht als Therapie nach Wahl des Prüfarztes erhalten","language":4,"languageDescription":"German"},{"id":12676542,"uuid":"e9bf2b48-15f1-44bd-9d4f-5e5747fb3eba","attributeTranslation":"5.\tCumplir los criterios siguientes relacionados con el tratamiento anterior:\n•\tAusencia de tratamiento sistémico previo para el cáncer metastásico o avanzado, lo que incluye quimioterapia, inmunoterapia o tratamientos selectivos.\n•\tAusencia de tratamientos previos regionales dirigidos al hígado, lo que incluye quimioterapia, radioterapia o embolización.\n•\tSe permiten ablaciones o resecciones quirúrgicas previas de oligometástasis.\n•\tSe admiten tratamientos prequirúrgicos o posquirúrgicos previos con fines curativos en participantes con tumor localizado y un mínimo de 4 semanas (28 días) transcurridos entre el final del tratamiento prequirúrgico o posquirúrgico y el inicio del tratamiento del estudio.\no\tLos participantes que hayan recibido una combinación de anti- ligando 1 de muerte celular programada (PD-L1) más anti- proteína 4 asociada al linfocito T citotóxico (CTLA-4) como tratamiento prequirúrgico o posquirúrgico previo no deben recibir ipilimumab + nivolumab como tratamiento de elección del investigador.\no\tLos participantes que hayan recibido algún anti-PDL1 como tratamiento prequirúrgico o posquirúrgico previo no deben recibir pembrolizumab como tratamiento de elección del investigador.\no\tLos participantes que hayan recibido alguna pauta con dacarbazina como tratamiento prequirúrgico o posquirúrgico previo no deben recibir dacarbazina como tratamiento de elección del investigador.","language":7,"languageDescription":"Spanish"},{"id":12676543,"uuid":"e9bf2b48-15f1-44bd-9d4f-5e5747fb3eba","attributeTranslation":"5.\tSpełnianie następujących kryteriów związanych z wcześniejszym leczeniem:\n•\tBrak wcześniejszego leczenia ogólnoustrojowego w stadium przerzutowym lub zaawansowanym, w tym chemioterapii, immunoterapii lub terapii celowanej\n•\tBrak wcześniejszej terapii miejscowej, ukierunkowanej na wątrobę, w tym chemioterapii, radioterapii lub embolizacji\n•\tDozwolone są wcześniejsze ablacje lub chirurgiczna resekcja choroby oligometastatycznej\n•\tWcześniejsze leczenie neoadjuwantowe lub adjuwantowe jest dozwolone w leczeniu uczestników z miejscową chorobą ale upłynęło co najmniej 4 tygodnie (28 dni) od zakończenia leczenia neoadjuwantowego/adjuwantowego do rozpoczęcia leczenia w ramach badania.\no\tUczestnicy, którzy otrzymali skojarzenie leków przeciwko ligandowi programowanej śmierci komórki 1 (PD-L1) i przeciwko białku 4 związanemu z cytotoksycznymi limfocytami T (CTLA-4) jako wcześniejsze leczenie neoadjuwantowe/adjuwantowe, nie powinni otrzymywać ipilimumabu i niwolumabu jako terapii wybranej przez badacza\no\tUczestnicy, którzy otrzymali lek anty-PD-L1 jako wcześniejsze leczenie neoadjuwantowe/adjuwantowe, nie powinni otrzymywać pembrolizumabu jako leczenia wybieranego przez badacza\no\tUczestnicy, którzy otrzymali schemat leczenia zawierający dakarbazynę jako wcześniejsze leczenie neoadjuwantowe/adjuwantowe, nie powinni otrzymywać dakarbazyny jako leczenia wybieranego przez badacza","language":19,"languageDescription":"Polish"},{"id":12676541,"uuid":"e9bf2b48-15f1-44bd-9d4f-5e5747fb3eba","attributeTranslation":"5.\tMoeten voldoen aan de volgende criteria met betrekking tot eerdere behandeling:\n•\tGeen eerdere systemische behandeling in de gemetastaseerde of gevorderde setting, waaronder chemotherapie, immunotherapie of beoogde therapie\n•\tGeen eerdere regionale, levergerichte behandeling waaronder chemotherapie, radiotherapie of embolisatie\n•\tEerdere ablaties of chirurgische resectie van oligometastatische ziekte zijn toegestaan\n•\tEerdere neoadjuvante of adjuvante behandeling is toegestaan mits toegediend in de curatieve setting bij deelnemers met gelokaliseerde ziekte en er minimaal 4 weken (28 dagen) zijn verstreken tussen het einde van de neoadjuvante/adjuvante behandeling en de start van de onderzoeksbehandeling.\no\tDeelnemers die een combinatie van anti-geprogrammeerde celdood-ligand 1 (PD-L1) plus anti-cytotoxische T-lymfocyt-geassocieerd eiwit 4 (CTLA-4) als eerdere neoadjuvante/adjuvante behandeling hebben gekregen, mogen geen ipilimumab + nivolumab krijgen als behandeling naar keuze van de onderzoeker\no\tDeelnemers die een anti-PD-L1-middel hebben gekregen als eerdere neoadjuvante/adjuvante behandeling mogen geen pembrolizumab krijgen als behandeling naar keuze van de onderzoeker\no\tDeelnemers die een regime hebben gekregen dat dacarbazine bevat als eerdere neoadjuvante/adjuvante behandeling mogen geen dacarbazine krijgen als behandeling naar keuze van de onderzoeker","language":18,"languageDescription":"Dutch"},{"id":12676544,"uuid":"e9bf2b48-15f1-44bd-9d4f-5e5747fb3eba","attributeTranslation":"5.\tRépondre aux critères suivants liés au traitement antérieur :\n•\tAucun traitement systémique antérieur dans un cadre métastatique ou avancé, notamment chimiothérapie, immunothérapie ou thérapie ciblée.\n•\tAucun traitement antérieur régional dirigé contre le foie, notamment chimiothérapie, radiothérapie ou embolisation.\n•\tLes ablations ou résections chirurgicales antérieures concernant une maladie oligométastatique sont autorisées.\n•\tUn traitement néoadjuvant ou adjuvant antérieur est autorisé à condition qu’il ait été administré dans un cadre curatif chez des participants atteints d’une maladie localisée et qu’un minimum de 4 semaines\n(28 jours) se soient écoulées entre la fin du traitement néoadjuvant/adjuvant et le début du traitement à l’étude.\no\tLes participants ayant reçu une association d’anti-ligand 1 de mort cellulaire programmée (PD-L1) plus anti-protéine 4 associée aux lymphocytes T cytotoxiques (CTLA-4) comme traitement néoadjuvant/adjuvant antérieur ne doivent pas recevoir d’ipilimumab + nivolumab comme traitement choisi par l’investigateur.\no\tLes participants ayant reçu un agent anti-PD-L1 comme traitement néoadjuvant/adjuvant antérieur ne doivent pas recevoir de pembrolizumab comme traitement choisi par l’investigateur.\no\tLes participants ayant reçu un schéma thérapeutique à base de dacarbazine comme traitement néoadjuvant/adjuvant antérieur ne doivent pas recevoir de dacarbazine comme traitement choisi par l’investigateur.","language":10,"languageDescription":"French"},{"id":12676540,"uuid":"e9bf2b48-15f1-44bd-9d4f-5e5747fb3eba","attributeTranslation":"5.\tSoddisfacimento di tutti i seguenti criteri correlati al trattamento precedente:\n•\tNessuna precedente terapia sistemica nel contesto metastatico o avanzato, tra cui chemioterapia, immunoterapia o terapia mirata.\n•\tNessuna precedente terapia regionale diretta al fegato, tra cui chemioterapia, radioterapia o embolizzazione.\n•\tSono consentite precedenti procedure di ablazione o resezione chirurgica per malattia oligometastatica.\n•\tÈ consentita una precedente terapia neoadiuvante o adiuvante, a condizione che sia stata somministrata con intento curativo a partecipanti con malattia localizzata e che sia trascorso un minimo di 4 settimane (28 giorni) tra la fine del trattamento neoadiuvante/adiuvante e l’avvio del trattamento dello studio.\no\tI partecipanti che hanno ricevuto una combinazione di agenti anti-proteina di morte cellulare programmata-ligando 1 (PD-L1) più anti-antigene 4 associato ai linfociti T citotossici (CTLA-4) come precedente trattamento neoadiuvante/adiuvante non devono ricevere ipilimumab + nivolumab come terapia scelta dallo sperimentatore.\no\tI partecipanti che hanno ricevuto un agente anti-PD-L1 come precedente trattamento neoadiuvante/adiuvante non devono ricevere pembrolizumab come terapia scelta dallo sperimentatore.\no\tI partecipanti che hanno ricevuto un regime contenente dacarbazina come precedente trattamento neoadiuvante/adiuvante non devono ricevere dacarbazina come terapia scelta dallo sperimentatore.","language":14,"languageDescription":"Italian"}]},{"id":1013267,"number":6,"principalInclusionCriteria":"Has a representative archival metastatic tumor specimen in paraffin blocks with an associated pathology report or a minimum of 16 formalin-fixed paraffin embedded (FFPE) slides is mandatory. If archival tissue block is exhausted or not available, then a tissue biopsy FFPE sample is required unless a biopsy is not medically feasible. Only tissue from a surgical resection or a core needle, punch, or excisional/incisional biopsy sample collection will be accepted. Fine needle aspiration (FNA) samples are not acceptable. • The participants in this study are frontline MUM patients. Participants are eligible for this trial if they are initially diagnosed with MUM or after therapy for localized UM that has subsequently metastasized. In both examples of eligible participants, confirmation of the metastatic pathology is needed to confirm MUM and not a second primary malignancy.","principalInclusionCriteriaTranslations":[{"id":12676550,"uuid":"3e74d057-845b-4322-9318-39430e1621b2","attributeTranslation":"6.\tBeschikken over een representatief archief van gemetastaseerde tumormonsters in paraffineblokken met een bijbehorend pathologie-rapport of een verplicht minimum van 17 in formaline gefixeerde, in paraffine ingebedde (FFPE) objectglaasjes. Als gearchiveerd weefselblokje is opgebruikt of niet beschikbaar is, is een weefselbiopt FFPE-monster vereist, tenzij een biopsie niet medisch uitvoerbaar is. Alleen weefsel van een chirurgische resectie of een kernnaald, punch of excisie/incisie-biopsie lichaamsmateriaalafname wordt geaccepteerd. Monsters van fijnenaaldaspiratie zijn niet aanvaardbaar.\n•\tDe deelnemers aan dit onderzoek zijn eerstelijns MUM-patiënten. Deelnemers zijn geschikt voor dit onderzoek als ze in eerste instantie met MUM zijn gediagnosticeerd of na behandeling voor lokale UM dat vervolgens is gemetastaseerd. Voor beide geschikte deelnemersgroepen is bevestiging van het gemetastaseerde ziektebeeld vereist, zodat MUM wordt bevestigd en niet een tweede primaire maligniteit.","language":18,"languageDescription":"Dutch"},{"id":12676549,"uuid":"3e74d057-845b-4322-9318-39430e1621b2","attributeTranslation":"6.\tAvoir un échantillon représentatif de tumeur métastatique archivé en blocs inclus en paraffine avec un rapport de pathologie associé, ou un minimum de 17 lames d’échantillons fixés au formol et inclus en paraffine (FFPE). Si le bloc de tissu archivé est épuisé ou indisponible, un échantillon FFPE de biopsie tissulaire sera nécessaire, sauf si une biopsie n’est pas médicalement réalisable. Seul du tissu provenant d’une résection chirurgicale ou d’un prélèvement d’échantillon par biopsie au trocart, à l’emporte-pièce ou par excision/incision sera accepté. Les échantillons par aspiration à l’aiguille fine  ne seront pas acceptés.\n•\tLes participants à cette étude sont des patients atteints d’un MUM en première ligne. Les participants sont éligibles à cet essai s’il ont reçu un diagnostic initial de MUM ou après un traitement pour un MUM localisé qui s’est ensuite métastasé. Dans les deux cas d'exemples de participants éligibles, la confirmation de la pathologie métastatique est nécessaire pour confirmer qu'il s'agit bien d'un MUM et non d'une seconde malignité primaire.","language":10,"languageDescription":"French"},{"id":12676548,"uuid":"3e74d057-845b-4322-9318-39430e1621b2","attributeTranslation":"6.\tEs obligatorio disponer de una muestra representativa de tumor metastásico de archivo en tacos de parafina con un informe anatomopatológico asociado o un mínimo de 17 portaobjetos fijados en formol e incluidos en parafina (FFIP). Si el taco de tejido de archivo se ha agotado o no está disponible, se necesita una muestra FFIP de biopsia del tejido, a menos que no sea médicamente viable una biopsia. Solo se aceptará tejido procedente de una resección quirúrgica o de una obtención de muestras mediante biopsia con aguja gruesa, en sacabocados o por excisión/incisión. No se aceptan muestras de biopsia por aspiración con aguja fina (BAAF).\n•\tLos participantes en este estudio son pacientes de primera línea con MUM. Los participantes son aptos para este ensayo si se les diagnostica inicialmente MUM o con MU que después de la terapia para MU localizado ha hecho metástasis. En ambos ejemplos de participantes aptos, la confirmación de la patología metastásica es necesaria para confirmar el MUM y no una segunda neoplasia maligna primaria.","language":7,"languageDescription":"Spanish"},{"id":12676546,"uuid":"3e74d057-845b-4322-9318-39430e1621b2","attributeTranslation":"6.\tDostępność reprezentatywnej archiwalnej próbki guza z przerzutami w bloczkach parafinowych wraz z raportem histopatologicznym lub co najmniej 17 szkiełek utrwalonych w formalinie i zatopionych w parafinie (FFPE). Jeśli archiwalny bloczek tkankowy jest wyczerpany lub niedostępny, wymagana jest biopsja tkanki FFPE, chyba że biopsja jest niemożliwa z medycznego punktu widzenia. Dopuszczalna będzie tylko tkanka z resekcji chirurgicznej lub z biopsji gruboigłowej, sztancowej lub wycięciowej/nacięciowej. Próbki z biopsji aspiracyjnej cienkoigłowej nie są akceptowane.\n•\tUczestnicy tego badania to pacjenci z MUM objęci leczeniem pierwszego rzutu. Do udziału w tym badaniu kwalifikują się uczestnicy z pierwotnym rozpoznaniem MUM albo po przebytym leczeniu miejscowej postaci choroby, która następnie uległa przerzutom. W przypadku obu tych grup kwalifikujących się uczestników konieczne jest potwierdzenie występowania przerzutowej zmiany patologicznej w celu potwierdzenia występowania MUM, a nie drugiego pierwotnego nowotworu złośliwego.","language":19,"languageDescription":"Polish"},{"id":12676545,"uuid":"3e74d057-845b-4322-9318-39430e1621b2","attributeTranslation":"6.\tDisponibilità di un campione rappresentativo di tumore metastatico conservato in archivio in blocchetti di paraffina con un referto patologico associato o di un minimo di 17 vetrini fissati in formalina e inclusi in paraffina (FFPE). Laddove il blocchetto di tessuto d’archivio sia esaurito o non disponibile, è richiesto un campione FFPE di tessuto bioptico, a meno che l’esecuzione di una biopsia sia clinicamente infattibile. Sarà accettato solo il tessuto ottenuto da una resezione chirurgica o da un campione prelevato mediante biopsia con ago tranciante, biopsia con bisturi circolare o biopsia escissionale/incisionale. Non sono ammessi campioni ottenuti mediante aspirazione con ago sottile. \n•\tI partecipanti in questo studio sono pazienti con MUM in prima linea. I partecipanti sono idonei a questa sperimentazione se hanno ricevuto inizialmente una diagnosi di MUM o dopo una terapia per UM localizzato con successive metastasi. In entrambi gli esempi di partecipanti idonei, la conferma di patologia metastatica è necessaria per la conferma del MUM e non di una seconda malignità primaria.","language":14,"languageDescription":"Italian"},{"id":12676547,"uuid":"3e74d057-845b-4322-9318-39430e1621b2","attributeTranslation":"6.\tEine repräsentative archivierte Probe des metastasierten Tumors in Paraffinblöcken mit einem zugehörigen Pathologiebericht oder mit mindestens 17 Objektträgern mit formalinfixiertem Paraffin (FFPE- Gewebe) ist obligatorisch. Wenn der archivierte Gewebeblock erschöpft oder nicht verfügbar ist, ist eine Gewebebiopsie für FFPE-Gewebe erforderlich, es sei denn, eine Biopsie ist medizinisch nicht durchführbar. Es wird nur Gewebe aus einer chirurgischen Resektion oder einer Kernnadel, einem Stanzpräparat oder einer Exzisions-\n/Inzisionsbiopsieprobe akzeptiert. Proben aus Feinnadelaspiration sind nicht akzeptabel.\n•\tDie Teilnehmer dieser Studie sind MUM-Patienten mit metastasiertem Aderhautmelanom. Teilnehmer sind für diese Studie geeignet, wenn bei ihnen zunächst ein metastasiertes Aderhautmelanom (MUM) diagnostiziert wird oder wenn bei ihnen ein lokalisiertes Aderhautmelanom (UM) therapiert wurde, das anschließend metastasiert hat. In beiden Beispielen geeigneter Teilnehmer ist die Bestätigung der metastatischen Pathologie erforderlich, um das Aderhautmelanom MUM und nicht ein zweites primäres Malignom zu bestätigen.","language":4,"languageDescription":"German"}]},{"id":1013268,"number":7,"principalInclusionCriteria":"Has measurable disease per RECIST v1.1, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥10 mm with computer tomography (CT) or magnetic resonance imaging (MRI) scan. An enlarged lymph node must be ≥15 mm in short axis to be a measurable lesion.","principalInclusionCriteriaTranslations":[{"id":12676554,"uuid":"6a924242-c9f2-44a3-8ed5-79a6ff56fc64","attributeTranslation":"7.\tPadecer enfermedad medible según RECIST 1.1, definida como al menos una lesión que se pueda medir con exactitud al menos en una dimensión (se registrará el diámetro más largo) como >=10 mm mediante tomografía axial computarizada (TAC) o resonancia magnética (RM). Las linfadenomegalias deben tener >=15 mm en el eje corto para ser lesiones medibles.","language":7,"languageDescription":"Spanish"},{"id":12676552,"uuid":"6a924242-c9f2-44a3-8ed5-79a6ff56fc64","attributeTranslation":"7.\tHebben meetbare ziekte volgens RECIST 1.1, gedefinieerd als ten minste één laesie die nauwkeurig kan worden gemeten in ten minste één dimensie (langste diameter registreren) als >=10 mm met computertomografie (CT) of magnetische resonantiebeeldvorming (MRI) scan. Een vergrote lymfeklier moet in de korte as >=15 mm zijn om een meetbaar letsel te zijn.","language":18,"languageDescription":"Dutch"},{"id":12676555,"uuid":"6a924242-c9f2-44a3-8ed5-79a6ff56fc64","attributeTranslation":"7.\tChoroba jest mierzalna według kryteriów RECIST 1.1, definiowana jako co najmniej jedna zmiana, którą można dokładnie zmierzyć w co najmniej jednym wymiarze (najdłuższa średnica, którą należy zapisać) jako >=10 mm za pomocą tomografii komputerowej (TK) lub obrazowania metodą rezonansu magnetycznego (MRI). Powiększony węzeł chłonny musi mieć >=15 mm w osi krótkiej, aby stanowił zmianę mierzalną.","language":19,"languageDescription":"Polish"},{"id":12676551,"uuid":"6a924242-c9f2-44a3-8ed5-79a6ff56fc64","attributeTranslation":"7.\tSie haben eine messbare Erkrankung gemäß RECIST 1.1, definiert als mindestens eine Läsion, die in mindestens einer Dimension (längster Durchmesser muss aufgezeichnet werden) >= 10 mm misst und mit Computertomografie (CT) oder Magnetresonanztomografie (MRT) genau gemessen werden kann. Ein vergrößerter Lymphknoten muss auf der kurzen Achse >= 15 mm messen, um als messbare Läsion zu gelten.","language":4,"languageDescription":"German"},{"id":12676556,"uuid":"6a924242-c9f2-44a3-8ed5-79a6ff56fc64","attributeTranslation":"7.\tPrésenter une maladie mesurable selon les critères RECIST 1.1, définie comme présentant au moins une lésion pouvant être mesurée avec précision dans au moins une dimension (diamètre le plus long enregistré), soit >=10 mm par tomodensitométrie (TDM) ou imagerie par résonance magnétique (IRM). Un ganglion lymphatique hypertrophié doit mesurer >= 15 mm sur son plus petit axe pour constituer une lésion mesurable.","language":10,"languageDescription":"French"},{"id":12676553,"uuid":"6a924242-c9f2-44a3-8ed5-79a6ff56fc64","attributeTranslation":"7.\tMalattia misurabile secondo i criteri RECIST 1.1, definita come presenza di almeno una lesione che possa essere accuratamente misurata in almeno una dimensione (deve essere registrato il diametro più lungo) come >=10 mm all’esame di tomografia computerizzata (TC) o risonanza magnetica (RM). Un linfonodo ingrossato deve presentare un asse corto >=15 mm per essere considerato una lesione misurabile.","language":14,"languageDescription":"Italian"}]},{"id":1013269,"number":8,"principalInclusionCriteria":"Able to be safely administered and absorb study therapy","principalInclusionCriteriaTranslations":[{"id":12676558,"uuid":"5a52a473-3766-4de6-929d-8d5ce5150f0f","attributeTranslation":"8.\tIn staat zijn om veilig te worden toegediend en de onderzoeksbehandeling te absorberen","language":18,"languageDescription":"Dutch"},{"id":12676559,"uuid":"5a52a473-3766-4de6-929d-8d5ce5150f0f","attributeTranslation":"8.\tDie Studientherapie muss beim Teilnehmer auf sichere Weise verabreichbar und verarbeitbar sein.","language":4,"languageDescription":"German"},{"id":12676560,"uuid":"5a52a473-3766-4de6-929d-8d5ce5150f0f","attributeTranslation":"8.\tPartecipante in grado di ricevere in modo sicuro e di assorbire la terapia dello studio.","language":14,"languageDescription":"Italian"},{"id":12676561,"uuid":"5a52a473-3766-4de6-929d-8d5ce5150f0f","attributeTranslation":"8.\tÊtre en mesure de recevoir en toute sécurité et d’absorber le traitement à l’étude.","language":10,"languageDescription":"French"},{"id":12676557,"uuid":"5a52a473-3766-4de6-929d-8d5ce5150f0f","attributeTranslation":"8.\tMożliwość bezpiecznego podawania i wchłaniania badanego leczenia","language":19,"languageDescription":"Polish"},{"id":12676562,"uuid":"5a52a473-3766-4de6-929d-8d5ce5150f0f","attributeTranslation":"8.\tSusceptible de que se le pueda administrar de forma segura el tratamiento del estudio y de absorberlo.","language":7,"languageDescription":"Spanish"}]},{"id":1013270,"number":9,"principalInclusionCriteria":"Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.","principalInclusionCriteriaTranslations":[{"id":12676566,"uuid":"281608ff-dcad-4f22-a2c2-9cd01a97b6cf","attributeTranslation":"9.\tPresentar un estado funcional de 0 o 1 según la escala del Grupo Oncológico Cooperativo de la Costa Este (ECOG).","language":7,"languageDescription":"Spanish"},{"id":12676565,"uuid":"281608ff-dcad-4f22-a2c2-9cd01a97b6cf","attributeTranslation":"9.\tStato di validità secondo il Gruppo orientale cooperativo di oncologia (ECOG) pari a 0 o 1.","language":14,"languageDescription":"Italian"},{"id":12676568,"uuid":"281608ff-dcad-4f22-a2c2-9cd01a97b6cf","attributeTranslation":"9.\tAvoir un statut de performance ECOG de 0 ou 1.","language":10,"languageDescription":"French"},{"id":12676563,"uuid":"281608ff-dcad-4f22-a2c2-9cd01a97b6cf","attributeTranslation":"9.\tOcena stanu pacjenta w skali ECOG równa 0 lub 1","language":19,"languageDescription":"Polish"},{"id":12676564,"uuid":"281608ff-dcad-4f22-a2c2-9cd01a97b6cf","attributeTranslation":"9. Sie haben einen ECOG-Leistungsstatus von 0 oder 1.","language":4,"languageDescription":"German"},{"id":12676567,"uuid":"281608ff-dcad-4f22-a2c2-9cd01a97b6cf","attributeTranslation":"9.\tHebben ECOG performance status 0 of 1.","language":18,"languageDescription":"Dutch"}]}],"principalExclusionCriteria":[{"id":1728918,"number":1,"principalExclusionCriteria":"1. Has received previous treatment with a PKC inhibitor (including prior treatment with IDE196), an inhibitor directly targeting MET, or an inhibitor directly targeting GNAQ/11.","principalExclusionCriteriaTranslations":[{"id":12676359,"uuid":"3fc98ac8-614c-4cda-9acc-5bf06235693f","attributeTranslation":"1.\tWcześniejsze leczenie inhibitorem PKC (w tym wcześniejsze leczenie IDE196) lub inhibitorem bezpośrednio ukierunkowanym na MET lub inhibitorem bezpośrednio ukierunkowanym na GNAQ/11.","language":19,"languageDescription":"Polish"},{"id":12676357,"uuid":"3fc98ac8-614c-4cda-9acc-5bf06235693f","attributeTranslation":"1.\tHaber recibido tratamiento previo con inhibidores de PKC (incluidos los tratamientos previos con IDE196) o inhibidores dirigidos directamente a MET, o inhibidores dirigidos directamente a GNAQ/11.","language":7,"languageDescription":"Spanish"},{"id":12676358,"uuid":"3fc98ac8-614c-4cda-9acc-5bf06235693f","attributeTranslation":"1.\tAvoir reçu un traitement antérieur par un inhibiteur de la PKC (dont un traitement antérieur par IDE196) ou un inhibiteur ciblant directement la MET, ou un inhibiteur ciblant directement le GNAQ/11.","language":10,"languageDescription":"French"},{"id":12676361,"uuid":"3fc98ac8-614c-4cda-9acc-5bf06235693f","attributeTranslation":"1.\tWerd eerder behandeld met een PKC-remmer (inclusief eerdere behandeling met IDE196) of een remmer die zich direct richt op MET, of een remmer die zich direct richt op GNAQ/11.","language":18,"languageDescription":"Dutch"},{"id":12676360,"uuid":"3fc98ac8-614c-4cda-9acc-5bf06235693f","attributeTranslation":"1.\tVorbehandlung mit einem PKC-Inhibitor (einschließlich vorheriger Behandlung mit IDE196) oder einem Inhibitor erhalten, der direkt auf MET oder auf GNAQ/11 abzielt.","language":4,"languageDescription":"German"},{"id":12676356,"uuid":"3fc98ac8-614c-4cda-9acc-5bf06235693f","attributeTranslation":"1.\tPrecedente trattamento con un inibitore di PKC (incluso il precedente trattamento con IDE196) o un inibitore mirato direttamente a MET o un inibitore mirato direttamente a GNAQ/11.","language":14,"languageDescription":"Italian"}]},{"id":1728919,"number":10,"principalExclusionCriteria":"18. Has an allergy to mammalian meat products or gelatin.","principalExclusionCriteriaTranslations":[{"id":12676365,"uuid":"23fe2444-fab6-4aa8-976a-0496140b7480","attributeTranslation":"18.\tUczulenie na produkty mięsne ssaków lub żelatynę.","language":19,"languageDescription":"Polish"},{"id":12676366,"uuid":"23fe2444-fab6-4aa8-976a-0496140b7480","attributeTranslation":"18.\tAllergie auf Fleischprodukte oder Gelatine von Säugetieren.","language":4,"languageDescription":"German"},{"id":12676364,"uuid":"23fe2444-fab6-4aa8-976a-0496140b7480","attributeTranslation":"18.\tTener alergia a productos derivados de la carne de mamíferos o la gelatina","language":7,"languageDescription":"Spanish"},{"id":12676367,"uuid":"23fe2444-fab6-4aa8-976a-0496140b7480","attributeTranslation":"18.\tÊtre allergique aux produits à base de viande ou de gélatine de mammifères.","language":10,"languageDescription":"French"},{"id":12676363,"uuid":"23fe2444-fab6-4aa8-976a-0496140b7480","attributeTranslation":"18.\tAllergia ai prodotti a base di carne di mammifero o alla gelatina.","language":14,"languageDescription":"Italian"},{"id":12676362,"uuid":"23fe2444-fab6-4aa8-976a-0496140b7480","attributeTranslation":"18.\tHeeft een allergie voor vleesproducten of gelatine afkomstig van zoogdieren","language":18,"languageDescription":"Dutch"}]},{"id":1728920,"number":11,"principalExclusionCriteria":"19. Contraindication for treatment with investigator’s choice alternatives (dacarbazine, ipilimumab + nivolumab, and pembrolizumab) as per applicable labelling. Participants may have a contraindication to one or two of the choices if he/she is a candidate for dosing with at least one investigator’s choice and meets all other study eligibility criteria. Choice of dacarbazine should only be made in the setting where treatment with immunotherapy is deemed likely to result in irreversible serious (or life threatening) AEs (e.g., severe active autoimmune disease requiring potent immunosuppression) and must be discussed with the Sponsor Medical Monitor.","principalExclusionCriteriaTranslations":[{"id":12676368,"uuid":"19f787e3-bd3f-4314-a625-424ab35674c5","attributeTranslation":"19.\tContre-indication aux traitements choisis par l’investigateur (dacarbazine, ipilimumab + nivolumab, et pembrolizumab) conformément à l’étiquetage correspondant. Les participants pourront présenter une contre-indication à un ou deux des choix s’ils sont candidats à l’administration d’au moins un traitement choisi par l’investigateur et s’ils répondent à tous les autres critères d’éligibilité de l’étude. Le choix de la dacarbazine ne devra être fait que si un traitement par immunothérapie est considéré comme susceptible d’entraîner des EI graves (ou mettant en jeu le pronostic vital) et irréversibles (p. ex., maladie auto-immune active sévère nécessitant une immunosuppression puissante) et devra faire l’objet d’une discussion avec le moniteur médical du promoteur.","language":10,"languageDescription":"French"},{"id":12676372,"uuid":"19f787e3-bd3f-4314-a625-424ab35674c5","attributeTranslation":"19.\tContraindicación para el tratamiento con las alternativas de elección del investigador (dacarbazina, ipilimumab+nivolumab y pembrolizumab), según la ficha técnica pertinente. Los participantes pueden tener una contraindicación para una o dos de las opciones si son candidatos para la administración de al menos una elección del investigador, y si cumplen todos los demás criterios de aptitud del estudio. La elección de dacarbazina solo debe realizarse en caso de que se considere que el tratamiento con inmunoterapia sea probable que provoque AA graves (o potencialmente mortales) irreversibles (p. ej., enfermedad autoinmunitaria activa grave que requiera inmunodepresión potente), y debe comentarse con el monitor clínico del promotor.","language":7,"languageDescription":"Spanish"},{"id":12676369,"uuid":"19f787e3-bd3f-4314-a625-424ab35674c5","attributeTranslation":"19.\tPrzeciwwskazania do leczenia z wykorzystaniem alternatywnych opcji wyboru przez badacza (dakarbazyna, ipilimumab + niwolumab i pembrolizumab) zgodnie z obowiązującymi wskazaniami. Uczestnicy mogą mieć przeciwwskazania do jednej lub dwóch opcji, jeśli są kandydatami do dawkowania z co najmniej jednym wyborem badacza i spełniają wszystkie pozostałe kryteria kwalifikacyjne badania. Wyboru dakarbazyny należy dokonać tylko w przypadku, gdy leczenie immunoterapią uznaje się za prawdopodobnie prowadzące do nieodwracalnych ciężkich (lub zagrażających życiu) AE (np. ciężkiej aktywnej choroby autoimmunologicznej wymagającej silnej immunosupresji) i ten wybór należy omówić z monitorem medycznym Sponsora.","language":19,"languageDescription":"Polish"},{"id":12676370,"uuid":"19f787e3-bd3f-4314-a625-424ab35674c5","attributeTranslation":"19.\tPresenza di controindicazioni al trattamento con le alternative scelte dallo sperimentatore (dacarbazina, ipilimumab + nivolumab e pembrolizumab) in base all’etichettatura in vigore. I partecipanti possono presentare controindicazioni a una o due delle scelte se sono candidati al trattamento con almeno una scelta dello sperimentatore e soddisfano tutti gli altri criteri di eleggibilità dello studio. La dacarbazina deve essere scelta solo nel caso in cui il trattamento con immunoterapia sia ritenuto poter causare EA seri (o pericolosi per la vita) irreversibili (per es., malattia autoimmune grave in fase attiva con necessità di potente immunosoppressione) e la scelta va discussa con il medical monitor dello sponsor.","language":14,"languageDescription":"Italian"},{"id":12676373,"uuid":"19f787e3-bd3f-4314-a625-424ab35674c5","attributeTranslation":"19.\tKontraindikation für die Behandlung mit Alternativen nach Wahl des Prüfarztes (Dacarbazin, Ipilimumab + Nivolumab und Pembrolizumab) gemäß geltender Kennzeichnung. Die Teilnehmer können eine Kontraindikation für eine oder zwei der Auswahlmöglichkeiten haben, wenn sie für die Behandlung mit mindestens einer Wahl des Prüfarztes infrage kommen und alle anderen Eignungskriterien für die Studie erfüllen. Die Wahl von Dacarbazin sollte nur dann getroffen werden, wenn die Behandlung mit einer Immuntherapie wahrscheinlich zu irreversiblen schwerwiegenden (oder lebensbedrohlichen) UE führen würde (z. B. schwere aktive Autoimmunerkrankung, die eine starke Immunsuppression erfordert); dies ist mit dem Medical Monitor des Sponsors zu besprechen.","language":4,"languageDescription":"German"},{"id":12676371,"uuid":"19f787e3-bd3f-4314-a625-424ab35674c5","attributeTranslation":"19.\tContra-indicatie voor behandeling met alternatieven naar keuze van de onderzoeker (dacarbazine, ipilimumab + nivolumab en pembrolizumab) volgens de toepasselijke etikettering. Deelnemers kunnen een contra- indicatie hebben voor een of twee van de keuzes als hij/zij een kandidaat is voor dosering met ten minste één keuze van de onderzoeker en voldoet aan alle andere geschiktheidscriteria voor het onderzoek. De keuze van dacarbazine mag alleen worden gemaakt in de setting waarin behandeling met immunotherapie waarschijnlijk leidt tot onomkeerbare ernstige (of levensbedreigende) AE’s (bijv. ernstige actieve auto-immuunziekte die krachtige immunosuppressie vereist) en moet worden besproken met de medische monitor van de opdrachtgever.","language":18,"languageDescription":"Dutch"}]},{"id":1728921,"number":12,"principalExclusionCriteria":"2. Malignant disease, other than that being treated in this study. Exceptions to this exclusion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers; any malignancy considered to be indolent and that has never required therapy; and completely resected carcinoma in situ of any type.","principalExclusionCriteriaTranslations":[{"id":12676378,"uuid":"a59e5ada-2955-49d0-96e2-84d69f464f9e","attributeTranslation":"2.\tMaladie maligne, autre que celle traitée dans cette étude. Les exceptions à cette exclusion comprennent : tumeurs malignes qui ont été traitées de manière curative et n’ont pas récidivé dans les 2 ans précédant le traitement à l’étude ; cancers de la peau basocellulaires et épidermoïdes entièrement réséqués ; toute tumeur maligne considérée comme indolente et n’ayant jamais nécessité de traitement ; et carcinome in situ de tout type entièrement réséqué.","language":10,"languageDescription":"French"},{"id":12676374,"uuid":"a59e5ada-2955-49d0-96e2-84d69f464f9e","attributeTranslation":"2.\tMaligne ziekte, anders dan die in dit onderzoek wordt behandeld. Uitzonderingen op deze uitsluiting zijn onder meer: maligniteiten die curatief zijn behandeld en niet zijn teruggekomen binnen 2 jaar voorafgaand aan de onderzoeksbehandeling; volledig gereseceerde basaalcel- en plaveiselcelkankers van de huid; elke maligniteit die als indolent wordt beschouwd en die nooit behandeling nodig had; en volledig gereseceerd carcinoom in situ van welk type dan ook.","language":18,"languageDescription":"Dutch"},{"id":12676376,"uuid":"a59e5ada-2955-49d0-96e2-84d69f464f9e","attributeTranslation":"2.\tChoroba nowotworowa, inna niż leczona w tym badaniu. Wyjątkami od tego wyłączenia są: nowotwory złośliwe, które został wyleczone i nie nawracały w ciągu 2 lat przed leczeniem w ramach badania; całkowicie wycięte podstawnokomórkowe i płaskonabłonkowe nowotwory skóry; wszelkie nowotwory złośliwe uznawane za powolne i które nigdy nie wymagały leczenia; oraz całkowicie wycięty rak in situ dowolnego rodzaju.","language":19,"languageDescription":"Polish"},{"id":12676377,"uuid":"a59e5ada-2955-49d0-96e2-84d69f464f9e","attributeTranslation":"2.\tNeoplasia maligna distinta de la que se trata en este estudio. Las excepciones a esta exclusión son, entre otras: neoplasias malignas tratadas de forma curativa que no hayan reaparecido en los 2 años anteriores al tratamiento del estudio; carcinoma de piel epidermoide y basocelular resecado íntegramente; cualquier neoplasia maligna considerada de escasa malignidad que nunca haya necesitado tratamiento; y carcinoma in situ de cualquier tipo resecado íntegramente.","language":7,"languageDescription":"Spanish"},{"id":12676375,"uuid":"a59e5ada-2955-49d0-96e2-84d69f464f9e","attributeTranslation":"2.\tEine sonstige maligne Erkrankung, die nicht in dieser Studie behandelt wird. Ausnahmen von diesem Ausschlusskriterium sind: Malignome, die kurativ behandelt wurden und innerhalb von 2 Jahren vor der Studienbehandlung nicht erneut aufgetreten sind; vollständig resezierte Basalzell- und Plattenepithelkarzinome der Haut; jegliche Malignome, die als indolent angesehen werden und die nie eine Therapie erfordert haben; sowie ein vollständig reseziertes Carcinoma in situ jeglicher Art.","language":4,"languageDescription":"German"},{"id":12676379,"uuid":"a59e5ada-2955-49d0-96e2-84d69f464f9e","attributeTranslation":"2.\tMalattia neoplastica diversa da quella trattata nell’ambito di questo studio. Le eccezioni a questo criterio di esclusione includono: neoplasie che siano state trattate in modo curativo e non abbiano recidivato nei 2 anni precedenti il trattamento dello studio; tumori cutanei basocellulari e squamocellulari sottoposti a resezione completa; qualsiasi neoplasia considerata indolente e che non abbia mai richiesto una terapia; e carcinoma in situ di qualsiasi tipo sottoposto a resezione completa.","language":14,"languageDescription":"Italian"}]},{"id":1728922,"number":13,"principalExclusionCriteria":"20. History of stroke within the last 6 months of the first dose of study drug.","principalExclusionCriteriaTranslations":[{"id":12676380,"uuid":"f25dfe5f-4316-444c-a619-b615f61e558d","attributeTranslation":"20.\tAnamnesi di ictus nei 6 mesi precedenti la prima dose del farmaco dello studio.","language":14,"languageDescription":"Italian"},{"id":12676382,"uuid":"f25dfe5f-4316-444c-a619-b615f61e558d","attributeTranslation":"20.\tAntecedentes de accidente cerebrovascular en los últimos 6 meses antes de la primera dosis del fármaco del estudio.","language":7,"languageDescription":"Spanish"},{"id":12676383,"uuid":"f25dfe5f-4316-444c-a619-b615f61e558d","attributeTranslation":"20.\tVoorgeschiedenis van beroerte in de 6 maanden vóór de eerste dosis onderzoeksgeneesmiddel.","language":18,"languageDescription":"Dutch"},{"id":12676385,"uuid":"f25dfe5f-4316-444c-a619-b615f61e558d","attributeTranslation":"20.\tVorgeschichte von Schlaganfall innerhalb der letzten 6 Monate vor der ersten Dosis der Studienbehandlung.","language":4,"languageDescription":"German"},{"id":12676381,"uuid":"f25dfe5f-4316-444c-a619-b615f61e558d","attributeTranslation":"20.\tAntécédents d’accident vasculaire cérébral au cours des 6 derniers mois précédant la première dose du médicament à l’étude.","language":10,"languageDescription":"French"},{"id":12676384,"uuid":"f25dfe5f-4316-444c-a619-b615f61e558d","attributeTranslation":"20.\tUdar mózgu w wywiadzie w okresie ostatnich 6 miesięcy przed podaniem pierwszej dawki badanego leku.","language":19,"languageDescription":"Polish"}]},{"id":1728923,"number":14,"principalExclusionCriteria":"3. Has AEs from prior anti-cancer therapy that have not resolved to Grade ≤1 except for alopecia or anemia: • Any ongoing diarrhea requires discussion with the Sponsor Medical Monitor • Endocrinopathies resulting from previous immunotherapy are considered part of medical history and not an AE • Stable Grade 2 neuropathy is allowed","principalExclusionCriteriaTranslations":[{"id":12676386,"uuid":"1515384d-1185-42e9-8ada-b72b03b6bea6","attributeTranslation":"3.\tU uczestnika występują zdarzenia niepożądane związane z wcześniejszą terapią przeciwnowotworową, z brakiem poprawy do 1. stopnia <=, z wyjątkiem łysienia lub niedokrwistości.\n•\tKażda utrzymująca się biegunka wymaga omówienia z monitorem medycznym sponsora\n•\tEndokrynopatie wynikające z wcześniejszej immunoterapii uznaje się za część wywiadu medycznego, a nie AE.\n•\tDopuszczalna jest stabilna neuropatia stopnia 2.","language":19,"languageDescription":"Polish"},{"id":12676390,"uuid":"1515384d-1185-42e9-8ada-b72b03b6bea6","attributeTranslation":"3.\tHaber experimentado AA con tratamientos antineoplásicos anteriores que no se hayan resuelto a grado <=1, excepto alopecia o anemia.\n•\tCualquier diarrea en curso requiere consultar con el monitor clínico del promotor.\n•\tLas endocrinopatías resultantes de inmunoterapias previas se consideran parte de los antecedentes médicos, y no AA.\n•\tSe permiten neuropatías estables de grado 2","language":7,"languageDescription":"Spanish"},{"id":12676391,"uuid":"1515384d-1185-42e9-8ada-b72b03b6bea6","attributeTranslation":"3.\tPrésenter des EI dus à un traitement anticancéreux antérieur qui ne sont pas revenus à un grade <= 1, à l’exception d’une alopécie ou d’une anémie.\n•\tToute diarrhée en cours nécessite une discussion avec le moniteur médical du promoteur.\n•\tLes endocrinopathies résultant d’une immunothérapie antérieure sont considérées comme faisant partie des antécédents médicaux et non pas comme des EI.\n•\tUne neuropathie de grade 2 stable est autorisée.","language":10,"languageDescription":"French"},{"id":12676388,"uuid":"1515384d-1185-42e9-8ada-b72b03b6bea6","attributeTranslation":"3.\tHeeft bijwerkingen van eerdere antikankertherapie die niet zijn verdwenen tot graad <=1, behalve alopecia of anemie.\n•\tElke aanhoudende diarree vereist overleg met de medische monitor van de opdrachtgever\n•\tEndocrinopathieën als gevolg van eerdere immunotherapie worden beschouwd als onderdeel van de medische voorgeschiedenis en niet als een AE.\n•\tStabiele neuropathie graad 2 is toegestaan","language":18,"languageDescription":"Dutch"},{"id":12676389,"uuid":"1515384d-1185-42e9-8ada-b72b03b6bea6","attributeTranslation":"3.\tEin UE aufgrund einer früheren Krebstherapie, das nicht auf <= Grad 1 abgeklungen ist, mit Ausnahme von Alopezie oder Anämie.\n•\tJeder anhaltende Durchfall muss mit dem Medical Monitor des Sponsors besprochen werden\n•\tEndokrinopathien infolge einer früheren Immuntherapie gelten als Teil der Krankengeschichte und nicht als UE\n•\tEine stabile Neuropathie von Grad 2 ist zulässig","language":4,"languageDescription":"German"},{"id":12676387,"uuid":"1515384d-1185-42e9-8ada-b72b03b6bea6","attributeTranslation":"3.\tPresenza di EA correlati a una precedente terapia antitumorale che non si sono risolti a un grado <=1, eccetto alopecia o anemia.\n•\tUn’eventuale diarrea in corso dovrà essere discussa con il medical monitor dello sponsor.\n•\tLe endocrinopatie conseguenti a una precedente immunoterapia sono considerate parte dell’anamnesi medica, e non un EA.\n•\tSono ammessi partecipanti con neuropatia di grado 2 stabile.","language":14,"languageDescription":"Italian"}]},{"id":1728924,"number":15,"principalExclusionCriteria":"4. Presence of symptomatic or untreated central nervous system (CNS) metastases, or CNS metastases that require doses of corticosteroids within the prior 3 weeks to study Day 1. Participants with brain metastases are eligible if lesions have been treated with localized therapy and there is no evidence of progression for at least 4 weeks by MRI prior to the first dose of study drug.","principalExclusionCriteriaTranslations":[{"id":12676392,"uuid":"6c2d5875-b594-408d-a718-4d505d3f00e3","attributeTranslation":"4.\tPresencia de metástasis en el sistema nervioso central (SNC) sintomáticas o sin tratar, o metástasis en el SNC que requieran dosis de corticoesteroides en las 3 semanas anteriores al día 1 del estudio. Los participantes con metástasis cerebrales serán aptos si las lesiones se han tratado de forma localizada y no hay indicios de progresión durante al menos 4 semanas según una RM antes de la primera dosis del fármaco del estudio.","language":7,"languageDescription":"Spanish"},{"id":12676395,"uuid":"6c2d5875-b594-408d-a718-4d505d3f00e3","attributeTranslation":"4.\tObecność objawowych lub nieleczonych przerzutów do ośrodkowego układu nerwowego (OUN) lub przerzutów do OUN, które wymagają podania dawek kortykosteroidów w ciągu ostatnich 3 tygodni do Dnia 1 badania. Uczestnicy z przerzutami do mózgu kwalifikują się do udziału w badaniu, jeżeli zmiany były leczone miejscową terapią i nie stwierdzono progresji choroby przez co najmniej 4 tygodnie w badaniu MRI przed podaniem pierwszej dawki badanego leku","language":19,"languageDescription":"Polish"},{"id":12676396,"uuid":"6c2d5875-b594-408d-a718-4d505d3f00e3","attributeTranslation":"4.\tPresenza di metastasi del sistema nervoso centrale (SNC) sintomatiche o non trattate o di metastasi del SNC che richiedono dosi di corticosteroidi nelle 3 settimane precedenti il Giorno 1 dello studio. I partecipanti con metastasi cerebrali sono considerati idonei se le lesioni sono state trattate con terapia locale e non vi è evidenza di progressione alla RM per almeno 4 settimane prima della prima dose di farmaco dello studio.","language":14,"languageDescription":"Italian"},{"id":12676393,"uuid":"6c2d5875-b594-408d-a718-4d505d3f00e3","attributeTranslation":"4.\tPrésence de métastases symptomatiques ou non traitées dans le système nerveux central (SNC), ou de métastases dans le SNC nécessitant des doses de corticoïdes au cours des 3 semaines précédant le Jour 1 de l’étude. Les participants présentant des métastases cérébrales seront éligibles si les lésions ont été traitées par un traitement localisé et s’il n’y a pas de preuve de progression par IRM pendant au moins 4 semaines avant la première dose du médicament à l’étude.","language":10,"languageDescription":"French"},{"id":12676394,"uuid":"6c2d5875-b594-408d-a718-4d505d3f00e3","attributeTranslation":"4.\tAanwezigheid van symptomatische of onbehandelde metastasen in het centrale zenuwstelsel (CZS) of metastasen in het CZS die doses corticosteroïden vereisen binnen de voorafgaande 3 weken tot onderzoeksdag 1. Deelnemers met hersenmetastasen komen in aanmerking als laesies zijn behandeld met gelokaliseerde therapie en er geen bewijs is van progressie gedurende ten minste 4 weken door MRI voorafgaand aan de eerste dosis onderzoeksgeneesmiddel.","language":18,"languageDescription":"Dutch"},{"id":12676397,"uuid":"6c2d5875-b594-408d-a718-4d505d3f00e3","attributeTranslation":"4.\tVorhandensein von symptomatischen oder unbehandelten Metastasen im Zentralnervensystem (ZNS) oder von ZNS-Metastasen, die innerhalb der 3 Wochen vor dem ersten Studientag Kortikosteroide erfordern. Teilnehmer mit Hirnmetastasen sind geeignet, wenn Läsionen mit einer lokalisierten Therapie behandelt wurden und es für mindestens 4 Wochen vor der ersten Studienbehandlung keine MRT-Nachweise einer Progression gibt.","language":4,"languageDescription":"German"}]},{"id":1728925,"number":16,"principalExclusionCriteria":"5. Known acquired immunodeficiency syndrome (AIDS)-related illness. NOTE: Human immunodeficiency virus (HIV) seropositive participants who are healthy and low risk for AIDS related outcomes could be considered eligible. Eligibility criteria for HIV positive participants should be evaluated and discussed with Sponsor Medical Monitor and will be based on current and past cluster of differentiation 4 (CD4) and T cell counts, history (if any) of AIDS defining conditions (e.g., opportunistic infections), and status of HIV treatment. Also, the potential for drug-drug interactions (DDI) should be taken into consideration.","principalExclusionCriteriaTranslations":[{"id":12676403,"uuid":"cc37bae4-be2c-4a39-adb0-f7839b88b2f4","attributeTranslation":"5.\tRozpoznana choroba związana z zespołem nabytego niedoboru odporności (AIDS). UWAGA: uczestnicy z dodatnim wynikiem badania na obecność ludzkiego wirusa niedoboru odporności (HIV), którzy są zdrowi i mają niskie ryzyko wystąpienia objawów związanych z AIDS, mogą zostać uznani za kwalifikujących się do udziału w badaniu. Kryteria kwalifikacyjne dla uczestników z dodatnim wynikiem badania na obecność wirusa HIV należy ocenić i omówić z monitorem medycznym Sponsora i będą one oparte na obecnej i wcześniejszej wartości (CD4 i liczbie limfocytów T, wywiadzie (jeśli dotyczy) chorób definiujących AIDS (np. zakażenia oportunistyczne) oraz statusie leczenia HIV. Należy również wziąć pod uwagę możliwość wystąpienia interakcji między lekami (DDI).","language":19,"languageDescription":"Polish"},{"id":12676401,"uuid":"cc37bae4-be2c-4a39-adb0-f7839b88b2f4","attributeTranslation":"5.\tEine bekannte Erkrankung im Zusammenhang mit AIDS. HINWEIS: Seropositive Teilnehmer mit HIV, die gesund sind und ein geringes Risiko für AIDS-bedingte Ergebnisse aufweisen, könnten als geeignet angesehen werden. Die Eignungskriterien für HIV-positive Teilnehmer müssen mit dem Medical Monitor des Sponsors beurteilt und besprochen werden und basieren auf aktuellen und früheren CD4- (cluster of differentiation 4) und T-Zellzahlen, den AIDS-definierenden Erkrankungen (falls vorhanden) in der Vorgeschichte (z. B. opportunistische Infektionen) und dem Status der HIV-Behandlung. Außerdem ist das Potenzial für (unerwünschte) Arzneimittelwechselwirkungen (DDI – drug-drug interactions) zu berücksichtigen.","language":4,"languageDescription":"German"},{"id":12676402,"uuid":"cc37bae4-be2c-4a39-adb0-f7839b88b2f4","attributeTranslation":"5.\tConnaissance d’une maladie liée au syndrome d’immunodéficience acquise (SIDA). REMARQUE : les participants séropositifs au virus de l’immunodéficience humaine (VIH) qui sont en bonne santé et présentent un faible risque d’issue liée au SIDA pourraient être considérés comme éligibles. Les critères d’éligibilité pour les participants séropositifs au VIH devront être évalués et faire l’objet d’une discussion avec le moniteur médical du promoteur et seront basés sur le cluster de différenciation 4 (CD4) et le nombre de lymphocytes T passés et actuels, les antécédents (le cas échéant) d’affections définissant le SIDA (p. ex., infections opportunistes) et le statut du traitement du VIH. En outre, le potentiel d’interactions médicamenteuses (PIM) devra être pris en compte.","language":10,"languageDescription":"French"},{"id":12676399,"uuid":"cc37bae4-be2c-4a39-adb0-f7839b88b2f4","attributeTranslation":"5.\tMalattia nota correlata alla sindrome da immunodeficienza acquisita (AIDS). NOTA: i partecipanti sieropositivi al virus dell’immunodeficienza umana (HIV) che siano in salute e presentino un basso rischio di esiti correlati all’AIDS potrebbero essere considerati idonei. I criteri di eleggibilità per i partecipanti HIV-positivi vanno valutati e discussi con il medical monitor dello sponsor e si baseranno sulle conte attuali e pregresse delle cellule CD4 (cluster di differenziazione 4) e T, sull’anamnesi (se presente) di condizioni diagnostiche di AIDS (per es., infezioni opportunistiche) e sullo stato del trattamento per l’HIV. Dovrà inoltre essere tenuto in considerazione il potenziale di interazioni farmacologiche (DDI).","language":14,"languageDescription":"Italian"},{"id":12676398,"uuid":"cc37bae4-be2c-4a39-adb0-f7839b88b2f4","attributeTranslation":"5.\tBekende ziekte gerelateerd aan het verworven immunodeficiëntiesyndroom (AIDS). OPMERKING: seropositieve deelnemers met humaan immunodeficiëntievirus (hiv) die gezond zijn en een laag risico hebben op AIDS-gerelateerde resultaten, kunnen als geschikt worden beschouwd. De geschiktheidscriteria voor hiv-positieve deelnemers moeten worden beoordeeld en besproken met de medische monitor van de opdrachtgever en worden gebaseerd op het huidige en eerdere cluster van differentiatie 4 (CD4) en T-celtellingen, voorgeschiedenis (indien van toepassing) van door AIDS gedefinieerde aandoeningen (bijv. opportunistische infecties) en status van hiv-behandeling. Ook moet rekening worden gehouden met de mogelijkheid van interacties tussen geneesmiddelen.","language":18,"languageDescription":"Dutch"},{"id":12676400,"uuid":"cc37bae4-be2c-4a39-adb0-f7839b88b2f4","attributeTranslation":"5.\tEnfermedad conocida relacionada con el síndrome de inmunodeficiencia adquirida (SIDA). NOTA: Los participantes seropositivos para el virus de la inmunodeficiencia humana (VIH) que estén sanos y presenten un bajo riesgo de consecuencias relacionadas con el SIDA podrían considerarse aptos. Los criterios de aptitud para los participantes positivos para VIH deben evaluarse y comentarse con el monitor clínico del promotor, y se basarán en las cifras en curso y pasadas de linfocitos T y del grupo de diferenciación 4 (CD4), en los antecedentes (si los hubiera) de afecciones definitorias del SIDA (p. ej., infecciones oportunistas) y en el estado del tratamiento contra el VIH. Además, debe tenerse en cuenta el potencial de interacciones farmacológicas (IF).","language":7,"languageDescription":"Spanish"}]},{"id":1728926,"number":17,"principalExclusionCriteria":"6. Active adrenal insufficiency (e.g., not stable on replacement therapy), active colitis, or active inflammatory bowel disease.","principalExclusionCriteriaTranslations":[{"id":12676405,"uuid":"9744d4e0-2693-4772-891b-5a83c2aca738","attributeTranslation":"6.\tInsuficiencia suprarrenal activa (p. ej., inestabilidad con tratamientos de reposición), colitis activa o enfermedad inflamatoria intestinal activa.","language":7,"languageDescription":"Spanish"},{"id":12676406,"uuid":"9744d4e0-2693-4772-891b-5a83c2aca738","attributeTranslation":"6.\tActieve bijnierinsufficiëntie (bijv. niet stabiel bij vervangingstherapie), actieve colitis of ontstekingsziekte van de darm.","language":18,"languageDescription":"Dutch"},{"id":12676409,"uuid":"9744d4e0-2693-4772-891b-5a83c2aca738","attributeTranslation":"6.\tInsufficienza surrenalica attiva (per es., non stabile in corso di terapia sostitutiva), colite attiva o malattia infiammatoria intestinale attiva.","language":14,"languageDescription":"Italian"},{"id":12676404,"uuid":"9744d4e0-2693-4772-891b-5a83c2aca738","attributeTranslation":"6.\tInsuffisance surrénalienne active (p. ex., non stable sous traitement substitutif), colite active ou maladie intestinale inflammatoire active.","language":10,"languageDescription":"French"},{"id":12676407,"uuid":"9744d4e0-2693-4772-891b-5a83c2aca738","attributeTranslation":"6.\tCzynna niewydolność kory nadnerczy (np. niestabilna przy terapii zastępczej), czynne zapalenie jelita grubego lub czynna choroba zapalna jelit.","language":19,"languageDescription":"Polish"},{"id":12676408,"uuid":"9744d4e0-2693-4772-891b-5a83c2aca738","attributeTranslation":"6.\tAktive Nebenniereninsuffizienz (d. h. ohne Stabilität unter einer Substitutionstherapie), aktive Kolitis oder aktive entzündliche Darmerkrankung.","language":4,"languageDescription":"German"}]},{"id":1728927,"number":18,"principalExclusionCriteria":"7. History of interstitial lung disease, active pneumonitis, or history of pneumonitis from prior therapies requiring corticosteroid treatment. However, history of Grade 1 only pneumonitis OR prior radiation pneumonitis can be discussed with the Medical Monitor for consideration of inclusion.","principalExclusionCriteriaTranslations":[{"id":12676413,"uuid":"7a7f0c81-9266-4ab0-8dd6-114d34cec8f4","attributeTranslation":"7.\tInterstitielle Lungenerkrankung in der Vorgeschichte, aktive Pneumonitis oder eine Pneumonitis infolge früherer Therapien, die eine Kortikosteroidbehandlung erforderten, in der Vorgeschichte. Eine Pneumonitis von Grad 1 in der Vorgeschichte ODER eine vorherige Strahlenpneumonitis kann bezüglich Berücksichtigung mit dem Medical Monitor besprochen werden.","language":4,"languageDescription":"German"},{"id":12676411,"uuid":"7a7f0c81-9266-4ab0-8dd6-114d34cec8f4","attributeTranslation":"7.\tAntécédents de maladie pulmonaire interstitielle, de pneumopathie inflammatoire active ou antécédents de pneumopathie inflammatoire résultant de traitements antérieurs nécessitant un traitement par corticoïdes. Cependant, les antécédents de pneumopathie inflammatoire de grade 1 uniquement OU de pneumopathie inflammatoire ayant fait l’objet d’une radiothérapie pourront faire l’objet d’une discussion avec le moniteur médical afin d’envisager une inclusion.","language":10,"languageDescription":"French"},{"id":12676412,"uuid":"7a7f0c81-9266-4ab0-8dd6-114d34cec8f4","attributeTranslation":"7.\tVoorgeschiedenis van interstitiële longziekte, actieve pneumonitis of voorgeschiedenis van pneumonitis van eerdere behandelingen die behandeling met corticosteroïden vereist. Voorgeschiedenis van alleen pneumonitis van graad 1 OF eerdere bestralingspneumonitis kan echter worden besproken met de medische monitor om inclusie te overwegen.","language":18,"languageDescription":"Dutch"},{"id":12676415,"uuid":"7a7f0c81-9266-4ab0-8dd6-114d34cec8f4","attributeTranslation":"7.\tAnamnesi di malattia polmonare interstiziale, polmonite attiva o anamnesi di polmonite correlata a precedenti terapie con necessità di trattamento corticosteroideo. Tuttavia, potrà essere discussa con il medical monitor la possibilità di includere un partecipante che presenti un’anamnesi di sola polmonite di Grado 1 O di pregressa polmonite da radiazioni.","language":14,"languageDescription":"Italian"},{"id":12676414,"uuid":"7a7f0c81-9266-4ab0-8dd6-114d34cec8f4","attributeTranslation":"7.\tAntecedentes de enfermedad pulmonar intersticial, neumonitis activa o antecedentes de neumonitis producida por tratamientos previos que haya exigido corticoesteroides. Sin embargo, tener solo antecedentes de neumonitis de grado 1 o de neumonitis por radiación previa se pueden comentar con el monitor clínico para contemplar la inclusión.","language":7,"languageDescription":"Spanish"},{"id":12676410,"uuid":"7a7f0c81-9266-4ab0-8dd6-114d34cec8f4","attributeTranslation":"7.\tStwierdzona w wywiadzie śródmiąższowa choroba płuc, aktywne zapalenie płuc lub stwierdzone w wywiadzie zapalenie płuc wywołane wcześniejszymi terapiami wymagającymi leczenia kortykosteroidami. Jednak w wywiadzie tylko zapalenie płuc 1. stopnia LUB wcześniejsze popromienne zapalenie płuc można omówić z monitorem medycznym w celu rozważenia włączenia do badania.","language":19,"languageDescription":"Polish"}]},{"id":1728928,"number":19,"principalExclusionCriteria":"8. History of syncope (except due to an acute medical condition [e.g., hemorrhage] within 6 months of the first dose of study treatment and is not likely to reoccur). Any history of potential syncope should be clarified and verified if possible. All participants with prior history of syncope should be discussed with the Sponsor Medical Monitor. Participants at high risk of falls should be considered ineligible.","principalExclusionCriteriaTranslations":[{"id":12676416,"uuid":"76f6433f-900b-495e-be3b-ca7b92d8db88","attributeTranslation":"8. Stwierdzone w wywiadzie omdlenie (z wyjątkiem ostrego schorzenia [np. krwotoku] w ciągu 6 miesięcy od\npodania pierwszej dawki badanego leku, w przypadku którego niemożliwe jest ponowne wystąpienie). Wszelkie przypadki\npotencjalnego omdlenia w wywiadzie należy wyjaśnić i zweryfikować, jeśli to możliwe. Wszyscy uczestnicy z\nwcześniejszym omdleniem powinni zostać omówieni z monitorem medycznym sponsora. Uczestników z dużym ryzykiem\nupadków należy uznać za niekwalifikujących się do udziału w badaniu.","language":19,"languageDescription":"Polish"},{"id":12676417,"uuid":"76f6433f-900b-495e-be3b-ca7b92d8db88","attributeTranslation":"8. Antécédents de syncope (sauf en raison d’une affection médicale aiguë [p. ex., hémorragie] dans les 6 mois\nprécédant la première dose du traitement à l’étude et non susceptible de se reproduire). Tout antécédent de syncope\npotentielle devra être clarifié et vérifié dans la mesure du possible. Tous les participants ayant des antécédents de\nsyncope doivent faire l’objet d’une discussion avec le moniteur médical du promoteur. Les participants présentant un\nrisque élevé de chute doivent être considérés comme non éligibles.","language":10,"languageDescription":"French"},{"id":12676419,"uuid":"76f6433f-900b-495e-be3b-ca7b92d8db88","attributeTranslation":"8. Antecedentes de síncope (excepto debido a alguna afección médica aguda [p. ej., hemorragia] dentro de los 6\nmeses previos a la primera dosis del tratamiento del estudio y que no sea probable que vuelva a ocurrir). Debe aclararse\ny verificarse, si es posible, cualquier antecedente de posible síncope. Todos los participantes con antecedentes de\nsíncope deben comentarse con el monitor clínico del promotor. Los pacientes con riesgo alto de sufrir caídas deberían\nconsiderarse no aptos.","language":7,"languageDescription":"Spanish"},{"id":12676418,"uuid":"76f6433f-900b-495e-be3b-ca7b92d8db88","attributeTranslation":"8. Eine Synkope in der Vorgeschichte (außer aufgrund von akuten Beschwerden [z. B. einer Blutung], die innerhalb\nvon 6 Monaten vor der ersten Studienbehandlung auftrat und wahrscheinlich nicht erneut auftritt). Jede potenzielle\nSynkope in der Vorgeschichte sollte geklärt und nach Möglichkeit verifiziert werden. Alle Teilnehmer mit Synkopen in der\nVorgeschichte sind mit dem Medical Monitor des Sponsors zu besprechen. Teilnehmer mit hohem Risiko für Stürze\nsollten als nicht geeignet erachtet werden.","language":4,"languageDescription":"German"},{"id":12676420,"uuid":"76f6433f-900b-495e-be3b-ca7b92d8db88","attributeTranslation":"8. Voorgeschiedenis van syncope (behalve als gevolg van een acute medische aandoening [bijv. een bloeding]\nbinnen 6 maanden vóór de eerste dosis onderzoeksbehandeling die zich waarschijnlijk niet opnieuw zal voordoen). Elke\nvoorgeschiedenis van mogelijke syncope moet worden verduidelijkt en geverifieerd indien mogelijk. Alle deelnemers met\neen voorgeschiedenis van syncope moeten worden besproken met de medische monitor van de opdrachtgever.\nDeelnemers met een hoog risico op vallen moeten als ongeschikt worden beschouwd.","language":18,"languageDescription":"Dutch"},{"id":12676421,"uuid":"76f6433f-900b-495e-be3b-ca7b92d8db88","attributeTranslation":"8. Anamnesi di sincope (eccetto se dovuta a una condizione medica acuta [per es., emorragia] entro 6 mesi dalla\nprima dose di trattamento dello studio e senza probabilità di nuova occorrenza). Qualsiasi anamnesi di possibile sincope\ndeve essere chiarita e verificata, ove possibile. Tutti i partecipanti con anamnesi pregressa di sincope devono essere\ndiscussi con il medical monitor dello sponsor. I partecipanti ad alto rischio di cadute devono essere considerati non idonei.","language":14,"languageDescription":"Italian"}]},{"id":1728929,"number":2,"principalExclusionCriteria":"10. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection per institutional protocol. Testing for HBV or HCV status is not necessary unless clinically indicated or the participant has a history of HBV or HCV infection. NOTE: participants with suspected hepatitis or HIV should be discussed with the Sponsor Medical Monitor.","principalExclusionCriteriaTranslations":[{"id":12676425,"uuid":"599e24cf-cb0e-4185-9e06-12f10916cc4a","attributeTranslation":"10.\tInfección activa por el virus de la hepatitis B (VHB) o el virus de la hepatitis C (VHC) según el protocolo institucional. No es necesario realizar pruebas de detección de VHB o VHC, a menos que esté clínicamente indicado o que el participante tenga antecedentes de infección por VHB o VHC. NOTA: Los participantes con sospecha de hepatitis o VIH deben consultarse con el monitor clínico del promotor.","language":7,"languageDescription":"Spanish"},{"id":12676427,"uuid":"599e24cf-cb0e-4185-9e06-12f10916cc4a","attributeTranslation":"10.\tInfezione attiva da virus dell’epatite B (HBV) o virus dell’epatite C (HCV) secondo il protocollo istituzionale. Il test per lo stato HBV o HCV non è necessario, salvo se clinicamente indicato o se il partecipante presenta un’anamnesi di infezione da HBV o HCV. NOTA: i partecipanti con sospetta epatite o infezione da HIV devono essere discussi con il medical monitor dello sponsor.","language":14,"languageDescription":"Italian"},{"id":12676423,"uuid":"599e24cf-cb0e-4185-9e06-12f10916cc4a","attributeTranslation":"10.\tActieve infectie met hepatitis B-virus (HBV) of hepatitis C-virus (HCV) volgens het protocol van de instelling. Testen op HBV- of HCV-status is niet nodig tenzij klinisch geïndiceerd of als de deelnemer een voorgeschiedenis heeft van HBV- of HCV-infectie. OPMERKING: deelnemers met vermoede hepatitis of hiv moeten worden besproken met de medische monitor van de opdrachtgever.","language":18,"languageDescription":"Dutch"},{"id":12676424,"uuid":"599e24cf-cb0e-4185-9e06-12f10916cc4a","attributeTranslation":"10.\tInfection active par le virus de l’hépatite B (VHB) ou le virus de l’hépatite C (VHC) selon le protocole de l’établissement. Le dépistage du\nVHB ou du VHC n’est pas nécessaire, sauf si cela est cliniquement indiqué ou si le participant a des antécédents d’infection par le VHB ou le VHC. REMARQUE : les participants chez qui un virus de l’hépatite ou un VIH\nest suspecté devront faire l’objet d’une discussion avec le moniteur médical du promoteur.","language":10,"languageDescription":"French"},{"id":12676422,"uuid":"599e24cf-cb0e-4185-9e06-12f10916cc4a","attributeTranslation":"10.\tCzynne zakażenie wirusem zapalenia wątroby typu B (HBV) lub wirusem zapalenia wątroby typu C (HCV) zgodnie z protokołem placówki. Badanie pod kątem obecności HBV lub HCV nie jest konieczne, chyba że istnieją wskazania kliniczne lub u uczestnika stwierdzono w wywiadzie zakażenie HBV lub HCV. UWAGA: przypadki uczestników z podejrzeniem\nzapalenia wątroby lub wirusa HIV należy omówić z monitorem medycznym Sponsora.","language":19,"languageDescription":"Polish"},{"id":12676426,"uuid":"599e24cf-cb0e-4185-9e06-12f10916cc4a","attributeTranslation":"10.\tAktive Infektionen mit dem Hepatitis-B- (HBV) oder -C-Virus (HCV) werden gemäß den Vorschriften der jeweiligen Einrichtung gehandhabt. Tests auf HBV- oder HCV-Status sind nicht erforderlich, außer es ist klinisch indiziert oder der Teilnehmer hat eine HBV- oder HCV-Infektion in der Vorgeschichte. HINWEIS: Teilnehmer mit Verdacht auf Hepatitis oder HIV sind mit dem Medical Monitor des Sponsors zu besprechen.","language":4,"languageDescription":"German"}]},{"id":1728930,"number":20,"principalExclusionCriteria":"9. Active infection requiring systemic antibiotic therapy. Participants requiring systemic antibiotics for infection must have completed therapy at least one week prior to the first dose of study drug.","principalExclusionCriteriaTranslations":[{"id":12676431,"uuid":"45f257e8-4dfe-4824-905f-659937a1cfa2","attributeTranslation":"9.\tInfezione attiva con necessità di terapia antibiotica sistemica. I partecipanti che abbiano richiesto una terapia antibiotica sistemica per infezione devono aver completato la terapia almeno una settimana prima della prima dose di farmaco dello studio.","language":14,"languageDescription":"Italian"},{"id":12676433,"uuid":"45f257e8-4dfe-4824-905f-659937a1cfa2","attributeTranslation":"9.\tActieve infectie waarvoor systemische antibioticatherapie nodig is. Deelnemers die systemische antibiotica voor infectie nodig hebben, moeten de behandeling ten minste één week voorafgaand aan de eerste dosis onderzoeksgeneesmiddel hebben voltooid","language":18,"languageDescription":"Dutch"},{"id":12676430,"uuid":"45f257e8-4dfe-4824-905f-659937a1cfa2","attributeTranslation":"9.\tInfection active nécessitant une antibiothérapie systémique. Les participants nécessitant des antibiotiques systémiques pour une infection doivent avoir terminé le traitement au moins une semaine avant la première dose du médicament à l’étude.","language":10,"languageDescription":"French"},{"id":12676432,"uuid":"45f257e8-4dfe-4824-905f-659937a1cfa2","attributeTranslation":"9.\tEine aktive Infektion, die eine systemische Antibiotikatherapie erfordert. Teilnehmer, die systemische Antibiotika für Infektionen benötigen, müssen die Therapie mindestens eine Woche vor der ersten Studienbehandlung abgeschlossen haben","language":4,"languageDescription":"German"},{"id":12676429,"uuid":"45f257e8-4dfe-4824-905f-659937a1cfa2","attributeTranslation":"9.\tCzynne zakażenie wymagające antybiotykoterapii ogólnoustrojowej. Uczestnicy wymagający ogólnoustrojowych antybiotyków z powodu zakażenia muszą ukończyć leczenie co najmniej jeden tydzień przed podaniem pierwszej dawki badanego leku","language":19,"languageDescription":"Polish"},{"id":12676428,"uuid":"45f257e8-4dfe-4824-905f-659937a1cfa2","attributeTranslation":"9.\tInfección activa que requiera antibioticoterapia sistémica. Los participantes que requieran antibióticos sistémicos para alguna infección deben haber terminado el tratamiento al menos una semana antes de la primera dosis del fármaco del estudio.","language":7,"languageDescription":"Spanish"}]},{"id":1728931,"number":21,"principalExclusionCriteria":"21. Has any other condition that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the opinion of the investigator, would make the participant inappropriate for entry into the study, including institutionalization on the basis of an official or court order.","principalExclusionCriteriaTranslations":[{"id":12676435,"uuid":"4c0dfd8a-9f19-4baa-a43c-e9275d112d0b","attributeTranslation":"21. Heeft een andere aandoening die het risico in verband met deelname aan het onderzoek kan verhogen of de interpretatie van de onderzoeksresultaten kan verstoren en die, naar het oordeel van de onderzoeker, de deelnemer ongeschikt zou maken voor deelname aan het onderzoek, , inclusief institutionalisering op basis van een officieel of gerechtelijk bevel.","language":18,"languageDescription":"Dutch"},{"id":12676438,"uuid":"4c0dfd8a-9f19-4baa-a43c-e9275d112d0b","attributeTranslation":"21. Présenter toute autre affection pouvant augmenter les risques associés à une participation à l’étude ou pouvant interférer avec l’interprétation des résultats de l’étude et, de l’avis de l’investigateur, rendant le participant inapproprié à une inclusion dans l’étude, incluant les personnes faisant l’objet d’une mesure de protection juridique.","language":10,"languageDescription":"French"},{"id":12676436,"uuid":"4c0dfd8a-9f19-4baa-a43c-e9275d112d0b","attributeTranslation":"21. U uczestnika występuje jakakolwiek inna choroba, która może zwiększać ryzyko związane z udziałem w badaniu lub może zakłócać interpretację wyników badania i w opinii badacza sprawiać, że uczestnik nie może zostać włączony do badania, w tym instytucjonalizacja na podstawie\nnakazu urzędowego lub sądowego.","language":19,"languageDescription":"Polish"},{"id":12676437,"uuid":"4c0dfd8a-9f19-4baa-a43c-e9275d112d0b","attributeTranslation":"21.  Presenza di qualsiasi altra condizione che possa aumentare il rischio associato alla partecipazione allo studio o interferire con l’interpretazione dei risultati dello studio e, a giudizio dello sperimentatore, rendere il partecipante non idoneo all’ingresso nello studio, compresa l'istituzionalizzazione sulla base di un funzionario od ordine del tribunale.","language":14,"languageDescription":"Italian"},{"id":12676434,"uuid":"4c0dfd8a-9f19-4baa-a43c-e9275d112d0b","attributeTranslation":"21. Eine andere Erkrankung, die das mit der Studienteilnahme verbundene Risiko erhöhen oder die Interpretation der Studienergebnisse beeinträchtigen könnte und nach Ansicht des Prüfarztes den Patienten für die Aufnahme in die Studie ungeeignet machen würde, , einschließlich der Einweisung auf der Grundlage einer behördlichen oder gerichtlichen Anordnung.","language":4,"languageDescription":"German"},{"id":12676439,"uuid":"4c0dfd8a-9f19-4baa-a43c-e9275d112d0b","attributeTranslation":"21. Tener cualquier otra afección que pueda aumentar el riesgo asociado a la participación en el estudio o que pueda interferir en la interpretación de los resultados de este y que, en opinión del investigador, haga que el participante no sea adecuado para entrar en el estudio, incluida la institucionalización sobre la base de una orden oficial o judicial.","language":7,"languageDescription":"Spanish"}]},{"id":1728932,"number":3,"principalExclusionCriteria":"11. Major surgery within 2 weeks of the first dose of study drug (minimally invasive procedures such as bronchoscopy, tumor biopsy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery and are not exclusionary).","principalExclusionCriteriaTranslations":[{"id":12676441,"uuid":"aedfa2ea-ed77-4d10-a58a-4053c5061004","attributeTranslation":"11.\tCirugía mayor dentro de las 2 semanas anteriores a la primera dosis del fármaco del estudio (los procedimientos mínimamente invasivos, como broncoscopias, biopsias tumorales, inserción de dispositivos de acceso venoso central e inserción de sondas de alimentación no se consideran cirugía mayor y no son excluyentes).","language":7,"languageDescription":"Spanish"},{"id":12676442,"uuid":"aedfa2ea-ed77-4d10-a58a-4053c5061004","attributeTranslation":"11.\tIntervento di chirurgia maggiore entro 2 settimane dalla prima dose di farmaco dello studio (le procedure minimamente invasive come broncoscopia, biopsia tumorale, inserimento di un dispositivo di accesso venoso centrale e inserimento di un sondino non sono considerate interventi di chirurgia maggiore e non costituiscono un motivo di esclusione).","language":14,"languageDescription":"Italian"},{"id":12676444,"uuid":"aedfa2ea-ed77-4d10-a58a-4053c5061004","attributeTranslation":"11.\tEine größere Operation innerhalb von 2 Wochen vor der ersten Studienbehandlung (minimalinvasive Verfahren wie Bronchoskopie, Tumorbiopsie, Einführen eines zentralvenösen Zugangs und Einführen einer Ernährungssonde gelten nicht als größere Operation und sind kein Ausschlusskriterium).","language":4,"languageDescription":"German"},{"id":12676443,"uuid":"aedfa2ea-ed77-4d10-a58a-4053c5061004","attributeTranslation":"11.\tIntervention chirurgicale majeure dans les 2 semaines précédant la première dose du médicament à l’étude (les procédures mini-invasives telles que bronchoscopie, biopsie tumorale, insertion d’un dispositif d’accès veineux central et insertion d’une sonde gastrique ne sont pas considérées comme des interventions chirurgicales majeures et ne constituent pas un critère d’exclusion).","language":10,"languageDescription":"French"},{"id":12676445,"uuid":"aedfa2ea-ed77-4d10-a58a-4053c5061004","attributeTranslation":"11.\tEen grote chirurgische ingreep binnen 2 weken van de eerste dosis onderzoeksgeneesmiddel (minimaal invasieve ingrepen zoals bronchoscopie, tumorbiopsie, inbrengen van een centraal veneus toegangsapparaat en inbrengen van een voedingssonde worden niet beschouwd als grote chirurgische ingrepen en zijn niet uitsluitend)","language":18,"languageDescription":"Dutch"},{"id":12676440,"uuid":"aedfa2ea-ed77-4d10-a58a-4053c5061004","attributeTranslation":"11.\tPoważny zabieg chirurgiczny w ciągu 2 tygodni przed podaniem pierwszej dawki badanego leku (zabiegi minimalnie inwazyjne, takie jak bronchoskopia, biopsja guza, wprowadzenie centralnego dostępu żylnego i wprowadzenie sondy do żywienia nie są uważane za poważny zabieg chirurgiczny i nie stanowią kryterium wyłączenia)","language":19,"languageDescription":"Polish"}]},{"id":1728933,"number":4,"principalExclusionCriteria":"12. Radiotherapy within 2 weeks of the first dose of study drug, with the exception of palliative radiotherapy to a limited field, such as for the treatment of bone pain or a focally painful tumor mass.","principalExclusionCriteriaTranslations":[{"id":12676448,"uuid":"8e797e9e-4447-4cee-9dfb-fbd44ca71326","attributeTranslation":"12.\tRadioterapia dentro de las 2 semanas anteriores a la primera dosis del fármaco del estudio, a excepción de radioterapia paliativa en un campo limitado, por ejemplo, para el tratamiento del dolor óseo o para una masa tumoral focalmente dolorosa","language":7,"languageDescription":"Spanish"},{"id":12676451,"uuid":"8e797e9e-4447-4cee-9dfb-fbd44ca71326","attributeTranslation":"12.\tRadiotherapie binnen 2 weken vóór de eerste dosis van het onderzoeksgeneesmiddel, met uitzondering van palliatieve radiotherapie op een beperkt gebied, zoals voor de behandeling van botpijn of een focaal pijnlijke tumormassa","language":18,"languageDescription":"Dutch"},{"id":12676447,"uuid":"8e797e9e-4447-4cee-9dfb-fbd44ca71326","attributeTranslation":"12.\tRadioterapia entro 2 settimane dalla prima dose di farmaco dello studio, ad eccezione della radioterapia palliativa somministrata su un campo limitato, per esempio per il trattamento del dolore osseo o di una massa tumorale con dolore focale.","language":14,"languageDescription":"Italian"},{"id":12676449,"uuid":"8e797e9e-4447-4cee-9dfb-fbd44ca71326","attributeTranslation":"12.\tStrahlentherapie innerhalb von 2 Wochen vor der ersten Studienbehandlung, mit Ausnahme einer palliativen Strahlentherapie in einem begrenzten Bereich, wie z. B. zur Behandlung von Knochenschmerzen oder einer fokal schmerzhaften Tumormasse.","language":4,"languageDescription":"German"},{"id":12676450,"uuid":"8e797e9e-4447-4cee-9dfb-fbd44ca71326","attributeTranslation":"12.\tRadioterapia w ciągu 2 tygodni przed podaniem pierwszej dawki badanego leku, z wyjątkiem radioterapii paliatywnej w ograniczonym polu, np. w celu leczenia bólu kości lub ogniskowo bolesnej masy guza","language":19,"languageDescription":"Polish"},{"id":12676446,"uuid":"8e797e9e-4447-4cee-9dfb-fbd44ca71326","attributeTranslation":"12.\tRadiothérapie dans les 2 semaines précédant la première dose du médicament à l’étude, à l’exception d’une radiothérapie palliative dans un champ limité, par exemple pour le traitement de douleurs osseuses ou d’une masse tumorale localement douloureuse.","language":10,"languageDescription":"French"}]},{"id":1728934,"number":5,"principalExclusionCriteria":"13. Use of hematopoietic colony-stimulating factors (CSF) (eg, granulocyte [G]-CSF, granulocyte-macrophage [GM]-CSF, macrophage [M]-CSF) within2 weeks prior to start of study drug. An erythroid-stimulating agent is allowed as long as it was initiated at least 2 weeks prior to the first dose of study treatment and the participant is not red blood cell transfusion dependent.","principalExclusionCriteriaTranslations":[{"id":12676456,"uuid":"554cf158-a584-44ab-9151-3219e0c35570","attributeTranslation":"13.\tAnwendung von hämatopoetischen koloniestimulierenden Faktoren (CSF) (z. B. G-CSF [Granulozyten], GM-CSF [Granulozyten und Makrophagen] oder M-CSF [MAKROPHAGEN]) innerhalb von 2 Wochen vor Beginn der Studienbehandlung. Ein die Erythropoese stimulierendes Mittel ist zulässig, solange es mindestens 2 Wochen vor der ersten Studienbehandlung eingeleitet wurde und der Teilnehmer nicht von Erythrozytentransfusionen abhängig ist.","language":4,"languageDescription":"German"},{"id":12676452,"uuid":"554cf158-a584-44ab-9151-3219e0c35570","attributeTranslation":"13.\tUtilisation de facteurs de stimulation des colonies hématopoïétiques (FSC) (p. ex., granulocytes [G]-FSC, granulocytes-macrophages [GM]-FSC, macrophages [M]-FSC) dans les 2 semaines précédant l’instauration du médicament à l’étude. Les agents stimulant les érythrocytes sont autorisés à condition qu’ils aient été instaurés au moins 2 semaines avant la première dose du traitement à l’étude et que le participant ne soit pas dépendant de transfusions de globules rouges.","language":10,"languageDescription":"French"},{"id":12676454,"uuid":"554cf158-a584-44ab-9151-3219e0c35570","attributeTranslation":"13.\tUso di fattori stimolanti le colonie (CSF) ematopoietiche (per es., granulocitarie [G-CSF], granulocitarie-macrofagiche [GM-CSF], macrofagiche [M-CSF]) nelle 2 settimane precedenti l’avvio del farmaco dello studio. È consentito l’uso di un agente di stimolazione eritroide a condizione che sia stato iniziato almeno 2 settimane prima della prima dose di trattamento dello studio e che il partecipante non sia dipendente dalla trasfusione di globuli rossi","language":14,"languageDescription":"Italian"},{"id":12676455,"uuid":"554cf158-a584-44ab-9151-3219e0c35570","attributeTranslation":"13.\tUso de factores estimulantes de colonias hematopoyéticas (FEC) (p. ej., de granulocitos [G]-FEC, de granulocitos-macrófagos [GM]-FEC, de macrófagos [M]-FEC) en las 2 semanas anteriores al inicio del fármaco del estudio. Se permiten estimulantes de eritrocitos, siempre que se instauren al menos 2 semanas antes de la primera dosis del tratamiento del estudio y el participante no dependa de transfusiones de eritrocitos.","language":7,"languageDescription":"Spanish"},{"id":12676453,"uuid":"554cf158-a584-44ab-9151-3219e0c35570","attributeTranslation":"13.\tStosowanie czynników stymulujących tworzenie kolonii krwiotwórczych (PMR) (np. granulocytów [G]-CSF, granulocytów-makrofagów [GM]-CSF, makrofagów [M]-CSF) w ciągu 2 tygodni przed rozpoczęciem przyjmowania badanego leku. Dozwolony jest czynnik stymulujący erytroidy, o ile został on włączony co najmniej 2 tygodnie przed podaniem pierwszej dawki badanego leku i uczestnik nie jest zależny od transfuzji krwinek czerwonych.","language":19,"languageDescription":"Polish"},{"id":12676457,"uuid":"554cf158-a584-44ab-9151-3219e0c35570","attributeTranslation":"13.\tGebruik van hematopoïetische koloniestimulerende factoren (CSF) (bijv. granulocyt [G]-CSF, granulocyt-macrofaag [GM]-CSF, macrofaag [M]-CSF) binnen 2 weken voorafgaand aan de start van het onderzoeksgeneesmiddel. Een erytroïde-stimulerend middel is toegestaan zolang het ten minste 2 weken voorafgaand aan de eerste dosis onderzoeksbehandeling is gestart en de deelnemer niet afhankelijk is van transfusie van rode bloedcellen.","language":18,"languageDescription":"Dutch"}]},{"id":1728935,"number":6,"principalExclusionCriteria":"14. Receives treatment with medications that cannot be discontinued prior to study entry and that are considered to be any of the following (see Table 18): • Other antineoplastic therapies (not including palliative radiotherapy) or investigational therapies other than IDE196 • Known risk for QT prolongation, except for the specific use of oral ondansetron for the management of nausea and vomiting (Note: intravenous [IV] formulations of ondansetron are to be used with caution.) •\tNarrow therapeutic index sensitive substrates of P-glycoprotein (P-gp) or breast cancer resistant protein (BCRP) • Known to be strong inducers or inhibitors of cytochrome P (CYP)3A4/5 • Known to be substrates of CYP3A4/5 with a narrow therapeutic index","principalExclusionCriteriaTranslations":[{"id":12676462,"uuid":"e4a19f8a-d6af-4fe4-9304-471ea4024f1b","attributeTranslation":"14.\tTrattamento in corso con farmaci che non possono essere interrotti prima dell’ingresso nello studio e che si ritiene rientrino in una qualsiasi delle seguenti categorie (vedere Tabella 18):\n•\tAltre terapie antineoplastiche (esclusa la radioterapia palliativa) o terapie sperimentali diverse da IDE196 \n•\tFarmaci con rischio noto di prolungamento dell’intervallo QT, ad eccezione dell’uso specifico di ondansetron orale per la gestione di nausea e vomito (nota: le formulazioni per via endovenosa [EV] di ondansetron devono essere usate con cautela).\n•\tSubstrati sensibili della P-glicoproteina (P-gp) o della proteina di resistenza del cancro al seno (BCRP) con indice terapeutico ristretto.\n•\tFarmaci noti per essere forti induttori o inibitori del citocromo P (CYP)3A4/5.\n•\tFarmaci noti per essere substrati di CYP3A4/5 dotati di un indice terapeutico ristretto.","language":14,"languageDescription":"Italian"},{"id":12676461,"uuid":"e4a19f8a-d6af-4fe4-9304-471ea4024f1b","attributeTranslation":"14.\tRecevoir un traitement par des médicaments qui ne peuvent pas être interrompus avant l’entrée dans l’étude et qui sont considérés comme étant l’un de ceux qui suivent (voir Tableau 18):\n•\tAutres traitements antinéoplasiques (hors radiothérapie palliative) ou traitements expérimentaux autres que l’IDE196\n•\tRisque connu d’allongement de l’intervalle QT, à l’exception de la prise par voie orale d’a ondansétron pour la prise en charge de nausées et de vomissements (remarque : les formulations intra-veineuses [IV] d’ondansétron doivent être utilisées avec prudence)\n•\tSubstrats de p-glycoprotéine (P-gp) ou protéine résistante du can-cer du sein (PRCS) sensibles présentant un indice thérapeutique étroit\n•\tConnus pour être de puissants inducteurs ou inhibiteurs du cyto-chrome P (CYP)3A4/5\n•\tConnus pour être des substrats du CYP3A4/5 avec un index thérapeutique étroit","language":10,"languageDescription":"French"},{"id":12676458,"uuid":"e4a19f8a-d6af-4fe4-9304-471ea4024f1b","attributeTranslation":"14.\tOntvangt behandeling met geneesmiddelen die niet kunnen worden stopgezet vóór opname in het onderzoek en die worden beschouwd als een van het volgende (zie tabel 18):\n•\tAndere antineoplastische behandelingen (palliatieve radiotherapie valt niet hieronder) of andere onderzoeksbehandelingen dan die van IDE196\n•\tbekend risico op QT-verlenging, met uitzondering van het specifieke gebruik van orale  ondansetron voor de behandeling van misselijkheid en braken (let op: intraveneuze [IV] toedieningen van, ondansetron, moeten behoedzaam worden uitgevoerd)\n•\tgevoelige substraten van P-glycoproteïne (P-gp) met een smalle therapeutische index, of borstkanker-resistentie-eiwit (BCRP)\n•\tbekend als sterke inductoren of remmers van cytochroom P (CYP)3A4/5\n•\tbekend als substraten van CYP3A4/5 met een smalle therapeutische index","language":18,"languageDescription":"Dutch"},{"id":12676460,"uuid":"e4a19f8a-d6af-4fe4-9304-471ea4024f1b","attributeTranslation":"14.\tBehandlung mit Medikamenten, die vor Studieneintritt nicht abgesetzt werden können und auf die einer der folgenden Punkte zutrifft (siehe Tab. 18):\n•\tAndere antineoplastische Therapien (ohne palliative Strahlentherapie) oder andere Prüftherapien als IDE196\n•\tBekanntes Risiko einer QT-Verlängerung, mit Ausnahme der spezifischen Anwendung von oralem Ondansetron zur Behandlung von Übelkeit und Erbrechen (Hinweis: Eine intravenöse [IV]-Formulierung von Ondansetron darf nur mit Vorsicht angewendet werden.)\n•\tEnger therapeutischer Index, empfindliche Substrate für P-Glykoprotein (P-gp) oder brustkrebsresistentes Protein (BCRP)\n•\tBekannte starke Induktoren oder Inhibitoren von Cytochrom P450 3A4/5 (CYP 3A4/5)\n•\tBekannte Substrate von CYP 3A4/5 mit einem engen therapeutischen Index","language":4,"languageDescription":"German"},{"id":12676459,"uuid":"e4a19f8a-d6af-4fe4-9304-471ea4024f1b","attributeTranslation":"14.\tRecibir tratamiento con medicamentos que no se puedan interrumpir antes de entrar en el estudio y con los que se considere que puede darse cualquiera de lo siguiente (véase la Tabla 18):\n•\totras terapias antineoplásicas (sin incluir la radioterapia paliativa) o terapias en investigación distintas de IDE196\n•\triesgo conocido de prolongación del intervalo QT, excepto el uso específico de ondansetrón oral para el tratamiento de las náuseas y los vómitos (nota: las formulaciones intravenosas [IV] de granisetrón, ondansetrón y dolansetrón);\n•\tsustratos de P-glicoproteína (P-gp) con un índice terapéutico estrecho o proteína de resistencia del cáncer de mama (BCRP)\n•\tque se sepa que son inductores o inhibidores potentes del citocromo P (CYP)3A4/5;\n•\tque se sepa que son sustratos de CYP3A4/5 con un índice terapéutico estrecho;","language":7,"languageDescription":"Spanish"},{"id":12676463,"uuid":"e4a19f8a-d6af-4fe4-9304-471ea4024f1b","attributeTranslation":"14.\tPrzyjmowanie leków, których nie można przerwać przed włączeniem do badania i które uważa się za należące do jednej z poniższych kategorii (patrz Tabela 18):\n•\tinne metody leczenia przeciwnowotworowego (z wyjątkiem radioterapii paliatywnej) albo leki eksperymentalne inne niż IDE196\n•\tZe znanym ryzykiem wydłużenia odstępu QT, z wyjątkiem swoistego stosowania doustnego ondansetronu w leczeniu nudności i wymiotów (uwaga: należy zachować ostrożność w przypadku stosowania ondansetronu w postaci preparatów dożylnych [i.v.])\n•\twrażliwe substraty P-glikoproteiny (P-gp) o wąskim indeksie terapeutycznym albo białko oporności lekowej w raku piersi (BCRP)\n•\tznane jako silne induktory lub inhibitory cytochromu P (CYP)3A4/5\n•\tznane jako substraty CYP3A4/5 o wąskim indeksie terapeutycznym","language":19,"languageDescription":"Polish"}]},{"id":1728936,"number":7,"principalExclusionCriteria":"15. Females who are pregnant or breastfeeding","principalExclusionCriteriaTranslations":[{"id":12676465,"uuid":"7e852dad-b01c-47d4-b095-561c24a25e3c","attributeTranslation":"15.\tSchwangere und stillende Frauen","language":4,"languageDescription":"German"},{"id":12676466,"uuid":"7e852dad-b01c-47d4-b095-561c24a25e3c","attributeTranslation":"15.\tFemmes enceintes ou qui allaitent","language":10,"languageDescription":"French"},{"id":12676464,"uuid":"7e852dad-b01c-47d4-b095-561c24a25e3c","attributeTranslation":"15.\tKobiety w ciąży lub karmiące piersią","language":19,"languageDescription":"Polish"},{"id":12676468,"uuid":"7e852dad-b01c-47d4-b095-561c24a25e3c","attributeTranslation":"15.\tMujeres embarazadas o que estén amamantando","language":7,"languageDescription":"Spanish"},{"id":12676469,"uuid":"7e852dad-b01c-47d4-b095-561c24a25e3c","attributeTranslation":"15.\tVrouwen die zwanger zijn of borstvoeding geven","language":18,"languageDescription":"Dutch"},{"id":12676467,"uuid":"7e852dad-b01c-47d4-b095-561c24a25e3c","attributeTranslation":"15.\tDonne in gravidanza o allattamento.","language":14,"languageDescription":"Italian"}]},{"id":1728937,"number":8,"principalExclusionCriteria":"16. History of severe hypersensitivity reactions (e.g., anaphylaxis) to other biologic drugs or monoclonal antibodies","principalExclusionCriteriaTranslations":[{"id":12676475,"uuid":"95d73915-4e2c-4af7-a989-9a9c12d8680c","attributeTranslation":"16.\tAntecedentes de reacciones de hipersensibilidad graves (p. ej., anafilaxia) a otros fármacos biológicos o anticuerpos monoclonales","language":7,"languageDescription":"Spanish"},{"id":12676473,"uuid":"95d73915-4e2c-4af7-a989-9a9c12d8680c","attributeTranslation":"16.\tVoorgeschiedenis van ernstige overgevoeligheidsreacties (bijv. anafylaxie) op andere biologische geneesmiddelen of monoklonale antilichamen","language":18,"languageDescription":"Dutch"},{"id":12676470,"uuid":"95d73915-4e2c-4af7-a989-9a9c12d8680c","attributeTranslation":"16.\tAntécédents de réactions d’hypersensibilité sévères (p. ex., anaphylaxie) à d’autres médicaments biologiques ou anticorps monoclonaux.","language":10,"languageDescription":"French"},{"id":12676472,"uuid":"95d73915-4e2c-4af7-a989-9a9c12d8680c","attributeTranslation":"16.\tSchwere Überempfindlichkeitsreaktionen (z. B. Anaphylaxie) auf andere Biologika oder monoklonale Antikörper in der Vorgeschichte","language":4,"languageDescription":"German"},{"id":12676474,"uuid":"95d73915-4e2c-4af7-a989-9a9c12d8680c","attributeTranslation":"16.\tCiężkie reakcje nadwrażliwości w wywiadzie (np. anafilaksja) na inne leki biologiczne lub przeciwciała monoklonalne","language":19,"languageDescription":"Polish"},{"id":12676471,"uuid":"95d73915-4e2c-4af7-a989-9a9c12d8680c","attributeTranslation":"16.\tAnamnesi di gravi reazioni di ipersensibilità (per es., anafilassi) ad altri farmaci biologici o anticorpi monoclonali.","language":14,"languageDescription":"Italian"}]},{"id":1728938,"number":9,"principalExclusionCriteria":"17. Impaired cardiac function or clinically significant cardiac diseases, including any of the following: • A history or presence of ventricular tachyarrhythmia • Presence of unstable atrial fibrillation (ventricular response > 100 beats per minute [bpm]); participants with stable atrial fibrillation are eligible, provided they do not meet any of the other cardiac exclusion criteria • Has had angina pectoris or acute myocardial infarction ≤ 6 months prior to study treatment • Has congestive heart failure requiring treatment. For New York Heart Association Class 1, inclusion can be considered with discussion and agreement with the Sponsor Medical Monitor • Has other clinically significant heart disease (e.g., uncontrolled arrhythmia or hypertension; history of labile hypertension or poor compliance with an antihypertensive regimen, symptomatic bradycardia) • Has a drug eluting stent for cardiovascular purposes placed ≤ 2 months prior to study treatment • Corrected QT interval using Fridericia’s formula (QTcF) (see Appendix 2, Section 14.2): o QTcF > 470 msec on baseline ECG (mean of baseline values). If electrolytes are abnormal, they may be corrected, and baseline ECGs should be repeated. In addition, participants with asymptomatic persistent heart rate < 55 bpm must be discussed with the Sponsor Medical Monitor for inclusion. NOTE: For participants with a significantly prolonged QRS complex (> 110 msec) due to a bundle branch block or an intraventricular conduction delay, an “adjusted” QTcF for the QRS widening will be used to evaluate study eligibility. “Adjusted QTcF” = measured QTcF – [measured QRS – 90 msec]","principalExclusionCriteriaTranslations":[{"id":12676476,"uuid":"dbf35540-8013-45cb-a783-480331b922f9","attributeTranslation":"17.\tPrésence d’une insuffisance cardiaque ou d’une cardiopathie cliniquement significative, avec l’un des éléments suivants :\n•\tAntécédents ou présence de tachyarythmie ventriculaire\n•\tPrésence d’une fibrillation auriculaire instable (réponse ventriculaire\n> 100 battements par minute [bpm]) ; les participants présentant une fibrillation auriculaire stable sont éligibles, à condition qu’ils ne remplissent aucun autre critère d’exclusion cardiaque\n•\tAvoir eu une angine de poitrine ou un infarctus aigu du myocarde\n 6 mois avant le traitement à l’étude\n•\tPrésenter une insuffisance cardiaque congestive nécessitant un traitement. Pour une Classe 1 de la New York Heart Association, l’inclusion peut être envisagée après discussion et accord avec le moniteur médical du promoteur\n•\tPrésenter une autre maladie cardiaque cliniquement significative (p. ex., arythmie ou hypertension non contrôlée ; antécédents d’hypertension labile ou mauvaise observance d’un schéma thérapeutique antihypertenseur, bradycardie symptomatique)\n•\tAvoir une endoprothèse à élution médicamenteuse à des fins cardiovasculaires placée  2 mois avant le traitement à l’étude\n•\tIntervalle QT corrigé par la formule de Fridericia (QTcF) (voir Annexe 2, Section 14.2 :\n-\tQTcF > 470 ms à l’ECG de référence (moyenne des valeurs de référence). Si les électrolytes sont anormaux, ils peuvent être corrigés, et les ECG de référence devront être renouvelés. En outre, les participants présentant une fréquence cardiaque asymptomatique persistante < 55 bpm devront faire l’objet d’une discussion avec le moniteur médical du promoteur en vue de leur éventuelle inclusion. REMARQUE : Chez les participants présentant un complexe QRS significativement prolongé (> 110 ms) en raison d’un bloc de branche ou d’un retard de conduction intraventriculaire, un QTcF\n« ajusté » en matière d’élargissement du QRS servira à évaluer l’éligibilité à l’étude. « QTcF ajusté » = QTcF mesuré - [QRS mesuré - 90 ms]","language":10,"languageDescription":"French"},{"id":12676478,"uuid":"dbf35540-8013-45cb-a783-480331b922f9","attributeTranslation":"17.\tFunzione cardiaca compromessa o malattie cardiache clinicamente significative, compresa una qualsiasi delle seguenti condizioni:\n•\tAnamnesi o presenza di tachiaritmia ventricolare.\n•\tPresenza di fibrillazione atriale instabile (risposta ventricolare >100 battiti al minuto [bpm]); i partecipanti con fibrillazione atriale stabile sono considerati idonei, purché non soddisfino alcuno degli altri criteri di esclusione di natura cardiaca.\n•\tAnamnesi di angina pectoris o infarto miocardico acuto 6 mesi prima del trattamento dello studio.\n•\tInsufficienza cardiaca congestizia con necessità di trattamento. Le forme di classe 1 secondo la classificazione della New York Heart Association possono essere valutate per l’inclusione, previa discussione e in accordo con il medical monitor dello sponsor.\n•\tPresenza di un’altra cardiopatia clinicamente significativa (per es., aritmia o ipertensione non controllata; anamnesi di ipertensione labile o scarsa aderenza a un regime antipertensivo; bradicardia sintomatica).\n•\tPosizionamento di stent medicato 2 mesi prima del trattamento dello studio per scopi cardiovascolari.\n•\tIntervallo QT corretto con formula di Fridericia (QTcF) (vedere Appendice 2, Sezione 14.2):\n-\tQTcF >470 msec all’ECG basale (media dei valori basali). Eventuali anomalie elettrolitiche possono essere corrette, con successiva ripetizione degli ECG basali. Inoltre, deve essere discussa con il medical monitor dello sponsor l’eventuale inclusione di partecipanti con frequenza cardiaca persistentemente\n<55 bpm e asintomatici. NOTA: per i partecipanti con prolungamento significativo del complesso QRS (>110 msec) dovuto a un blocco di branca o a un ritardo della conduzione intraventricolare, la valutazione dell’idoneità allo studio si baserà su un QTcF “aggiustato” per l’ampliamento del QRS. “QTcF aggiustato” = QTcF misurato - [QRS misurato - 90 msec].","language":14,"languageDescription":"Italian"},{"id":12676477,"uuid":"dbf35540-8013-45cb-a783-480331b922f9","attributeTranslation":"17.\tBeeinträchtigte Herzfunktion oder klinisch signifikante Herzerkrankungen, einschließlich eines der Folgenden:\n•\tVorgeschichte oder Vorliegen einer ventrikulären Tachyarrhythmie\n•\tVorliegen eines instabilen Vorhofflimmerns (ventrikuläre Reaktion\n> 100 Schläge pro Minute); Teilnehmer mit stabilem Vorhofflimmern sind geeignet, sofern sie keine der anderen kardialen Ausschlusskriterien erfüllen\n•\tAngina pectoris oder akuter Myokardinfarkt  6 Monate vor der Studienbehandlung\n•\tKongestive Herzinsuffizienz, die eine Behandlung erfordert (bei Stadium 1 nach der Klassifikation der New York Heart Association kann eine Aufnahme nach Absprache und Übereinstimmung mit dem Medical Monitor des Sponsors erwogen werden)\n•\tEine andere klinisch signifikante Herzerkrankung (z. B. unkontrollierte Arrhythmie oder Hypertonie, Vorgeschichte von labiler Hypertonie oder schlechte Compliance mit einem antihypertensiven Behandlungsschema, symptomatische Bradykardie)\n•\tEin medikamentenfreisetzender Stent für kardiovaskuläre Zwecke, der\n 2 Monate vor der Studienbehandlung implantiert wurde\n•\tKorrigiertes QT-Intervall mittels Fridericia-Formel (QTcF) (siehe Anhang 2, Abschnitt 14.2):\n-\tQTcF > 470 ms auf dem Baseline- EKG (Mittelwert der Baseline-Werte). Wenn die Elektrolyte auffällig sind, können sie korrigiert werden, und die Baseline-EKG sollten wiederholt werden. Darüber hinaus muss die Aufnahme von Teilnehmern mit einer asymptomatischen persistierenden Herzfrequenz von < 55 bpm mit dem Medical Monitor des Sponsors besprochen werden. HINWEIS: Bei Teilnehmern mit einem signifikant verlängerten QRS-Komplex (> 110 ms) aufgrund eines Schenkelblocks oder einer intraventrikulären Leitungsverzögerung wird ein „angepasstes” QTcF für die QRS- Verbreiterung zur Beurteilung der Studieneignung verwendet.\n„Angepasstes QTcF” = gemessenes QTcF – [QRS- Messung – 90 ms]","language":4,"languageDescription":"German"},{"id":12676479,"uuid":"dbf35540-8013-45cb-a783-480331b922f9","attributeTranslation":"17.\tVerminderde hartfunctie of klinisch significante hartziekten, waaronder een van de volgende:\n•\tEen voorgeschiedenis of aanwezigheid van ventriculaire tachyaritmie\n•\tAanwezigheid van instabiel atriumfibrilleren (ventriculaire respons\n>100 slagen per minuut [bpm]); deelnemers met stabiel atriumfibrilleren komen in aanmerking, op voorwaarde dat ze niet voldoen aan een van de andere cardiale exclusiecriteria\n•\tHeeft angina pectoris of acuut myocardinfarct gehad 6 maanden voorafgaand aan de onderzoeksbehandeling\n•\tHeeft congestief hartfalen waarvoor behandeling nodig is. Voor New York Heart Association klasse 1 kan inclusie worden overwogen met bespreking en overeenstemming met de medische monitor van de opdrachtgever\n•\tHeeft andere klinisch belangrijke hartziekte (bijv. ongecontroleerde aritmie of hypertensie; voorgeschiedenis van labiele hypertensie of slechte naleving van een antihypertensief regime, symptomatische bradycardie)\n•\tHeeft een ‘drug-eluting’ stent voor cardiovasculaire doeleinden die 2 maanden voorafgaand aan de onderzoeksbehandeling werd geplaatst\n•\tGecorrigeerd QT-interval met behulp van de formule van Fridericia (QTcF) (zie bijlage 2, sectie 14.2):\nQTcF >470 msec op baseline ECG (gemiddelde van baselinewaarden). Als elektrolyten abnormaal zijn, kunnen ze worden gecorrigeerd en moeten ECG’s bij de baseline worden herhaald. Daarnaast moeten deelnemers met een asymptomatische aanhoudende hartslag <55 spm worden besproken met de medische monitor van de opdrachtgever voor inclusie. LET OP: Voor deelnemers met een significant verlengd QRS-complex (>110 msec) als gevolg van een bundeltakblok of een intraventriculaire geleidingsvertraging, wordt een “aangepaste” QTcF voor de QRS-verwijding gebruikt om de geschiktheid voor het onderzoek te beoordelen. “Aangepaste QTcF” = gemeten QTcF - [gemeten QRS - 90 msec]","language":18,"languageDescription":"Dutch"},{"id":12676480,"uuid":"dbf35540-8013-45cb-a783-480331b922f9","attributeTranslation":"17.\tAlteración del funcionamiento cardíaco o enfermedades cardíacas de importancia clínica, incluida cualquiera de las siguientes:\n•\tAntecedentes o presencia de taquiarritmia ventricular.\n•\tPresencia de fibrilación auricular inestable (respuesta ventricular\n>100 latidos por minuto [lpm]); los participantes con fibrilación auricular estable serán aptos, siempre que no cumplan ninguno de los otros criterios de exclusión cardíacos.\n•\tHaber sufrido angina de pecho o infarto agudo de miocardio 6 meses antes del tratamiento del estudio.\n•\tTener insuficiencia cardíaca congestiva que requiera tratamiento. En los casos situados dentro de la clase 1 de la Asociación Neoyorquina de Cardiología (New York Heart Association), se puede contemplar la inclusión previa consulta y acuerdo con el monitor clínico del promotor.\n•\tTener otra cardiopatía de importancia clínica (p. ej., arritmia o \nhipertensión sin controlar; antecedentes de hipertensión lábil o mal cumplimiento de una pauta antihipertensiva, bradicardia sintomática).\n•\tImplantación de una endoprótesis farmacoactiva con fines cardiovasculares 2 meses antes del tratamiento del estudio.\n•\tIntervalo QT corregido según la fórmula de Fridericia (QTcF) (véase el Apéndice 2, Sección 14.2):\n-\tQTcF >470 ms en el ECG inicial (media de los valores iniciales). Si el valor de los electrólitos es anómalo, se pueden corregir, y se deben repetir los ECG iniciales. Además, los participantes con una frecuencia cardíaca persistente asintomática\n<55 lpm deben comentarse con el monitor clínico del promotor para su inclusión. NOTA: En el caso de los participantes con un complejo QRS significativamente prolongado (>110 ms) debido a un bloqueo de rama o a un retraso de la conducción intraventricular, se utilizará un QTcF «ajustado» para el ensanchamiento del QRS con el fin de evaluar la idoneidad para el estudio. «QTcF ajustado» = QTcF medido - [QRS medido -\n90 ms]","language":7,"languageDescription":"Spanish"},{"id":12676481,"uuid":"dbf35540-8013-45cb-a783-480331b922f9","attributeTranslation":"17.\tZaburzenia czynności serca lub klinicznie istotne choroby serca, w tym którekolwiek z poniższych:\n•\tWystępowanie tachyarytmii komorowej w wywiadzie lub obecnie\n•\tObecność niestabilnego migotania przedsionków (odpowiedź komór\n>100 uderzeń na minutę [bpm]); uczestnicy ze stabilnym migotaniem przedsionków kwalifikują się do udziału w badaniu, pod warunkiem że nie spełniają żadnego z pozostałych kryteriów wykluczających z udziału w badaniu.\n•\tDławica piersiowa lub ostry zawał mięśnia sercowego 6 miesięcy przed rozpoczęciem leczenia w ramach badania\n•\tZastoinowa niewydolność serca wymagająca leczenia. W przypadku klasy 1 wg Nowojorskiego Towarzystwa Kardiologicznego włączenie do badania można rozważyć po omówieniu i uzgodnieniu z monitorem medycznym Sponsora\n•\tInne klinicznie istotne choroby serca (np. niekontrolowane zaburzenia rytmu serca lub nadciśnienie tętnicze; w wywiadzie nadciśnienie labilne lub słaba zgodność ze schematem leczenia nadciśnienia, objawowa bradykardia)\n•\tStent uwalniający lek w schorzeniach sercowo-naczyniowych umieszczony 2 miesiące przed leczeniem w ramach badania\n•\tSkorygowany odstęp QT przy użyciu wzoru Fridericii (QTcF) (patrz Załącznik 2, punkt 14.2):\no\t-\tQTcF >470 ms w badaniu EKG w punkcie wyjściowym (średnia z wartości wyjściowych). Jeśli poziom elektrolitów jest nieprawidłowy, można je skorygować i powtórzyć wyjściowe badania EKG. Ponadto przypadki uczestników z bezobjawową utrzymującą się częstością akcji serca\n<55 uderzeń na minutę należy omówić z monitorem medycznym Sponsora w celu włączenia do badania. UWAGA: W przypadku uczestników ze znacznie wydłużonym zespołem QRS (>110 ms) z powodu bloku odnogi pęczka Hisa lub opóźnienia przewodzenia wewnątrzkomorowego do oceny kwalifikacji do badania zostanie wykorzystany „skorygowany” odstęp QTcF dla poszerzenia QRS.\n„skorygowany QTcF” = zmierzony QTcF – [zmierzony QRS – 90 ms]","language":19,"languageDescription":"Polish"}]}]},"endPoint":{"primaryEndPoints":[{"id":1184886,"number":1,"endPoint":"Dose-exposure-response (S&E) relationship; Plasma concentration profiles and PK parameters ;TEAEs, laboratory test abnormalities, ECG and vital sign changes; Study intervention discontinuation due to AEs; PFS, defined as the time from randomization to the first documented date of disease progression or death due to any cause, whichever occurs first; OS (time from randomization to date of death due to any cause","isPrimary":true,"endPointTranslations":[{"id":12676308,"uuid":"e9a28a0b-781a-423e-8d4f-836b7efd276f","attributeTranslation":"•\tBeziehung zwischen Dosis, Exposition und Ansprechen (Sicherheit und Wirksamkeit)\n•\tPlasmakonzentrationsprofile und pharmakokinetische (PK) Parameter, \n•\tAbbruch der Studienbehandlung aufgrund von UE\nPFS; OS","language":4,"languageDescription":"German"},{"id":12676312,"uuid":"e9a28a0b-781a-423e-8d4f-836b7efd276f","attributeTranslation":"•\tRelatie dosis-blootstelling-respons (veiligheid en werkzaamheid)\n•\tPlasmaconcentratieprofielen en farmacokinetische (PK) parameters \n PFS; OS\n•\tjako czas od randomizacji do zgonu z dowolnej przyczyny","language":18,"languageDescription":"Dutch"},{"id":12676310,"uuid":"e9a28a0b-781a-423e-8d4f-836b7efd276f","attributeTranslation":"•\tRapporto dose-esposizione-risposta (sicurezza ed efficacia)\n•\tProfili di concentrazione plasmatica e parametri farmacocinetici (PK), \n•\tEventi avversi emergenti dal trattamento (TEAE), anomalie nei test di laboratorio, variazioni nei parametri dell’elettrocardiogramma (ECG) e nei segni vitali\n•\tInterruzione del trattamento dello studio dovuta all’insorgenza di EA\nPFS; OS","language":14,"languageDescription":"Italian"},{"id":12676309,"uuid":"e9a28a0b-781a-423e-8d4f-836b7efd276f","attributeTranslation":"•\tZwiązek pomiędzy dawką, ekspozycją i odpowiedzią na leczenie (bezpieczeństwem i skutecznością)\n•\tProfile stężenia w osoczu i parametry farmakokinetyczne (PK), \n•\tZdarzenia niepożądane pojawiające się w trakcie leczenia (TEAE), nieprawidłowości w wynikach badań laboratoryjnych, badań elektrokardiograficznych (EKG) i zmiany w parametrach życiowych\n•\tPrzerwanie leczenia w ramach badania z powodu zdarzeń niepożądanych (AE)\n PFS ; OS","language":19,"languageDescription":"Polish"},{"id":12676311,"uuid":"e9a28a0b-781a-423e-8d4f-836b7efd276f","attributeTranslation":"•\tRelación dosis-exposición- respuesta (seguridad y eficacia)\n•\tPerfiles de concentración plasmática y parámetros farmacocinéticos (FC)\n•\tAcontecimientos adversos surgidos durante el tratamiento (AAST), anomalías en las pruebas analíticas, electrocardiograma (ECG) y cambios en las constantes vitales\n•\tInterrupción del tratamiento del estudio por AA\nSSP \nSG","language":7,"languageDescription":"Spanish"},{"id":12676313,"uuid":"e9a28a0b-781a-423e-8d4f-836b7efd276f","attributeTranslation":"•\tRelation dose-exposition-réponse (sécurité d’emploi et efficacité)\n•\tProfils de concentration plasmatique et paramètres pharmacocinétiques (PK), \n•\tLes événements indésirables apparus sous traitement (EIAT), anomalies des analyses biologiques, modifications de l’électrocardiogramme (ECG) et des signes vitaux\n•\tInterruption du traitement à l’étude en raison d’EI\nSSP; SG","language":10,"languageDescription":"French"}]}],"secondaryEndPoints":[{"id":1184887,"number":1,"endPoint":"ORR, defined as the proportion of participants with a complete response (CR) or a partial response (PR) as best objective response (BOR)","isPrimary":false,"endPointTranslations":[{"id":12676316,"uuid":"dec90945-3c38-4502-a055-a74266d310ed","attributeTranslation":"•\tTRO definida como la proporción de participantes con respuesta completa (RC) o respuesta parcial (RP) como mejor respuesta objetiva (MRO)","language":7,"languageDescription":"Spanish"},{"id":12676314,"uuid":"dec90945-3c38-4502-a055-a74266d310ed","attributeTranslation":"•\tORR, gedefinieerd als het aandeel deelnemers met een volledige respons (CR) of een gedeeltelijke respons (PR) als beste objectieve respons (BOR)","language":18,"languageDescription":"Dutch"},{"id":12676319,"uuid":"dec90945-3c38-4502-a055-a74266d310ed","attributeTranslation":"•\tLe TRO, défini comme la proportion de participants présentant une réponse complète (RC), ou une réponse partielle (RP) comme meilleure","language":10,"languageDescription":"French"},{"id":12676317,"uuid":"dec90945-3c38-4502-a055-a74266d310ed","attributeTranslation":"•\tORR definiowany jako odsetek uczestników z odpowiedzią całkowitą (CR) lub odpowiedzią częściową (PR) jako najlepszą odpowiedzią obiektywną (best objective response, BOR)","language":19,"languageDescription":"Polish"},{"id":12676318,"uuid":"dec90945-3c38-4502-a055-a74266d310ed","attributeTranslation":"•\tORR, definita come la proporzione dei partecipanti con risposta completa (CR) o risposta parziale (PR) come migliore risposta obiettiva (BOR)","language":14,"languageDescription":"Italian"},{"id":12676315,"uuid":"dec90945-3c38-4502-a055-a74266d310ed","attributeTranslation":"•\tORR, definiert als der Anteil der Teilnehmer mit einem vollständigen Ansprechen (CR) oder einem teilweisen Ansprechen (PR) als bestem objektiven Ansprechen (BOR)","language":4,"languageDescription":"German"}]},{"id":1184888,"number":2,"endPoint":"• PFS • ORR","isPrimary":false,"endPointTranslations":[{"id":12676322,"uuid":"833cbce4-19f4-4997-b9b2-29dd1c8a7fcc","attributeTranslation":"•\tSSP\n•\tTRO","language":7,"languageDescription":"Spanish"},{"id":12676324,"uuid":"833cbce4-19f4-4997-b9b2-29dd1c8a7fcc","attributeTranslation":"•\tPFS\n•\tORR","language":19,"languageDescription":"Polish"},{"id":12676323,"uuid":"833cbce4-19f4-4997-b9b2-29dd1c8a7fcc","attributeTranslation":"•\tSSP\n•\tTRO","language":10,"languageDescription":"French"},{"id":12676321,"uuid":"833cbce4-19f4-4997-b9b2-29dd1c8a7fcc","attributeTranslation":"•\tPFS\n•\tORR","language":18,"languageDescription":"Dutch"},{"id":12676325,"uuid":"833cbce4-19f4-4997-b9b2-29dd1c8a7fcc","attributeTranslation":"•\tPFS\n•\tORR","language":4,"languageDescription":"German"},{"id":12676320,"uuid":"833cbce4-19f4-4997-b9b2-29dd1c8a7fcc","attributeTranslation":"•\tPFS\n•\tORR","language":14,"languageDescription":"Italian"}]},{"id":1184889,"number":3,"endPoint":"• TEAEs, laboratory test abnormalities, ECG, and vital sign changes. • Study treatment discontinuation due to AEs","isPrimary":false,"endPointTranslations":[{"id":12676329,"uuid":"5d866479-3c23-41b6-9070-e434135d786f","attributeTranslation":"•\tTEAE’s, afwijkingen in laboratoriumtests, ECG en veranderingen in vitale functies\n•\tStopzetting van onderzoeksinterventie vanwege AE’s","language":18,"languageDescription":"Dutch"},{"id":12676326,"uuid":"5d866479-3c23-41b6-9070-e434135d786f","attributeTranslation":"•\tBBUE, Labortestanomalien, EKG und Veränderungen der Vitalfunktionen. \n•\tAbbruch der Studienbehandlung aufgrund von Nebenwirkungen","language":4,"languageDescription":"German"},{"id":12676327,"uuid":"5d866479-3c23-41b6-9070-e434135d786f","attributeTranslation":"•\tZdarzenia niepożądane pojawiające się w trakcie leczenia (TEAE), nieprawidłowości w wynikach badań laboratoryjnych, EKG i zmiany w parametrach życiowych. \n•\tPrzerwanie leczenia w ramach badania z powodu zdarzeń niepożądanych","language":19,"languageDescription":"Polish"},{"id":12676330,"uuid":"5d866479-3c23-41b6-9070-e434135d786f","attributeTranslation":"•\tEventi avversi emergenti dal trattamento (TEAE), anomalie nei test di laboratorio, variazioni nei parametri ECG e nei segni vitali\n•\tInterruzione del trattamento dello studio dovuta all’insorgenza di EA","language":14,"languageDescription":"Italian"},{"id":12676328,"uuid":"5d866479-3c23-41b6-9070-e434135d786f","attributeTranslation":"•\tAAST, anomalías en las pruebas analíticas, ECG y cambios en las constantes vitales.\n•\tInterrupción del tratamiento del estudio por AA","language":7,"languageDescription":"Spanish"},{"id":12676331,"uuid":"5d866479-3c23-41b6-9070-e434135d786f","attributeTranslation":"•\tEIAT, anomalies des analyses biologiques, ECG, et variation des signes vitaux\n•\tArrêt du traitement à l’étude en raison des EI","language":10,"languageDescription":"French"}]},{"id":1184890,"number":4,"endPoint":"• BOR • Disease control rate (DCR), defined as CR or PR, or stable disease (SD) ≥ 12 weeks • DOR, defined as the time from the first documented evidence of a CR or PR until disease progression or death due to the underlying disease, whichever occurs first • Time to response","isPrimary":false,"endPointTranslations":[{"id":12676333,"uuid":"ccda79d3-41d0-4088-ab54-a3c7a4dad896","attributeTranslation":"•\tMRO\n•\tTaux de contrôle de la maladie (TCM), défini comme une RC ou RP, ou une maladie stable (MS) ≥ 12 semaines\n•\tDR, définie comme le délai entre la première preuve documentée de RC ou RP jusqu’à la progression de la maladie ou le décès dû à une maladie sous-jacente, quelle que soit la première éventualité\n•\tDélai jusqu’à la réponse","language":10,"languageDescription":"French"},{"id":12676332,"uuid":"ccda79d3-41d0-4088-ab54-a3c7a4dad896","attributeTranslation":"•\tMRO\n•\tTasa de control de la enfermedad (TCE), definida como RC o RP, o estabilización de la enfermedad (EE) ≥ 12 semanas)\n•\tDuración de la respuesta (DR), \ndefinida como el tiempo transcurrido desde el primer indicio documentado de RC o RP hasta la progresión de la enfermedad o la muerte por LA enfermedad subyacente, lo que ocurra primero\n•\tTiempo transcurrido hasta la respuesta","language":7,"languageDescription":"Spanish"},{"id":12676335,"uuid":"ccda79d3-41d0-4088-ab54-a3c7a4dad896","attributeTranslation":"•\tBOR\n•\tWskaźnik kontroli choroby (disease control rate, DCR) definiowany jako CR lub PR lub stabilna choroba [SD] ≥12 tygodni\n•\tCzas trwania odpowiedzi (DOR), definiowany jako czas od pierwszego udokumentowanego potwierdzenia CR lub PR do progresji choroby lub zgonu z powodu choroby podstawowej, w zależności od tego, co nastąpi wcześniej\n•\tCzas do wystąpienia odpowiedzi","language":19,"languageDescription":"Polish"},{"id":12676336,"uuid":"ccda79d3-41d0-4088-ab54-a3c7a4dad896","attributeTranslation":"•\tBOR\n•\tTasso di controllo della malattia (DCR) (definito come CR o PR o stabilità di malattia [SD] 12 settimane)\n•\tDOR, definita come l’intervallo di tempo dalla prima evidenza documentata di CR o PR alla progressione di malattia o al decesso per qualsiasi causa, a seconda di quale evento si verifichi prima\n•\tTempo alla risposta","language":14,"languageDescription":"Italian"},{"id":12676334,"uuid":"ccda79d3-41d0-4088-ab54-a3c7a4dad896","attributeTranslation":"•\tBOR\n•\tZiektecontrolepercentage (DCR), gedefinieerd als CR of PR, of stabiele ziekte (SD) 12 weken\n•\tDOR, gedefinieerd als de tijd vanaf het eerste gedocumenteerde bewijs van een CR of PR tot ziekteprogressie of overlijden door welke oorzaak ook, afhankelijk van wat zich het eerst voordoet\n•\tTijd tot respons","language":18,"languageDescription":"Dutch"},{"id":12676337,"uuid":"ccda79d3-41d0-4088-ab54-a3c7a4dad896","attributeTranslation":"•\tBOR\n•\tKrankheitskontrollrate (DCR), definiert als CR oder PR, oder stabile Erkrankung (SD) ≥ 12 Wochen\n•\tDOR, definiert als die Zeit vom ersten dokumentierten Nachweis einer CR oder PR bis zum Fortschreiten der Krankheit oder dem Tod aufgrund der Grunderkrankung, je nachdem, was zuerst eintritt\n•\tZeit bis zum Ansprechen","language":4,"languageDescription":"German"}]},{"id":1184891,"number":5,"endPoint":"• PFS","isPrimary":false,"endPointTranslations":[{"id":12676341,"uuid":"33df74d7-9107-4dba-9525-f1689c5aae95","attributeTranslation":"Mejor respuesta objetiva (MRO)","language":7,"languageDescription":"Spanish"},{"id":12676342,"uuid":"33df74d7-9107-4dba-9525-f1689c5aae95","attributeTranslation":"Meilleure réponse objective (MRO)","language":10,"languageDescription":"French"},{"id":12676338,"uuid":"33df74d7-9107-4dba-9525-f1689c5aae95","attributeTranslation":"Migliore risposta obiettiva (BOR)","language":14,"languageDescription":"Italian"},{"id":12676343,"uuid":"33df74d7-9107-4dba-9525-f1689c5aae95","attributeTranslation":"Bestes objektives Ansprechen (BOR)","language":4,"languageDescription":"German"},{"id":12676339,"uuid":"33df74d7-9107-4dba-9525-f1689c5aae95","attributeTranslation":"Beste objectieve respons (BOR)","language":18,"languageDescription":"Dutch"},{"id":12676340,"uuid":"33df74d7-9107-4dba-9525-f1689c5aae95","attributeTranslation":"Najlepsza odpowiedź obiektywna (BCR)","language":19,"languageDescription":"Polish"}]},{"id":1184892,"number":6,"endPoint":"• BOR • ORR • DCR • DOR • Time to response","isPrimary":false,"endPointTranslations":[{"id":12676345,"uuid":"b6e786ee-8376-4ad0-a7e5-38bcd206f30f","attributeTranslation":"Tasso di controllo della malattia (DCR) (definito come CR o PR o stabilità di malattia [SD] ≥12 settimane)","language":14,"languageDescription":"Italian"},{"id":12676347,"uuid":"b6e786ee-8376-4ad0-a7e5-38bcd206f30f","attributeTranslation":"Wskaźnik kontroli choroby (DCR) definiowany jako CR lub PR lub stabilna choroba [SD] ≥12 tygodni","language":19,"languageDescription":"Polish"},{"id":12676344,"uuid":"b6e786ee-8376-4ad0-a7e5-38bcd206f30f","attributeTranslation":"Tasa de control de la enfermedad (TCE) (definida como RC o RP, o estabilización de la enfermedad [EE] ≥ 12 semanas)","language":7,"languageDescription":"Spanish"},{"id":12676348,"uuid":"b6e786ee-8376-4ad0-a7e5-38bcd206f30f","attributeTranslation":"Krankheitskontrollrate (DCR), definiert als CR oder PR oder stabile Erkrankung (SD) nach ≥ 12 Wochen","language":4,"languageDescription":"German"},{"id":12676346,"uuid":"b6e786ee-8376-4ad0-a7e5-38bcd206f30f","attributeTranslation":"Taux de contrôle de la maladie (TCM) (défini comme une RC ou une RP, ou une maladie stable (MS) ≥ 12 semaines)","language":10,"languageDescription":"French"},{"id":12676349,"uuid":"b6e786ee-8376-4ad0-a7e5-38bcd206f30f","attributeTranslation":"Ziektecontrolepercentage (DCR), gedefinieerd als CR of PR, of stabiele ziekte (SD) ≥12 weken","language":18,"languageDescription":"Dutch"}]},{"id":1184893,"number":7,"endPoint":"• Change from baseline over time and between treatment arms in European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and EuroQoL (EQ)-5D- 5L scores","isPrimary":false,"endPointTranslations":[{"id":12676353,"uuid":"e769bac0-a0af-44a5-970a-c93453c46430","attributeTranslation":"•\tVariation par rapport à la référence, dans le temps et entre les bras de traitement des scores aux questionnaires QLQ-C30 de l’Organisation européenne pour la recherche et le traitement du cancer (European Organization for Research and Treatment of Cancer, EORTC) et (EQ)-5D-5L d’EuroQoL","language":10,"languageDescription":"French"},{"id":12676351,"uuid":"e769bac0-a0af-44a5-970a-c93453c46430","attributeTranslation":"•\tÄnderung gegenüber dem Ausgangswert im Laufe der Zeit und zwischen den Behandlungsarmen in den QLQ-C30- und EuroQoL (EQ)-5D-5L-Werten der Europäischen Organisation für Forschung und Behandlung von Krebs (EORTC).","language":4,"languageDescription":"German"},{"id":12676350,"uuid":"e769bac0-a0af-44a5-970a-c93453c46430","attributeTranslation":"•\tZmiana w stosunku do punktu wyjściowego w czasie i pomiędzy grupami leczenia w wynikach QLQ-C30 Europejskiej Organizacji Badań i Leczenia Raka (European Organisation for Research and Treatment of Cancer) i EuroQoL (EQ)-5D-5L","language":19,"languageDescription":"Polish"},{"id":12676352,"uuid":"e769bac0-a0af-44a5-970a-c93453c46430","attributeTranslation":"Variazione rispetto al basale nel tempo e tra i bracci di trattamento nei punteggi del Questionario per misurare la qualità della vita - Modulo principale a 30 voci dell’Organizzazione europea per la ricerca e il trattamento del cancro (EORTC QLQ-C30) e del Questionario a 5 dimensioni e 5 livelli del gruppo EuroQoL (EQ- 5D-5L)","language":14,"languageDescription":"Italian"},{"id":12676354,"uuid":"e769bac0-a0af-44a5-970a-c93453c46430","attributeTranslation":"•\tVerandering ten opzichte van de baseline in de loop van de tijd en tussen de behandelingsgroepen in de QLQ-C30-score van de Europese organisatie voor onderzoek en behandeling van kanker (EORTC) en de 5D-5L-score van EuroQoL (EQ)","language":18,"languageDescription":"Dutch"},{"id":12676355,"uuid":"e769bac0-a0af-44a5-970a-c93453c46430","attributeTranslation":"•\tCambio con respecto al inicio a lo largo del tiempo y entre grupos de tratamiento en las puntuaciones del QLQ-C30 de la Organización Europea de Investigación y Tratamiento del Cáncer (EORTC) y del EuroQoL (EQ)-5D-5L","language":7,"languageDescription":"Spanish"}]}]},"trialDuration":{"estimatedGlobalEndDate":"2027-12-31","estimatedEndDate":"2027-12-31","estimatedRecruitmentStartDate":"2024-07-01"},"sourceOfMonetarySupport":[{"id":109491,"organisationName":"IDEAYA Biosciences, Inc."}],"populationOfTrialSubjects":{"ageRanges":[{"id":408144,"ageRangeCategoryCode":"4","ageRangeCategory":"4"},{"id":408145,"ageRangeCategoryCode":"3","ageRangeCategory":"3"}],"ageRangeSecondaryIds":[],"clinicalTrialGroups":[{"code":"2","name":"Patients"}],"isFemaleSubjects":true,"isMaleSubjects":true,"isVulnerablePopulationSelected":true},"individualParticipantData":{"planToShareIPD":"3"}},"protocolInformation":{"studyDesign":{"periodDetails":[{"id":210609,"businessKey":"1","title":"Phase 2a","description":"The Phase 2a part of study will include three treatment arms; involving two\ndoses of IDE196 (200 mg twice daily [BID] and 300 mg BID) in combination\nwith crizotinib (200 mg BID) compared with the comparator arm. This part of\nthe study will randomize up to approximately 150 participants to one of three\ntreatment arms on a 2:2:1 basis (approximately 60:60:30).\nSubsequently, following a minimum follow-up of two tumor assessments after\nCycle 1 Day 1 (C1D1) and appropriate tumor assessments from approximately\nthe first 30 participants in each IDE196 + crizotinib dosetreatment arm,\n(approximately 30:30:15), the data will be evaluated to determine if thean\noptimal combination dose can be selected. If thean optimal dose is not selected\nat this stage, the analysis will be repeated with approximately the first\n60 participants treated in each IDE196 + crizotinib treatment arm. At using 1-2\ntumor assessments per participant. When the point of optimal IDE196 +\ncrizotinib dose selectionis selected, the other dosetreatment arm will be dropped\nwith discontinuation of enrollment to that arm. Participants receiving the\nIDE196 dose (in combination with crizotinib) that is not selected, will be\noffered the choice to remain on the same dose or change to the chosen optimal\ndose. Phase 2 (Phase 2a [IDE196 with the selected optimal dose + crizotinib and\ncomparator] and Phase 2b)","blindingMethodCode":"3","blindedRoles":[],"armDetails":[{"description":"IDE196 (300 mg BID) + Crizotinib (200 mg BID)","title":"IDE196 (300 mg BID) + Crizotinib","id":116645},{"description":"IDE196 (200 mg BID) + Crizotinib (200 mg BID)","title":"IDE196 (200 mg BID) + Crizotinib","id":116646},{"description":"Investigator choice of: pembrolizumab, OR ipilimumab + nivolumab, OR dacarbazine","title":"Comparator Arm","id":116647}],"allocationMethod":"1"},{"id":210610,"businessKey":"2","title":"Phase 2b","description":"The Phase 2b part of the study will continue to enroll the combination treatment\nof IDE196 + crizotinib with the selected optimal dose of IDE196 compared\nwith the comparator arm. This part of the study will randomize approximately\n110 to 155 participants, depending on the number of participants required in\nPhase 2a to determine the optimal dose for IDE196. The randomization ratio is\n2:1 for IDE196 with the selected optimal dose + crizotinib versus the\ncomparator arm. Approximately 200 participants, including participants\nrandomized in both Phase 2a (excluding those in the dropped treatment arm)\nand Phase 2b, are planned to assess progression-free survival (PFS) (per blinded\nindependent central review [BICR]), which is the primary objective of Phase 2.","blindingMethodCode":"3","blindedRoles":[],"armDetails":[{"description":"IDE196 (dose decided from Phase 2a) + Crizotinib (200 mg BID)","title":"IDE196 (dose decided from Phase 2a) + Crizotinib","id":116648},{"description":"Investigator choice of: pembrolizumab, OR ipilimumab + nivolumab, OR dacarbazine","title":"Compartor Arm","id":116649}],"allocationMethod":"1"},{"id":210611,"businessKey":"3","title":"Phase 3","description":"The Phase 3 part of the study will continue to enroll the combination treatment\nof IDE196 + crizotinib with the selected dose of IDE196 compared with the\ncomparator arm. There are three options for this phase of the study, depending\non the outcome of Phase 2.\nOption 1: Approximately 160 participants will be randomized into the two\ntreatment arms at a ratio of 2:1 in this phase. This adds to the 200 participants\nfrom Phase 2, resulting in a total of approximately 360 (approximately 240:120)\nparticipants to assess overall survival (OS) for the primary objective of Phase 3.\nOption 2: An increased size of greater than 160 participants will be randomized\ninto the two treatment arms at a ratio of 2:1 in this phase. This adds to the\n200 participants from Phase 2, resulting in a total of more than 360 participants\nto assess OS for the primary objective. The sample size will be informed based\non the Phase 2 OS data.\nOption 3: The 200 participants in Phase 2 will not be included. Instead, a\nstandalone Phase 3 will enroll participants randomized at 2:1 ratio to the two\narms after Phase 2 to assess OS. The sample size will be informed based on the\nPhase 2 OS data. The Phase 3 part of the study will include all the participants\nthat are enrolled into the combination treatment of IDE196 + crizotinib with the\nselected dose of IDE196 and the comparator arm that are not included in the Phase 2 primary analysis. For the Option 3 scenario, the OS and PFS (by BICR)\nanalyses will not include the participants treated on the dropped treatment arm\nin Phase 2a.\nParticipants randomized to IDE196 + crizotinib, treatment will commence with\na 7-day run-in of IDE196 monotherapy (at the dose corresponding to the\ntreatment arm, and the run-in may be extended if clinically indicated) prior to\nstarting crizotinib.\nStudy treatment will continue until investigator-assessed disease progression,\ndeath (due to any cause), unacceptable toxicity or any treatment discontinuation\ncriteria are met as defined in Section 7.1.3.\nTumor responses will be assessed using Response Evaluation Criteria in Solid\nTumors (RECIST) v1.1. Confirmation of progression is required unless not\nfeasible (see efficacy assessment Section 7.2.1.2). Treatment beyond disease\nprogression is encouraged if meeting criteria as defined in Section 6.1.3.\nAdverse events (AEs) will be graded according to the guidelines in National\nCancer Institute (NCI) Common Terminology Criteria for Adverse Events\n(CTCAE) Version 5.0 or later.","blindingMethodCode":"3","blindedRoles":[],"armDetails":[{"description":"IDE196 (dose decided from Phase 2a) + Crizotinib (200 mg BID)","title":"IDE196 (dose decided from Phase 2a) + Crizotinib","id":116650},{"description":"Investigator choice of: pembrolizumab, OR ipilimumab + nivolumab, OR dacarbazine","title":"Comparator Arm","id":116651}],"allocationMethod":"1"}]}},"scientificAdviceAndPip":{"scientificAdvices":[],"paediatricInvestigationPlan":[]},"associatedClinicalTrials":[{"id":39577,"ctNumber":"2023-506686-66-00","sponsorName":"Ideaya Biosciences Inc.","fullTitle":"IDE196 (Darovasertib) in Combination with Crizotinib Versus Investigator’s Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma","sponsorAgreementOption":"NON_APPLICABLE","sponsorAgreementOptionName":"NON_APPLICABLE","parentClinicalTrialId":7060,"hasDocument":false,"associatedCtDocs":[]}],"references":[],"pubmedCode":[],"pubmedUrl":[]},"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-11-09","conclusionDate":"2026-11-09","therapeuticAreas":[{"code":"48","name":"Phenomena and Processes [G] - Ocular Physiological Phenomena [G14]"},{"code":"11","name":"Diseases [C] - Eye Diseases [C11]"},{"code":"4","name":"Diseases [C] - Neoplasms [C04]"}],"medicalConditions":[{"id":155726,"medicalCondition":"HLA-A2 negative metastatic uveal melanoma","isConditionRareDisease":true}],"sponsors":[{"id":169311,"primary":true,"publicContacts":[{"id":500012,"type":"Public","functionalName":"Candice Montagna","functionalEmailAddress":"cmontagna@ideayabio.com","telephone":"+17607174669","organisation":{"id":163656,"type":"Pharmaceutical company","typeCode":"10","name":"Ideaya Biosciences Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100043489","organisationLocationStatus":"Active"}}],"scientificContacts":[{"id":500013,"type":"Scientific","functionalName":"Candice Montagna","functionalEmailAddress":"cmontagna@ideayabio.com","telephone":"+17607174669","organisation":{"id":163656,"type":"Pharmaceutical company","typeCode":"10","name":"Ideaya Biosciences Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100043489","organisationLocationStatus":"Active"}}],"thirdParties":[{"id":780454,"organisationAddress":{"id":1054697,"organisation":{"id":1102303,"type":"Non-Pharmaceutical company","typeCode":"11","name":"Navitas LLP","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100023056","organisationLocationStatus":"Active"},"address":{"addressId":1193612,"oneLine":"27 Tank Bund Road, Nungambakkam","addressLine1":"27 Tank Bund Road","addressLine2":"Nungambakkam","addressLine3":"","addressLine4":"","city":"Chennai","postcode":"600034","country":356,"countryName":"India"},"phone":"+918043515700","email":"PV@navitaslifesciences.com","isBusinessKeyValidated":true,"businessKey":"LOC-100031805"},"sponsorDuties":[{"id":1207586,"code":"8"}],"phoneNumber":"+918043515700","email":"PV@navitaslifesciences.com"},{"id":780449,"organisationAddress":{"id":208253,"organisation":{"id":211876,"type":"Pharmaceutical company","typeCode":"10","name":"Labcorp Central Laboratory Services LP","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100032236","organisationLocationStatus":"Active"},"address":{"addressId":221502,"oneLine":"8211 Scicor Drive","addressLine1":"8211 Scicor Drive","addressLine2":"","addressLine3":"","addressLine4":"","city":"Indianapolis","postcode":"46214-2942","country":840,"countryName":"United States"},"phone":"0013173580216","email":"shannon.beckemeyer@labcorp.com","isBusinessKeyValidated":true,"businessKey":"ORG-100032236"},"sponsorDuties":[{"id":1207578,"code":"15","value":"cfDNA blood and tissue testing PK/PD testing"}],"phoneNumber":"0013173580216","email":"shannon.beckemeyer@labcorp.com"},{"id":780453,"organisationAddress":{"id":747005,"organisation":{"id":785575,"type":"Pharmaceutical company","typeCode":"10","name":"Veeda Clinical Research Limited","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100012827","organisationLocationStatus":"Active"},"address":{"addressId":822000,"oneLine":"Shivalik Plaza A, Near Atira IIM Road","addressLine1":"Shivalik Plaza A","addressLine2":"Near Atira IIM Road","addressLine3":"","addressLine4":"","city":"Ahmedabad","postcode":"380015","country":356,"countryName":"India"},"phone":"917967773000","email":"tulsidas.mishra@veedalifesciences.com","isBusinessKeyValidated":true,"businessKey":"ORG-100012827"},"sponsorDuties":[{"id":1207584,"code":"15","value":"Central Pharmacokinetic (PK) bioanalysis"},{"id":1207585,"code":"4"}],"phoneNumber":"917967773000","email":"tulsidas.mishra@veedalifesciences.com"},{"id":780448,"organisationAddress":{"id":208259,"organisation":{"id":211882,"type":"Pharmaceutical company","typeCode":"10","name":"United Biosource Corporation S.L.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100039092","organisationLocationStatus":"Active"},"address":{"addressId":221509,"oneLine":"Avenida Del Doctor Arce 14","addressLine1":"Avenida Del Doctor Arce 14","addressLine2":"","addressLine3":"","addressLine4":"","city":"Madrid","postcode":"28002","country":2027,"countryName":"Spain"},"phone":"004915111362202","email":"aurelie.etringer@ubc.com","isBusinessKeyValidated":true,"businessKey":"ORG-100039092"},"sponsorDuties":[{"id":1207574,"code":"1"},{"id":1207575,"code":"12"},{"id":1207576,"code":"2"},{"id":1207577,"code":"5"}],"phoneNumber":"004915111362202","email":"aurelie.etringer@ubc.com"},{"id":780451,"organisationAddress":{"id":1000693,"organisation":{"id":1044461,"type":"Pharmaceutical company","typeCode":"10","name":"Clario Medical Imaging Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100052770","organisationLocationStatus":"Active"},"address":{"addressId":1128092,"oneLine":"2033 6th Avenue Ste 333","addressLine1":"2033 6th Avenue Ste 333","addressLine2":"","addressLine3":"","addressLine4":"","city":"Seattle","postcode":"98121-2592","country":840,"countryName":"United States"},"phone":"+12159720420","email":"katherine.hayes@clario.com","isBusinessKeyValidated":true,"businessKey":"LOC-100093003"},"sponsorDuties":[{"id":1207581,"code":"15","value":"ECG Analysis"}],"phoneNumber":"+12159720420","email":"katherine.hayes@clario.com"},{"id":780452,"organisationAddress":{"id":208257,"organisation":{"id":211880,"type":"Non-Pharmaceutical company","typeCode":"11","name":"Suvoda LLC","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100043523","organisationLocationStatus":"Active"},"address":{"addressId":221507,"oneLine":"181 Washington Street Suite 100","addressLine1":"181 Washington Street Suite 100","addressLine2":"","addressLine3":"","addressLine4":"","city":"Conshohocken","postcode":"19428-2082","country":840,"countryName":"United States"},"phone":"0014844601522","email":"jsiroky@suvoda.com","isBusinessKeyValidated":true,"businessKey":"ORG-100043523"},"sponsorDuties":[{"id":1207582,"code":"14"},{"id":1207583,"code":"3"}],"phoneNumber":"0014844601522","email":"jsiroky@suvoda.com"},{"id":780450,"organisationAddress":{"id":747004,"organisation":{"id":785574,"type":"Pharmaceutical company","typeCode":"10","name":"QPS LLC","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100012847","organisationLocationStatus":"Active"},"address":{"addressId":821999,"oneLine":"3 Innovation Way Suite 204","addressLine1":"3 Innovation Way Suite 204","addressLine2":"","addressLine3":"","addressLine4":"","city":"Newark","postcode":"19711-5456","country":840,"countryName":"United States"},"phone":"3023695602","email":"sample@qps.com","isBusinessKeyValidated":true,"businessKey":"ORG-100012847"},"sponsorDuties":[{"id":1207579,"code":"15","value":"Central Pharmacokinetic (PK) bioanalysis & Plasma Protein Binding"},{"id":1207580,"code":"4"}],"phoneNumber":"3023695602","email":"sample@qps.com"}],"organisation":{"id":163656,"type":"Pharmaceutical company","typeCode":"10","name":"Ideaya Biosciences Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100043489","organisationLocationStatus":"Active"},"addresses":[{"id":160326,"organisation":{"id":163656,"type":"Pharmaceutical company","typeCode":"10","name":"Ideaya Biosciences Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100043489","organisationLocationStatus":"Active"},"address":{"addressId":169440,"oneLine":"7000 Shoreline Court Suite 350","addressLine1":"7000 Shoreline Court Suite 350","addressLine2":"","addressLine3":"","addressLine4":"","city":"South San Francisco","postcode":"94080-7604","country":840,"countryName":"United States"},"isBusinessKeyValidated":true,"businessKey":"LOC-100071933"}],"isCommercial":true,"commercial":"Commercial"}],"trialCategoryCode":"2","trialCategoryJustificationComment":"Phase 2/3 clinical trial, IDE196 (darovasertib) in combination with crizotinib versus investigator’s choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma. In line with EMA Guidance on Disclosure Rules, the study meets the criteria of a Category 2 trial.","partOneTherapeuticAreas":[{"id":1271883,"therapeuticArea":{"code":"48","name":"Phenomena and Processes [G] - Ocular Physiological Phenomena [G14]"}},{"id":1271882,"therapeuticArea":{"code":"11","name":"Diseases [C] - Eye Diseases [C11]"}},{"id":1271884,"therapeuticArea":{"code":"4","name":"Diseases [C] - Neoplasms [C04]"}}],"productRoleGroupInfos":[{"id":458762,"comments":"IDE196 (LXS196), IDE196 (LXS196)","miaNumber":"IMP11566/00001","productRoleCode":"1","productRoleName":"Test","products":[{"id":620448,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"10390877","productPharmForm":"TABLET","euMpNumber":"PRD10390877","prodAuthStatus":1,"prodName":"IDE196 (LXS196)","pharmForm":"TABLET","activeSubstanceName":"DAROVASERTIB","euSubstNumber":"SUB218613","nameOrg":"IDEAYA BIOSCIENCES INC.","productSubstances":[{"productPk":"10390877","substancePk":"320865","nameOrg":"IDEAYA BIOSCIENCES INC.","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"DAROVASERTIB","substanceEvCode":"SUB218613"}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"400","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"146","maxTreatmentPeriod":12,"timeUnitCode":"3","otherMedicinalProduct":"Chemical","evCode":"PRD10390877","sponsorProductCodeEdit":"IDE196","miaNumber":"IMP11566/00001","devices":[],"characteristics":["11"],"routes":["ORAL"],"allSubstancesChemicals":true,"productName":"IDE196 (LXS196)","jsonActiveSubstanceNames":"darovasertib","pharmaceuticalFormDisplay":"TABLET"},{"id":620449,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"10390878","productPharmForm":"TABLET","euMpNumber":"PRD10390878","prodAuthStatus":1,"prodName":"IDE196 (LXS196)","pharmForm":"TABLET","activeSubstanceName":"DAROVASERTIB","euSubstNumber":"SUB218613","nameOrg":"IDEAYA BIOSCIENCES INC.","productSubstances":[{"productPk":"10390878","substancePk":"320865","nameOrg":"IDEAYA BIOSCIENCES INC.","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"DAROVASERTIB","substanceEvCode":"SUB218613"}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"600","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"219","maxTreatmentPeriod":12,"timeUnitCode":"3","otherMedicinalProduct":"Chemical","evCode":"PRD10390878","sponsorProductCodeEdit":"IDE196","miaNumber":"IMP11566/00001","devices":[],"characteristics":["11"],"routes":["ORAL"],"allSubstancesChemicals":true,"productName":"IDE196 (LXS196)","jsonActiveSubstanceNames":"darovasertib","pharmaceuticalFormDisplay":"TABLET"}]},{"id":458759,"comments":"NIVOLUMAB","miaNumber":"DE_BB_01_MIA_2021_0008","productRoleCode":"2","productRoleName":"Comparator","products":[{"id":620444,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB122750","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"NIVOLUMAB","pharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","activeSubstanceName":"NIVOLUMAB","euSubstNumber":"SUB122750","productSubstances":[{"substancePk":"147067","actSubstOrigin":"Chemical","actSubstName":"NIVOLUMAB","substanceEvCode":"SUB122750"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":"Nivolumab 100mg/10 ml concentrate for solution for infusion"},"isPaediatricFormulation":false,"mpRoleInTrial":"2","orphanDrugEdit":false,"doseUom":"mg/Kg milligram(s)/kilogram","maxDailyDoseAmount":"1","doseUomTotal":"mg/Kg milligram(s)/kilogram","maxTotalDoseAmount":"4","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","miaNumber":"DE_BB_01_MIA_2021_0008","scientificProductEvCode":"SUB122750","devices":[],"characteristics":["7"],"routes":["INFUSION"],"allSubstancesChemicals":false,"productName":"NIVOLUMAB","jsonActiveSubstanceNames":"nivolumab"}]},{"id":458761,"comments":"CRIZOTINIB, CRIZOTINIB","miaNumber":"76364","productRoleCode":"1","productRoleName":"Test","products":[{"id":620446,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB32267","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"CRIZOTINIB","pharmForm":"CAPSULE, HARD","activeSubstanceName":"CRIZOTINIB","euSubstNumber":"SUB32267","productSubstances":[{"substancePk":"232804","actSubstOrigin":"Chemical","actSubstName":"CRIZOTINIB","substanceEvCode":"SUB32267"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":"Crizotinib 200mg hard capsules"},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"400","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"146","productChangedRelationMA":false,"maxTreatmentPeriod":12,"timeUnitCode":"3","otherMedicinalProduct":"Chemical","miaNumber":"76364","scientificProductEvCode":"SUB32267","devices":[],"characteristics":["11"],"routes":["ORAL"],"allSubstancesChemicals":false,"productName":"CRIZOTINIB","jsonActiveSubstanceNames":"crizotinib"},{"id":620447,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB32267","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"CRIZOTINIB","pharmForm":"CAPSULE, HARD","activeSubstanceName":"CRIZOTINIB","euSubstNumber":"SUB32267","productSubstances":[{"substancePk":"209620","actSubstOrigin":"Chemical","actSubstName":"CRIZOTINIB","substanceEvCode":"SUB32267"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":"Crizotinib 250 mg hard capsules"},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"250","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"91.25","productChangedRelationMA":false,"maxTreatmentPeriod":12,"timeUnitCode":"3","otherMedicinalProduct":"Chemical","miaNumber":"76364","scientificProductEvCode":"SUB32267","devices":[],"characteristics":["11"],"routes":["ORAL"],"allSubstancesChemicals":false,"productName":"CRIZOTINIB","jsonActiveSubstanceNames":"crizotinib"}]},{"id":458758,"comments":"DACARBAZINE","miaNumber":"DE_BB_01_MIA_2021_0008","productRoleCode":"2","productRoleName":"Comparator","products":[{"id":620443,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB06882MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"DACARBAZINE","pharmForm":"POWDER FOR SOLUTION FOR INFUSION","activeSubstanceName":"DACARBAZINE","euSubstNumber":"SUB06882MIG","productSubstances":[{"substancePk":"174830","actSubstOrigin":"Chemical","actSubstName":"DACARBAZINE","substanceEvCode":"SUB06882MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":"DACARBAZINE 1000 mg powder for solution for infusion"},"isPaediatricFormulation":false,"mpRoleInTrial":"2","orphanDrugEdit":false,"doseUom":"mg/m2 milligram(s)/sq. meter","maxDailyDoseAmount":"1000","doseUomTotal":"mg/m2 milligram(s)/square meter","maxTotalDoseAmount":"8670","productChangedRelationMA":false,"maxTreatmentPeriod":6,"timeUnitCode":"3","otherMedicinalProduct":"Chemical","sponsorProductCodeEdit":"DACARBAZINE 1000 mg powder for solution for infusion","miaNumber":"DE_BB_01_MIA_2021_0008","scientificProductEvCode":"SUB06882MIG","devices":[],"characteristics":["11"],"routes":["INTRAVENIOUS INFUSION"],"allSubstancesChemicals":false,"productName":"DACARBAZINE","jsonActiveSubstanceNames":"dacarbazine"}]},{"id":458763,"comments":"IPILIMUMAB","miaNumber":"DE_BB_01_MIA_2021_0008","productRoleCode":"2","productRoleName":"Comparator","products":[{"id":620450,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB29397","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"IPILIMUMAB","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"IPILIMUMAB","euSubstNumber":"SUB29397","productSubstances":[{"substancePk":"287482","actSubstOrigin":"Protein - Other","actSubstName":"IPILIMUMAB","substanceEvCode":"SUB29397"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":"YERVOY 5 mg/ml concentrate for solution for infusion"},"isPaediatricFormulation":false,"mpRoleInTrial":"2","orphanDrugEdit":false,"doseUom":"mg/kg milligram(s)/kilogram","maxDailyDoseAmount":"3","doseUomTotal":"mg/kg milligram(s)/kilogram","maxTotalDoseAmount":"12","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","miaNumber":"DE_BB_01_MIA_2021_0008","scientificProductEvCode":"SUB29397","devices":[],"characteristics":["7"],"routes":["INFUSION"],"allSubstancesChemicals":false,"productName":"IPILIMUMAB","jsonActiveSubstanceNames":"ipilimumab"}]},{"id":458760,"comments":"PEMBROLIZUMAB","miaNumber":"DE_BB_01_MIA_2021_0008","productRoleCode":"2","productRoleName":"Comparator","products":[{"id":620445,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB167136","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"PEMBROLIZUMAB","pharmForm":"CONCENTRATE FOR SOLUTION FOR INJECTION","activeSubstanceName":"PEMBROLIZUMAB","euSubstNumber":"SUB167136","productSubstances":[{"substancePk":"288763","actSubstOrigin":"Protein - Other","actSubstName":"PEMBROLIZUMAB","substanceEvCode":"SUB167136"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":"Pembrolizumab 100 mg concentrate for solution for injection; One vial of 4 mL of concentrate contains 100 mg of pembrolizumab;"},"isPaediatricFormulation":false,"mpRoleInTrial":"2","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"200","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"1.74","productChangedRelationMA":false,"maxTreatmentPeriod":6,"timeUnitCode":"3","miaNumber":"DE_BB_01_MIA_2021_0008","scientificProductEvCode":"SUB167136","devices":[],"characteristics":["7"],"routes":["INFUSION"],"allSubstancesChemicals":false,"productName":"PEMBROLIZUMAB","jsonActiveSubstanceNames":"pembrolizumab"}]}],"isLowIntervention":false},"authorizedPartsII":[{"id":332774,"mscId":25364,"mscInfo":{"id":25364,"clinicalTrialId":13093,"countryOrganisationId":2012,"reportingStatusCode":"Authorised","fromDate":"2024-06-13","toDate":"2024-06-13","isProposedRms":false,"expressDecision":"unwilling","countryName":"France","organisationInfo":{},"firstDecisionDate":"2024-09-13","trialStatus":"Authorised","trialPeriod":[{"id":39069,"trialStartDate":"2024-10-09","fromDate":"2024-10-18"},{"id":39070,"trialStartDate":"2024-10-09","fromDate":"2024-10-18"}],"trialRecruitmentPeriod":[{"id":51148,"recruitmentStartDate":"2024-10-09","fromDate":"2024-10-18"},{"id":51147,"recruitmentStartDate":"2024-10-09","fromDate":"2024-10-18"},{"id":51146,"recruitmentStartDate":"2024-10-09","fromDate":"2024-10-18"},{"id":118492,"recruitmentStartDate":"2024-10-09","recruitmentEndDate":"2026-07-15","fromDate":"2026-07-30"},{"id":118502,"recruitmentStartDate":"2024-10-09","recruitmentEndDate":"2026-07-15","fromDate":"2026-07-30"},{"id":118503,"recruitmentStartDate":"2024-10-09","recruitmentEndDate":"2026-07-15","fromDate":"2026-07-30"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":52596,"trialStartDate":"2024-10-09","fromDate":"2024-10-18"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2024-10-09","recruitmentEndDate":"2026-07-15"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":30774,"mscId":25364,"trialStatus":"Under evaluation","trialStatusDate":"2024-04-17T11:02:15.009"},{"id":47695,"mscId":25364,"trialStatus":"Authorised","trialStatusDate":"2024-08-09T15:31:01.42"}],"applicationTypeMsc":"1","mscName":"France","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-14","decision":"authorized","decisionDate":"2024-09-13"},"decisionDate":"2024-09-13","recruitmentSubjectCount":30,"trialSites":[{"id":2337689,"organisationAddressInfo":{"id":192446,"organisation":{"id":195958,"type":"Health care","typeCode":"2","name":"Centre Léon Bérard","commercial":false,"isBusinessKeyValidated":false,"businessKey":"ORL-000002363","organisationLocationStatus":"Active"},"address":{"addressId":204260,"oneLine":"Medical Oncology Department, Rue Laennec 28","addressLine1":"Medical Oncology Department","addressLine2":"Rue Laennec 28","addressLine3":"","addressLine4":"","city":"Lyon Cedex 08","postcode":"69373","country":2012,"countryName":"France"},"phone":"+33478782867","email":"evemarie.neidhardt@lyon.unicancer.fr","isBusinessKeyValidated":false,"businessKey":"ORL-000002363"},"personInfo":{"id":2591183,"firstName":"Eve-Marie","lastName":"Neidhardt","telephone":"+33478782867","email":"evemarie.neidhardt@lyon.unicancer.fr","title":"1"},"departmentName":"Medical Oncology"},{"id":2337690,"organisationAddressInfo":{"id":187473,"organisation":{"id":190959,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Institut Curie","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100009227","organisationLocationStatus":"Active"},"address":{"addressId":198925,"oneLine":"26 Rue D Ulm","addressLine1":"26 Rue D Ulm","addressLine2":"","addressLine3":"","addressLine4":"","city":"Paris","postcode":"75005","country":2012,"countryName":"France"},"phone":"0144324068","email":"sophie.piperno-neumann@curie.fr","isBusinessKeyValidated":true,"businessKey":"LOC-100014954"},"personInfo":{"id":2591184,"firstName":"Sophie","lastName":"Piperno-Neumann","telephone":"0144324068","email":"sophie.piperno-neumann@curie.fr","title":"1"},"departmentName":"Unité d'Investigation Clinique Adulte"}],"applicationStatusCode":"Authorised"},{"id":349022,"mscId":25365,"mscInfo":{"id":25365,"clinicalTrialId":13093,"countryOrganisationId":2029,"reportingStatusCode":"Authorised","fromDate":"2024-07-30","toDate":"2024-07-30","isProposedRms":true,"expressDecision":"willing","countryName":"Netherlands","organisationInfo":{},"firstDecisionDate":"2024-08-12","trialStatus":"Authorised","trialPeriod":[{"id":56535,"trialStartDate":"2025-02-18","fromDate":"2025-05-13"},{"id":56536,"trialStartDate":"2025-02-18","fromDate":"2025-05-13"}],"trialRecruitmentPeriod":[{"id":93816,"recruitmentStartDate":"2025-09-22","fromDate":"2025-11-26"},{"id":95058,"recruitmentStartDate":"2025-09-16","fromDate":"2025-12-09"},{"id":95059,"recruitmentStartDate":"2025-09-16","fromDate":"2025-12-09"},{"id":93817,"recruitmentStartDate":"2025-09-22","fromDate":"2025-11-26"},{"id":118493,"recruitmentStartDate":"2025-09-16","recruitmentEndDate":"2026-07-15","fromDate":"2026-07-30"},{"id":118504,"recruitmentStartDate":"2025-09-16","recruitmentEndDate":"2026-07-15","fromDate":"2026-07-30"},{"id":118505,"recruitmentStartDate":"2025-09-16","recruitmentEndDate":"2026-07-15","fromDate":"2026-07-30"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":82342,"trialStartDate":"2025-02-18","fromDate":"2025-05-13"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2025-09-16","recruitmentEndDate":"2026-07-15"},"isWillingAtDayThreeView":true,"clinicalTrialStatusHistory":[{"id":30778,"mscId":25365,"trialStatus":"Under evaluation","trialStatusDate":"2024-04-17T11:02:15.323"},{"id":47857,"mscId":25365,"trialStatus":"Authorised","trialStatusDate":"2024-08-12T15:15:23.82"}],"applicationTypeMsc":"1","mscName":"Netherlands","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-11-09","decision":"authorized_conditions","decisionDate":"2024-08-12"},"decisionDate":"2024-08-12","recruitmentSubjectCount":8,"trialSites":[{"id":2457578,"organisationAddressInfo":{"id":187499,"organisation":{"id":190986,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Academisch Ziekenhuis Leiden","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100014145","organisationLocationStatus":"Active"},"address":{"addressId":198953,"oneLine":"Albinusdreef 2","addressLine1":"Albinusdreef 2","addressLine2":"","addressLine3":"","addressLine4":"","city":"Leiden","postcode":"2333 ZA","country":2029,"countryName":"Netherlands"},"phone":"+31715261093","email":"h.w.kapiteijn@lumc.nl","isBusinessKeyValidated":true,"businessKey":"LOC-100019974"},"personInfo":{"id":2723410,"firstName":"Ellen (H.W.)","lastName":"Kapiteijn","telephone":"+31715261093","email":"h.w.kapiteijn@lumc.nl","title":"1"},"departmentName":"Department of Clinical Oncology"}],"applicationStatusCode":"Authorised"},{"id":332772,"mscId":25362,"mscInfo":{"id":25362,"clinicalTrialId":13093,"countryOrganisationId":2002,"reportingStatusCode":"Authorised","fromDate":"2024-07-10","toDate":"2024-07-10","isProposedRms":false,"expressDecision":"unwilling","countryName":"Belgium","organisationInfo":{},"firstDecisionDate":"2024-08-09","trialStatus":"Authorised","trialPeriod":[{"id":44377,"trialStartDate":"2024-11-26","fromDate":"2024-11-29"},{"id":44378,"trialStartDate":"2024-11-26","fromDate":"2024-11-29"}],"trialRecruitmentPeriod":[{"id":58693,"recruitmentStartDate":"2024-11-26","fromDate":"2024-11-29"},{"id":58694,"recruitmentStartDate":"2024-11-26","fromDate":"2024-11-29"},{"id":118490,"recruitmentStartDate":"2024-11-26","recruitmentEndDate":"2026-07-15","fromDate":"2026-07-30"},{"id":118498,"recruitmentStartDate":"2024-11-26","recruitmentEndDate":"2026-07-15","fromDate":"2026-07-30"},{"id":118499,"recruitmentStartDate":"2024-11-26","recruitmentEndDate":"2026-07-15","fromDate":"2026-07-30"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":60583,"trialStartDate":"2024-11-26","fromDate":"2024-11-29"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2024-11-26","recruitmentEndDate":"2026-07-15"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":30773,"mscId":25362,"trialStatus":"Under evaluation","trialStatusDate":"2024-04-17T11:02:14.919"},{"id":47609,"mscId":25362,"trialStatus":"Authorised","trialStatusDate":"2024-08-09T11:19:57.073"}],"applicationTypeMsc":"1","mscName":"Belgium","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-10-14","decision":"authorized_conditions","decisionDate":"2024-08-09"},"decisionDate":"2024-08-09","recruitmentSubjectCount":10,"trialSites":[{"id":2337683,"organisationAddressInfo":{"id":672612,"organisation":{"id":710690,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"UZ Leuven","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100006001","organisationLocationStatus":"Active"},"address":{"addressId":732677,"oneLine":"Herestraat 49","addressLine1":"Herestraat 49","addressLine2":"","addressLine3":"","addressLine4":"","city":"Leuven","postcode":"3000","country":2002,"countryName":"Belgium"},"phone":"016346912","email":"trialadministration@uzleuven.be","isBusinessKeyValidated":true,"businessKey":"ORG-100006001"},"personInfo":{"id":2591177,"firstName":"Paul","lastName":"Clement","telephone":"016346912","email":"trialadministration@uzleuven.be","title":"2"},"departmentName":"General Medical Oncology"},{"id":2337682,"organisationAddressInfo":{"id":187471,"organisation":{"id":190957,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Cliniques Universitaires Saint-Luc","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008950","organisationLocationStatus":"Active"},"address":{"addressId":198923,"oneLine":"Hippokrateslaan 10, Batiment 54","addressLine1":"Hippokrateslaan 10","addressLine2":"Batiment 54","addressLine3":"","addressLine4":"","city":"Sint-Lambrechts-Woluwe","postcode":"1200","country":2002,"countryName":"Belgium"},"phone":"003227645471","email":"jean-francois.baurain@saintluc.uclouvain.be","isBusinessKeyValidated":true,"businessKey":"LOC-100014498"},"personInfo":{"id":2591176,"firstName":"Jean Francois","lastName":"Baurain","telephone":"003227645471","email":"jean-francois.baurain@saintluc.uclouvain.be","title":"2"},"departmentName":"Medical Oncology"}],"applicationStatusCode":"Authorised"},{"id":332776,"mscId":25366,"mscInfo":{"id":25366,"clinicalTrialId":13093,"countryOrganisationId":2013,"reportingStatusCode":"Authorised","fromDate":"2024-07-01","toDate":"2024-07-01","isProposedRms":false,"expressDecision":"unwilling","countryName":"Germany","organisationInfo":{},"firstDecisionDate":"2024-08-12","trialStatus":"Authorised","trialPeriod":[{"id":56533,"trialStartDate":"2025-03-18","fromDate":"2025-05-13"},{"id":56534,"trialStartDate":"2025-03-18","fromDate":"2025-05-13"}],"trialRecruitmentPeriod":[{"id":76184,"recruitmentStartDate":"2025-03-18","fromDate":"2025-05-13"},{"id":76185,"recruitmentStartDate":"2025-03-18","fromDate":"2025-05-13"},{"id":118494,"recruitmentStartDate":"2025-03-18","recruitmentEndDate":"2026-07-15","fromDate":"2026-07-30"},{"id":118506,"recruitmentStartDate":"2025-03-18","recruitmentEndDate":"2026-07-15","fromDate":"2026-07-30"},{"id":118507,"recruitmentStartDate":"2025-03-18","recruitmentEndDate":"2026-07-15","fromDate":"2026-07-30"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":82339,"trialStartDate":"2025-03-18","fromDate":"2025-05-13"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2025-03-18","recruitmentEndDate":"2026-07-15"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":30775,"mscId":25366,"trialStatus":"Under evaluation","trialStatusDate":"2024-04-17T11:02:15.094"},{"id":47846,"mscId":25366,"trialStatus":"Authorised","trialStatusDate":"2024-08-12T14:22:55.886"}],"applicationTypeMsc":"1","mscName":"Germany","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-11","decision":"authorized_conditions","decisionDate":"2024-08-12"},"decisionDate":"2024-08-12","recruitmentSubjectCount":42,"trialSites":[{"id":2337692,"organisationAddressInfo":{"id":211438,"organisation":{"id":215078,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100022312","organisationLocationStatus":"Active"},"address":{"addressId":224944,"oneLine":"Fetscherstrasse 74, Johannstadt-Nord","addressLine1":"Fetscherstrasse 74","addressLine2":"Johannstadt-Nord","addressLine3":"","addressLine4":"","city":"Dresden","postcode":"01307","country":2013,"countryName":"Germany"},"phone":"+493514583677","email":"Friedegund.Meier@uniklinikum-dresden.de","isBusinessKeyValidated":true,"businessKey":"ORG-100022312"},"personInfo":{"id":2591186,"firstName":"Friedegund","lastName":"Meier","telephone":"+493514583677","email":"Friedegund.Meier@uniklinikum-dresden.de","title":"2"},"departmentName":"Klinik und Poliklinik für Dermatologie"},{"id":2337695,"organisationAddressInfo":{"id":211412,"organisation":{"id":215052,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitaetsklinikum Essen AöR","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100009964","organisationLocationStatus":"Active"},"address":{"addressId":224917,"oneLine":"Hufelandstrasse 55, Holsterhausen","addressLine1":"Hufelandstrasse 55","addressLine2":"Holsterhausen","addressLine3":"","addressLine4":"","city":"Essen","postcode":"45147","country":2013,"countryName":"Germany"},"phone":"+4920172385034","email":"halime.kalkavan@uk-essen.de","isBusinessKeyValidated":true,"businessKey":"ORG-100009964"},"personInfo":{"id":2591189,"firstName":"Halime","lastName":"Kalkavan","telephone":"+4920172385034","email":"halime.kalkavan@uk-essen.de","title":"1"},"departmentName":"Innere Klinik (Tumorforschung)"},{"id":2337696,"organisationAddressInfo":{"id":211432,"organisation":{"id":215072,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Charite Universitaetsmedizin Berlin KöR","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008480","organisationLocationStatus":"Active"},"address":{"addressId":224938,"oneLine":"Hindenburgdamm 30, Lichterfelde","addressLine1":"Hindenburgdamm 30","addressLine2":"Lichterfelde","addressLine3":"","addressLine4":"","city":"Berlin","postcode":"12203","country":2013,"countryName":"Germany"},"phone":"+4930450613594","email":"caroline-anna.peuker@charite.de","isBusinessKeyValidated":true,"businessKey":"ORG-100008480"},"personInfo":{"id":2591190,"firstName":"Caroline Anna","lastName":"Peuker","telephone":"+4930450613594","email":"caroline-anna.peuker@charite.de","title":"1"},"departmentName":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie"},{"id":2337694,"organisationAddressInfo":{"id":375710,"organisation":{"id":405322,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitaetsklinikum Heidelberg AöR","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100013733","organisationLocationStatus":"Active"},"address":{"addressId":401361,"oneLine":"Im Neuenheimer Feld 460, Neuenheim","addressLine1":"Im Neuenheimer Feld 460","addressLine2":"Neuenheim","addressLine3":"","addressLine4":"","city":"Heidelberg","postcode":"69120","country":2013,"countryName":"Germany"},"phone":"+496221568562","email":"Jessica.Hassel@med.uni-heidelber.de","isBusinessKeyValidated":true,"businessKey":"ORG-100013733"},"personInfo":{"id":2591188,"firstName":"Jessica","lastName":"Hassel","telephone":"+496221568562","email":"Jessica.Hassel@med.uni-heidelber.de","title":"2"},"departmentName":"NCT-DermatoOnkologie, DermatoOnkologie"},{"id":2337693,"organisationAddressInfo":{"id":211953,"organisation":{"id":215596,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"University Hospital Cologne AöR","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100012761","organisationLocationStatus":"Active"},"address":{"addressId":225510,"oneLine":"Kerpener Strasse 62, Lindenthal","addressLine1":"Kerpener Strasse 62","addressLine2":"Lindenthal","addressLine3":"","addressLine4":"","city":"Cologne","postcode":"50937","country":2013,"countryName":"Germany"},"phone":"+4922147882238","email":"Cindy.fraNKLIN@uk-koeln.de","isBusinessKeyValidated":true,"businessKey":"ORG-100012761"},"personInfo":{"id":2591187,"firstName":"Cindy","lastName":"Franklin","telephone":"+4922147882238","email":"Cindy.fraNKLIN@uk-koeln.de","title":"1"},"departmentName":"Klinik und Poliklinik für Dermatologie und Venerologie"}],"applicationStatusCode":"Authorised"},{"id":332771,"mscId":25361,"mscInfo":{"id":25361,"clinicalTrialId":13093,"countryOrganisationId":2018,"reportingStatusCode":"Authorised","fromDate":"2024-07-01","toDate":"2024-07-01","isProposedRms":false,"expressDecision":"unwilling","countryName":"Italy","organisationInfo":{},"firstDecisionDate":"2024-08-13","trialStatus":"Authorised","trialPeriod":[{"id":39071,"trialStartDate":"2024-10-16","fromDate":"2024-10-18"},{"id":39072,"trialStartDate":"2024-10-16","fromDate":"2024-10-18"}],"trialRecruitmentPeriod":[{"id":51149,"recruitmentStartDate":"2024-10-16","fromDate":"2024-10-18"},{"id":51150,"recruitmentStartDate":"2024-10-16","fromDate":"2024-10-18"},{"id":118489,"recruitmentStartDate":"2024-10-16","recruitmentEndDate":"2026-07-15","fromDate":"2026-07-30"},{"id":118496,"recruitmentStartDate":"2024-10-16","recruitmentEndDate":"2026-07-15","fromDate":"2026-07-30"},{"id":118497,"recruitmentStartDate":"2024-10-16","recruitmentEndDate":"2026-07-15","fromDate":"2026-07-30"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":52597,"trialStartDate":"2024-10-16","fromDate":"2024-10-18"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2024-10-16","recruitmentEndDate":"2026-07-15"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":30776,"mscId":25361,"trialStatus":"Under evaluation","trialStatusDate":"2024-04-17T11:02:15.173"},{"id":48038,"mscId":25361,"trialStatus":"Authorised","trialStatusDate":"2024-08-13T11:45:46.235"}],"applicationTypeMsc":"1","mscName":"Italy","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-10","decision":"authorized_conditions","decisionDate":"2024-08-13"},"decisionDate":"2024-08-13","recruitmentSubjectCount":20,"trialSites":[{"id":2337677,"organisationAddressInfo":{"id":207426,"organisation":{"id":211044,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"IRCCS Istituto Nazionale Tumori Fondazione Pascale","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100010025","organisationLocationStatus":"Active"},"address":{"addressId":220599,"oneLine":"Via Mariano Semmola 52","addressLine1":"Via Mariano Semmola 52","addressLine2":"","addressLine3":"","addressLine4":"","city":"Naples","postcode":"80131","country":2018,"countryName":"Italy"},"phone":"+3908117770443","email":"p.ascierto@istitutotumori.na.it","isBusinessKeyValidated":true,"businessKey":"ORG-100010025"},"personInfo":{"id":2591171,"firstName":"Paolo Antonio","lastName":"Ascierto","telephone":"+3908117770443","email":"p.ascierto@istitutotumori.na.it","title":"1"},"departmentName":"Melanoma. Cancer Immunotherapy and Development Therapeutics Unit"},{"id":2337679,"organisationAddressInfo":{"id":187492,"organisation":{"id":190979,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100014358","organisationLocationStatus":"Active"},"address":{"addressId":198945,"oneLine":"Largo Francesco Vito 1","addressLine1":"Largo Francesco Vito 1","addressLine2":"","addressLine3":"","addressLine4":"","city":"Rome","postcode":"00168","country":2018,"countryName":"Italy"},"phone":"+390630155202","email":"ernesto.rossi@policlinicogemelli.it","isBusinessKeyValidated":true,"businessKey":"LOC-100020237"},"personInfo":{"id":2591173,"firstName":"Ernesto","lastName":"Rossi","telephone":"+390630155202","email":"ernesto.rossi@policlinicogemelli.it","title":"1"},"departmentName":"Department of Medical and Surgical Sciences"},{"id":2337681,"organisationAddressInfo":{"id":207438,"organisation":{"id":211056,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Azienda Ospedaliera Universitaria Senese","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100023562","organisationLocationStatus":"Active"},"address":{"addressId":220611,"oneLine":"Viale Mario Bracci 2","addressLine1":"Viale Mario Bracci 2","addressLine2":"","addressLine3":"","addressLine4":"","city":"Siena","postcode":"53100","country":2018,"countryName":"Italy"},"phone":"+390577586335","email":"maio@unisi.it","isBusinessKeyValidated":true,"businessKey":"ORG-100023562"},"personInfo":{"id":2591175,"firstName":"Michele","lastName":"Maio","telephone":"+390577586335","email":"maio@unisi.it","title":"2"},"departmentName":"U.O.C. Immunoterapia Oncologica"},{"id":2337678,"organisationAddressInfo":{"id":207450,"organisation":{"id":211068,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Fondazione IRCCS Istituto Nazionale Dei Tumori","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008982","organisationLocationStatus":"Active"},"address":{"addressId":220623,"oneLine":"Via Giacomo Venezian 1","addressLine1":"Via Giacomo Venezian 1","addressLine2":"","addressLine3":"","addressLine4":"","city":"Milan","postcode":"20133","country":2018,"countryName":"Italy"},"phone":"+3902023902469","email":"lorenza.diguardo@istitutotumori.mi.it","isBusinessKeyValidated":true,"businessKey":"ORG-100008982"},"personInfo":{"id":2591172,"firstName":"Lorenza","lastName":"Di Guardo","telephone":"+3902023902469","email":"lorenza.diguardo@istitutotumori.mi.it","title":"1"},"departmentName":"Medical Oncology and Hematology"},{"id":2337680,"organisationAddressInfo":{"id":672599,"organisation":{"id":710677,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Istituto Oncologico Veneto","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100007494","organisationLocationStatus":"Active"},"address":{"addressId":732662,"oneLine":"Via Gattamelata 64","addressLine1":"Via Gattamelata 64","addressLine2":"","addressLine3":"","addressLine4":"","city":"Padova","postcode":"35128","country":2018,"countryName":"Italy"},"phone":"0498215931","email":"jacopo.pigozzo@iov.veneto.it","isBusinessKeyValidated":true,"businessKey":"ORG-100007494"},"personInfo":{"id":2591174,"firstName":"Jacopo","lastName":"Pigozzo","telephone":"0498215931","email":"jacopo.pigozzo@iov.veneto.it","title":"1"},"departmentName":"Melanoma Oncology Unit"}],"applicationStatusCode":"Authorised"},{"id":332773,"mscId":25363,"mscInfo":{"id":25363,"clinicalTrialId":13093,"countryOrganisationId":2027,"reportingStatusCode":"Authorised","fromDate":"2024-06-25","toDate":"2024-06-25","isProposedRms":false,"expressDecision":"unwilling","countryName":"Spain","organisationInfo":{},"firstDecisionDate":"2024-08-09","trialStatus":"Authorised","trialPeriod":[{"id":44375,"trialStartDate":"2024-10-15","fromDate":"2024-11-29"},{"id":44376,"trialStartDate":"2024-10-15","fromDate":"2024-11-29"},{"id":44374,"trialStartDate":"2024-10-15","fromDate":"2024-11-29"}],"trialRecruitmentPeriod":[{"id":58691,"recruitmentStartDate":"2024-10-16","fromDate":"2024-11-29"},{"id":58692,"recruitmentStartDate":"2024-10-16","fromDate":"2024-11-29"},{"id":118491,"recruitmentStartDate":"2024-10-16","recruitmentEndDate":"2026-07-15","fromDate":"2026-07-30"},{"id":118500,"recruitmentStartDate":"2024-10-16","recruitmentEndDate":"2026-07-15","fromDate":"2026-07-30"},{"id":118501,"recruitmentStartDate":"2024-10-16","recruitmentEndDate":"2026-07-15","fromDate":"2026-07-30"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":60581,"trialStartDate":"2024-10-15","fromDate":"2024-11-29"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2024-10-16","recruitmentEndDate":"2026-07-15"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":30777,"mscId":25363,"trialStatus":"Under evaluation","trialStatusDate":"2024-04-17T11:02:15.245"},{"id":47620,"mscId":25363,"trialStatus":"Authorised","trialStatusDate":"2024-08-09T11:58:30.598"}],"applicationTypeMsc":"1","mscName":"Spain","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-16","decision":"authorized_conditions","decisionDate":"2024-08-09"},"decisionDate":"2024-08-09","recruitmentSubjectCount":24,"trialSites":[{"id":2337686,"organisationAddressInfo":{"id":375723,"organisation":{"id":405335,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Complexo Hospitalario Universitario De Santiago","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100041171","organisationLocationStatus":"Active"},"address":{"addressId":401377,"oneLine":"Calle Choupana Da S/n","addressLine1":"Calle Choupana Da S/n","addressLine2":"","addressLine3":"","addressLine4":"","city":"Santiago De Compostela","postcode":"15706","country":2027,"countryName":"Spain"},"phone":"+34981950535","email":"chiquicuriel@gmail.com","isBusinessKeyValidated":true,"businessKey":"ORG-100041171"},"personInfo":{"id":2591180,"firstName":"Maria Teresa","lastName":"Curiel","telephone":"+34981950535","email":"chiquicuriel@gmail.com","title":"1"},"departmentName":"Servicio de Oncología"},{"id":2337684,"organisationAddressInfo":{"id":375749,"organisation":{"id":405361,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Universitario Virgen De La Macarena","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100041183","organisationLocationStatus":"Active"},"address":{"addressId":401407,"oneLine":"Avenida Del Doctor Fedriani 3","addressLine1":"Avenida Del Doctor Fedriani 3","addressLine2":"","addressLine3":"","addressLine4":"","city":"Sevilla","postcode":"41009","country":2027,"countryName":"Spain"},"phone":"+34629310196","email":"alamodelagala@gmail.com","isBusinessKeyValidated":true,"businessKey":"ORG-100041183"},"personInfo":{"id":2591178,"firstName":"Maria del Carmen","lastName":"Alamo","telephone":"+34629310196","email":"alamodelagala@gmail.com","title":"1"},"departmentName":"Servicio de Oncología"},{"id":2337687,"organisationAddressInfo":{"id":375750,"organisation":{"id":405362,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Universitario La Paz","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100028646","organisationLocationStatus":"Active"},"address":{"addressId":401410,"oneLine":"Paseo De La Castellana 261","addressLine1":"Paseo De La Castellana 261","addressLine2":"","addressLine3":"","addressLine4":"","city":"Madrid","postcode":"28046","country":2027,"countryName":"Spain"},"phone":"+34917277516","email":"eespinosa00@hotmail.com","isBusinessKeyValidated":true,"businessKey":"ORG-100028646"},"personInfo":{"id":2591181,"firstName":"Enrique","lastName":"Espinosa","telephone":"+34917277516","email":"eespinosa00@hotmail.com"},"departmentName":"Servicio de Oncología"},{"id":2337685,"organisationAddressInfo":{"id":213675,"organisation":{"id":217326,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Institut Catala D'oncologia","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100030394","organisationLocationStatus":"Active"},"address":{"addressId":227343,"oneLine":"Avinguda De La Gran Via De L'hospitalet 199-203","addressLine1":"Avinguda De La Gran Via De L'hospitalet 199-203","addressLine2":"","addressLine3":"","addressLine4":"","city":"L'hospitalet De Llobregat","postcode":"08908","country":2027,"countryName":"Spain"},"phone":"+34932607781","email":"jmpiulats@iconcologia.net","isBusinessKeyValidated":true,"businessKey":"ORG-100030394"},"personInfo":{"id":2591179,"firstName":"Josep Maria","lastName":"Piulats","telephone":"+34932607781","email":"jmpiulats@iconcologia.net","title":"1"},"departmentName":"Medical Oncology"},{"id":2337688,"organisationAddressInfo":{"id":375737,"organisation":{"id":405349,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital General Universitario De Valencia","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100023081","organisationLocationStatus":"Active"},"address":{"addressId":401392,"oneLine":"Avenida Del Tres Cruces 2","addressLine1":"Avenida Del Tres Cruces 2","addressLine2":"","addressLine3":"","addressLine4":"","city":"Valencia","postcode":"46014","country":2027,"countryName":"Spain"},"phone":"+34649967049","email":"berrocal.alf@gmail.com","isBusinessKeyValidated":true,"businessKey":"ORG-100023081"},"personInfo":{"id":2591182,"firstName":"Alfonso","lastName":"Berrocal","telephone":"+34649967049","email":"berrocal.alf@gmail.com","title":"1"},"departmentName":"Servicio de Oncología"}],"applicationStatusCode":"Authorised"},{"id":332777,"mscId":25367,"mscInfo":{"id":25367,"clinicalTrialId":13093,"countryOrganisationId":2031,"reportingStatusCode":"Authorised","fromDate":"2024-07-23","toDate":"2024-07-23","isProposedRms":false,"expressDecision":"unwilling","countryName":"Poland","organisationInfo":{},"firstDecisionDate":"2024-08-12","trialStatus":"Authorised","trialPeriod":[{"id":50046,"trialStartDate":"2024-12-17","fromDate":"2025-02-10"},{"id":50047,"trialStartDate":"2024-12-17","fromDate":"2025-02-10"}],"trialRecruitmentPeriod":[{"id":66845,"recruitmentStartDate":"2025-01-28","fromDate":"2025-02-10"},{"id":66825,"recruitmentStartDate":"2024-12-17","fromDate":"2025-02-10"},{"id":66826,"recruitmentStartDate":"2024-12-17","fromDate":"2025-02-10"},{"id":118495,"recruitmentStartDate":"2025-01-28","recruitmentEndDate":"2026-07-15","fromDate":"2026-07-30"},{"id":118508,"recruitmentStartDate":"2025-01-28","recruitmentEndDate":"2026-07-15","fromDate":"2026-07-30"},{"id":118509,"recruitmentStartDate":"2025-01-28","recruitmentEndDate":"2026-07-15","fromDate":"2026-07-30"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":70048,"trialStartDate":"2024-12-17","fromDate":"2025-02-10"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2025-01-28","recruitmentEndDate":"2026-07-15"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":30779,"mscId":25367,"trialStatus":"Under evaluation","trialStatusDate":"2024-04-17T11:02:15.393"},{"id":47830,"mscId":25367,"trialStatus":"Authorised","trialStatusDate":"2024-08-12T13:10:13.644"}],"applicationTypeMsc":"1","mscName":"Poland","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-10-02","decision":"authorized_conditions","decisionDate":"2024-08-12"},"decisionDate":"2024-08-12","recruitmentSubjectCount":20,"trialSites":[{"id":2337697,"organisationAddressInfo":{"id":201470,"organisation":{"id":205061,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100009191","organisationLocationStatus":"Active"},"address":{"addressId":214188,"oneLine":"Ul. Wilhelma Konrada Roentgena 5","addressLine1":"Ul. Wilhelma Konrada Roentgena 5","addressLine2":"","addressLine3":"","addressLine4":"","city":"Warsaw","postcode":"02-781","country":2031,"countryName":"Poland"},"phone":"+48225462184","email":"Piotr.Rutkowski@nio.gov.pl","isBusinessKeyValidated":true,"businessKey":"LOC-100017986"},"personInfo":{"id":2591191,"firstName":"Piotr","lastName":"Rutkowski","telephone":"+48225462184","email":"Piotr.Rutkowski@nio.gov.pl","title":"2"},"departmentName":"Kl. Nowotworow,Tk.Miekkich, Kosci i Czerniakow"},{"id":2337698,"organisationAddressInfo":{"id":375690,"organisation":{"id":405302,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Uniwersyteckie Centrum Kliniczne","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100042500","organisationLocationStatus":"Active"},"address":{"addressId":401340,"oneLine":"Ul. Mariana Smoluchowskiego 17","addressLine1":"Ul. Mariana Smoluchowskiego 17","addressLine2":"","addressLine3":"","addressLine4":"","city":"Gdansk","postcode":"80-214","country":2031,"countryName":"Poland"},"phone":"+48585844466","email":"mradomska@uck.gda.pl","isBusinessKeyValidated":true,"businessKey":"ORG-100042500"},"personInfo":{"id":2591192,"firstName":"Magdalena","lastName":"Blaszkowska","telephone":"+48585844466","email":"mradomska@uck.gda.pl","title":"1"},"departmentName":"Osrodek Badan Klinicznych Wczesnych Faz"}],"applicationStatusCode":"Authorised"}],"applicationInfo":[{"id":21115,"type":"INITIAL","status":"Authorised","ctNumber":"2023-506686-66-01","trialStatus":"Authorised","submissionDate":"2024-04-17","partI":{"assessmentOutcome":"acceptable_conditions","assessmentOutcomeDate":"2024-08-09"},"partIIInfo":[{"id":112672,"mscId":25363,"mscInfo":{"id":25363,"mscName":"Spain","countryOrganisationId":2027,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-07-15","decision":"authorized_conditions","decisionDate":"2024-08-09","reportingStatusCode":"Authorised","countryName":"Spain","trialStatus":"Authorised","firstDecisionDate":"2024-08-09"},"applicationStatusCode":"Authorised"},{"id":114487,"mscId":25366,"mscInfo":{"id":25366,"mscName":"Germany","countryOrganisationId":2013,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-07-31","decision":"authorized_conditions","decisionDate":"2024-08-12","reportingStatusCode":"Authorised","countryName":"Germany","trialStatus":"Authorised","firstDecisionDate":"2024-08-12"},"applicationStatusCode":"Authorised"},{"id":118069,"mscId":25362,"mscInfo":{"id":25362,"mscName":"Belgium","countryOrganisationId":2002,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-07-29","decision":"authorized_conditions","decisionDate":"2024-08-09","reportingStatusCode":"Authorised","countryName":"Belgium","trialStatus":"Authorised","firstDecisionDate":"2024-08-09"},"applicationStatusCode":"Authorised"},{"id":121802,"mscId":25367,"mscInfo":{"id":25367,"mscName":"Poland","countryOrganisationId":2031,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-08-05","decision":"authorized_conditions","decisionDate":"2024-08-12","reportingStatusCode":"Authorised","countryName":"Poland","trialStatus":"Authorised","firstDecisionDate":"2024-08-12"},"applicationStatusCode":"Authorised"},{"id":108944,"mscId":25364,"mscInfo":{"id":25364,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-08-01","decision":"authorized","decisionDate":"2024-09-13","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2024-09-13"},"applicationStatusCode":"Authorised"},{"id":123750,"mscId":25365,"mscInfo":{"id":25365,"mscName":"Netherlands","countryOrganisationId":2029,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-08-05","decision":"authorized_conditions","decisionDate":"2024-08-12","reportingStatusCode":"Authorised","countryName":"Netherlands","trialStatus":"Authorised","firstDecisionDate":"2024-08-12"},"applicationStatusCode":"Authorised"},{"id":114486,"mscId":25361,"mscInfo":{"id":25361,"mscName":"Italy","countryOrganisationId":2018,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-07-25","decision":"authorized_conditions","decisionDate":"2024-08-13","reportingStatusCode":"Authorised","countryName":"Italy","trialStatus":"Authorised","firstDecisionDate":"2024-08-13"},"applicationStatusCode":"Authorised"}],"decisionDate":"2024-08-09","ctMSCsByApplication":[{"id":25363,"mscName":"Spain","reportingStatusCode":"Authorised"},{"id":25366,"mscName":"Germany","reportingStatusCode":"Authorised"},{"id":25362,"mscName":"Belgium","reportingStatusCode":"Authorised"},{"id":25367,"mscName":"Poland","reportingStatusCode":"Authorised"},{"id":25364,"mscName":"France","reportingStatusCode":"Authorised"},{"id":25365,"mscName":"Netherlands","reportingStatusCode":"Authorised"},{"id":25361,"mscName":"Italy","reportingStatusCode":"Authorised"}],"businessKey":"IN-1","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":32916,"applicationId":21115,"mscId":25363,"mscName":"Spain","decisionDate":"2024-08-09T11:58:31.318","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":112672,"part1Id":46414,"applicationType":"INITIAL","isRMS":false},{"id":33288,"applicationId":21115,"mscId":25361,"mscName":"Italy","decisionDate":"2024-08-13T11:45:49.334","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":114486,"part1Id":46414,"applicationType":"INITIAL","isRMS":false},{"id":33090,"applicationId":21115,"mscId":25367,"mscName":"Poland","decisionDate":"2024-08-12T13:10:14.873","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":121802,"part1Id":46414,"applicationType":"INITIAL","isRMS":false},{"id":33122,"applicationId":21115,"mscId":25366,"mscName":"Germany","decisionDate":"2024-08-12T14:22:56.697","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":114487,"part1Id":46414,"applicationType":"INITIAL","isRMS":false},{"id":32906,"applicationId":21115,"mscId":25362,"mscName":"Belgium","decisionDate":"2024-08-09T11:19:58.047","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":118069,"part1Id":46414,"applicationType":"INITIAL","isRMS":false},{"id":32970,"applicationId":21115,"mscId":25364,"mscName":"France","decisionDate":"2024-08-09T15:31:02.948","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":108944,"part1Id":46414,"applicationType":"INITIAL","isRMS":false},{"id":33138,"applicationId":21115,"mscId":25365,"mscName":"Netherlands","decisionDate":"2024-08-12T15:15:24.995","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":123750,"part1Id":46414,"applicationType":"INITIAL","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"65173a79-1465-4904-b59d-e18a3d01d8aa","productRoleGroupId":144819},{"documentUuid":"a4791b00-5cba-4341-8540-092712bd45ad","productRoleGroupId":144816},{"documentUuid":"57385cc8-af02-4ffb-8391-723898f12bf3","productRoleGroupId":144821},{"documentUuid":"7fb78087-4c44-4484-97c3-0c3b80127f08","productRoleGroupId":144820},{"documentUuid":"74a2943e-2d8e-45a3-94d3-d7e3c0d428d6","productRoleGroupId":144817},{"documentUuid":"604a77c1-11d7-4350-937a-96db3dba2827","productRoleGroupId":144818}]},{"id":34754,"type":"NON SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2023-506686-66-01","trialStatus":"Authorised","submissionDate":"2024-09-06","partI":{"assessmentOutcome":"acceptable_conditions","assessmentOutcomeDate":"2024-08-09"},"partIIInfo":[{"id":134062,"mscId":25366,"mscInfo":{"id":25366,"mscName":"Germany","countryOrganisationId":2013,"decision":"authorized_conditions","decisionDate":"2024-08-12","reportingStatusCode":"Authorised","countryName":"Germany","trialStatus":"Authorised","firstDecisionDate":"2024-08-12"},"applicationStatusCode":"Authorised"},{"id":134061,"mscId":25363,"mscInfo":{"id":25363,"mscName":"Spain","countryOrganisationId":2027,"decision":"authorized_conditions","decisionDate":"2024-08-09","reportingStatusCode":"Authorised","countryName":"Spain","trialStatus":"Authorised","firstDecisionDate":"2024-08-09"},"applicationStatusCode":"Authorised"},{"id":134063,"mscId":25367,"mscInfo":{"id":25367,"mscName":"Poland","countryOrganisationId":2031,"decision":"authorized_conditions","decisionDate":"2024-08-12","reportingStatusCode":"Authorised","countryName":"Poland","trialStatus":"Authorised","firstDecisionDate":"2024-08-12"},"applicationStatusCode":"Authorised"},{"id":134059,"mscId":25362,"mscInfo":{"id":25362,"mscName":"Belgium","countryOrganisationId":2002,"decision":"authorized_conditions","decisionDate":"2024-08-09","reportingStatusCode":"Authorised","countryName":"Belgium","trialStatus":"Authorised","firstDecisionDate":"2024-08-09"},"applicationStatusCode":"Authorised"},{"id":134060,"mscId":25361,"mscInfo":{"id":25361,"mscName":"Italy","countryOrganisationId":2018,"decision":"authorized_conditions","decisionDate":"2024-08-13","reportingStatusCode":"Authorised","countryName":"Italy","trialStatus":"Authorised","firstDecisionDate":"2024-08-13"},"applicationStatusCode":"Authorised"}],"decisionDate":"2024-09-06","ctMSCsByApplication":[{"id":25366,"mscName":"Germany","reportingStatusCode":"Authorised"},{"id":25363,"mscName":"Spain","reportingStatusCode":"Authorised"},{"id":25367,"mscName":"Poland","reportingStatusCode":"Authorised"},{"id":25362,"mscName":"Belgium","reportingStatusCode":"Authorised"},{"id":25361,"mscName":"Italy","reportingStatusCode":"Authorised"}],"businessKey":"NSM-2","modScope":"PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":36659,"applicationId":34754,"mscId":25366,"mscName":"Germany","decisionDate":"2024-09-06T17:20:06.192","decision":"authorized","eventType":"decision","part2Id":134062,"part1Id":53128,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":36662,"applicationId":34754,"mscId":25363,"mscName":"Spain","decisionDate":"2024-09-06T17:20:06.192","decision":"authorized","eventType":"decision","part2Id":134061,"part1Id":53128,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":36661,"applicationId":34754,"mscId":25362,"mscName":"Belgium","decisionDate":"2024-09-06T17:20:06.192","decision":"authorized","eventType":"decision","part2Id":134059,"part1Id":53128,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":36663,"applicationId":34754,"mscId":25367,"mscName":"Poland","decisionDate":"2024-09-06T17:20:06.192","decision":"authorized","eventType":"decision","part2Id":134063,"part1Id":53128,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":36660,"applicationId":34754,"mscId":25361,"mscName":"Italy","decisionDate":"2024-09-06T17:20:06.192","decision":"authorized","eventType":"decision","part2Id":134060,"part1Id":53128,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false}],"productRoleGroupDocument":[{"documentUuid":"65173a79-1465-4904-b59d-e18a3d01d8aa","productRoleGroupId":166329},{"documentUuid":"604a77c1-11d7-4350-937a-96db3dba2827","productRoleGroupId":166334},{"documentUuid":"57385cc8-af02-4ffb-8391-723898f12bf3","productRoleGroupId":166331},{"documentUuid":"74a2943e-2d8e-45a3-94d3-d7e3c0d428d6","productRoleGroupId":166333},{"documentUuid":"7fb78087-4c44-4484-97c3-0c3b80127f08","productRoleGroupId":166332},{"documentUuid":"a4791b00-5cba-4341-8540-092712bd45ad","productRoleGroupId":166330}]},{"id":34769,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2023-506686-66-01","trialStatus":"Authorised","submissionDate":"2024-09-06","partI":{"assessmentOutcome":"acceptable_conditions"},"partIIInfo":[{"id":134104,"mscId":25364,"mscInfo":{"id":25364,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-09-13","decision":"authorized","decisionDate":"2024-09-13","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2024-09-13"},"applicationStatusCode":"Authorised"}],"decisionDate":"2024-09-13","ctMSCsByApplication":[{"id":25364,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"SM-1","modScope":"PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":37555,"applicationId":34769,"mscId":25364,"mscName":"France","decisionDate":"2024-09-13T13:01:57.771","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":134104,"part1Id":53152,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false}],"productRoleGroupDocument":[{"documentUuid":"a4791b00-5cba-4341-8540-092712bd45ad","productRoleGroupId":166396},{"documentUuid":"57385cc8-af02-4ffb-8391-723898f12bf3","productRoleGroupId":166397},{"documentUuid":"7fb78087-4c44-4484-97c3-0c3b80127f08","productRoleGroupId":166398},{"documentUuid":"65173a79-1465-4904-b59d-e18a3d01d8aa","productRoleGroupId":166395},{"documentUuid":"74a2943e-2d8e-45a3-94d3-d7e3c0d428d6","productRoleGroupId":166399},{"documentUuid":"604a77c1-11d7-4350-937a-96db3dba2827","productRoleGroupId":166400}]},{"id":39455,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2023-506686-66-01","trialStatus":"Authorised","submissionDate":"2024-12-19","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-04-14"},"partIIInfo":[{"id":170943,"mscId":25367,"mscInfo":{"id":25367,"mscName":"Poland","countryOrganisationId":2031,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-03-06","decision":"authorized_conditions","decisionDate":"2024-08-12","reportingStatusCode":"Authorised","countryName":"Poland","trialStatus":"Authorised","firstDecisionDate":"2024-08-12"},"applicationStatusCode":"Authorised"},{"id":170942,"mscId":25366,"mscInfo":{"id":25366,"mscName":"Germany","countryOrganisationId":2013,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-02-26","decision":"authorized_conditions","decisionDate":"2024-08-12","reportingStatusCode":"Authorised","countryName":"Germany","trialStatus":"Authorised","firstDecisionDate":"2024-08-12"},"applicationStatusCode":"Authorised"},{"id":170938,"mscId":25362,"mscInfo":{"id":25362,"mscName":"Belgium","countryOrganisationId":2002,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-03-06","decision":"authorized_conditions","decisionDate":"2024-08-09","reportingStatusCode":"Authorised","countryName":"Belgium","trialStatus":"Authorised","firstDecisionDate":"2024-08-09"},"applicationStatusCode":"Authorised"},{"id":190715,"mscId":25365,"mscInfo":{"id":25365,"mscName":"Netherlands","countryOrganisationId":2029,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-04-03","decision":"authorized_conditions","decisionDate":"2024-08-12","reportingStatusCode":"Authorised","countryName":"Netherlands","trialStatus":"Authorised","firstDecisionDate":"2024-08-12"},"applicationStatusCode":"Authorised"},{"id":170939,"mscId":25363,"mscInfo":{"id":25363,"mscName":"Spain","countryOrganisationId":2027,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-03-04","decision":"authorized_conditions","decisionDate":"2024-08-09","reportingStatusCode":"Authorised","countryName":"Spain","trialStatus":"Authorised","firstDecisionDate":"2024-08-09"},"applicationStatusCode":"Authorised"},{"id":170937,"mscId":25361,"mscInfo":{"id":25361,"mscName":"Italy","countryOrganisationId":2018,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-02-13","decision":"authorized_conditions","decisionDate":"2024-08-13","reportingStatusCode":"Authorised","countryName":"Italy","trialStatus":"Authorised","firstDecisionDate":"2024-08-13"},"applicationStatusCode":"Authorised"},{"id":182861,"mscId":25364,"mscInfo":{"id":25364,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-03-05","decision":"authorized","decisionDate":"2024-09-13","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2024-09-13"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-04-14","ctMSCsByApplication":[{"id":25367,"mscName":"Poland","reportingStatusCode":"Authorised"},{"id":25366,"mscName":"Germany","reportingStatusCode":"Authorised"},{"id":25362,"mscName":"Belgium","reportingStatusCode":"Authorised"},{"id":25365,"mscName":"Netherlands","reportingStatusCode":"Authorised"},{"id":25363,"mscName":"Spain","reportingStatusCode":"Authorised"},{"id":25361,"mscName":"Italy","reportingStatusCode":"Authorised"},{"id":25364,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"SM-2","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":66984,"applicationId":39455,"mscId":25366,"mscName":"Germany","decisionDate":"2025-04-15T11:20:39.186","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":170942,"part1Id":69937,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":67303,"applicationId":39455,"mscId":25365,"mscName":"Netherlands","decisionDate":"2025-04-16T14:20:32.797","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":190715,"part1Id":69937,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true},{"id":67533,"applicationId":39455,"mscId":25364,"mscName":"France","decisionDate":"2025-04-17T17:47:38.604","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":182861,"part1Id":69937,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":66731,"applicationId":39455,"mscId":25362,"mscName":"Belgium","decisionDate":"2025-04-14T14:50:01.865","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":170938,"part1Id":69937,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":67703,"applicationId":39455,"mscId":25367,"mscName":"Poland","decisionDate":"2025-04-22T08:45:04.785","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":170943,"part1Id":69937,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":66916,"applicationId":39455,"mscId":25361,"mscName":"Italy","decisionDate":"2025-04-15T09:59:03.579","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":170937,"part1Id":69937,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":67219,"applicationId":39455,"mscId":25363,"mscName":"Spain","decisionDate":"2025-04-16T10:33:21.11","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":170939,"part1Id":69937,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false}],"productRoleGroupDocument":[{"documentUuid":"7fb78087-4c44-4484-97c3-0c3b80127f08","productRoleGroupId":218904},{"documentUuid":"74a2943e-2d8e-45a3-94d3-d7e3c0d428d6","productRoleGroupId":218907},{"documentUuid":"57385cc8-af02-4ffb-8391-723898f12bf3","productRoleGroupId":218906},{"documentUuid":"604a77c1-11d7-4350-937a-96db3dba2827","productRoleGroupId":218903},{"documentUuid":"65173a79-1465-4904-b59d-e18a3d01d8aa","productRoleGroupId":218902},{"documentUuid":"a4791b00-5cba-4341-8540-092712bd45ad","productRoleGroupId":218905}]},{"id":53967,"type":"NON SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2023-506686-66-01","trialStatus":"Authorised","submissionDate":"2025-04-24","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-04-14"},"partIIInfo":[],"decisionDate":"2025-04-24","ctMSCsByApplication":[{"id":25367,"mscName":"Poland","reportingStatusCode":"Authorised"},{"id":25366,"mscName":"Germany","reportingStatusCode":"Authorised"},{"id":25362,"mscName":"Belgium","reportingStatusCode":"Authorised"},{"id":25365,"mscName":"Netherlands","reportingStatusCode":"Authorised"},{"id":25363,"mscName":"Spain","reportingStatusCode":"Authorised"},{"id":25361,"mscName":"Italy","reportingStatusCode":"Authorised"},{"id":25364,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"NSM-3","modScope":"PART_I","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":68334,"applicationId":53967,"mscId":25367,"mscName":"Poland","decisionDate":"2025-04-24T11:11:45.522","decision":"authorized","eventType":"decision","part1Id":83237,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":68334,"applicationId":53967,"mscId":25366,"mscName":"Germany","decisionDate":"2025-04-24T11:11:45.522","decision":"authorized","eventType":"decision","part1Id":83237,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":68334,"applicationId":53967,"mscId":25362,"mscName":"Belgium","decisionDate":"2025-04-24T11:11:45.522","decision":"authorized","eventType":"decision","part1Id":83237,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":68334,"applicationId":53967,"mscId":25365,"mscName":"Netherlands","decisionDate":"2025-04-24T11:11:45.522","decision":"authorized","eventType":"decision","part1Id":83237,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":true},{"id":68334,"applicationId":53967,"mscId":25363,"mscName":"Spain","decisionDate":"2025-04-24T11:11:45.522","decision":"authorized","eventType":"decision","part1Id":83237,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":68334,"applicationId":53967,"mscId":25361,"mscName":"Italy","decisionDate":"2025-04-24T11:11:45.522","decision":"authorized","eventType":"decision","part1Id":83237,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":68334,"applicationId":53967,"mscId":25364,"mscName":"France","decisionDate":"2025-04-24T11:11:45.522","decision":"authorized","eventType":"decision","part1Id":83237,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false}],"productRoleGroupDocument":[{"documentUuid":"7fb78087-4c44-4484-97c3-0c3b80127f08","productRoleGroupId":259641},{"documentUuid":"65173a79-1465-4904-b59d-e18a3d01d8aa","productRoleGroupId":259645},{"documentUuid":"604a77c1-11d7-4350-937a-96db3dba2827","productRoleGroupId":259644},{"documentUuid":"57385cc8-af02-4ffb-8391-723898f12bf3","productRoleGroupId":259643},{"documentUuid":"74a2943e-2d8e-45a3-94d3-d7e3c0d428d6","productRoleGroupId":259642},{"documentUuid":"a4791b00-5cba-4341-8540-092712bd45ad","productRoleGroupId":259646}]},{"id":57449,"type":"NON SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2023-506686-66-01","trialStatus":"Authorised","submissionDate":"2025-06-12","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-04-14"},"partIIInfo":[],"decisionDate":"2025-06-12","ctMSCsByApplication":[{"id":25367,"mscName":"Poland","reportingStatusCode":"Authorised"},{"id":25366,"mscName":"Germany","reportingStatusCode":"Authorised"},{"id":25362,"mscName":"Belgium","reportingStatusCode":"Authorised"},{"id":25365,"mscName":"Netherlands","reportingStatusCode":"Authorised"},{"id":25363,"mscName":"Spain","reportingStatusCode":"Authorised"},{"id":25361,"mscName":"Italy","reportingStatusCode":"Authorised"},{"id":25364,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"NSM-4","modScope":"PART_I","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":75562,"applicationId":57449,"mscId":25367,"mscName":"Poland","decisionDate":"2025-06-12T09:25:34.89","decision":"authorized","eventType":"decision","part1Id":88682,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":75562,"applicationId":57449,"mscId":25366,"mscName":"Germany","decisionDate":"2025-06-12T09:25:34.89","decision":"authorized","eventType":"decision","part1Id":88682,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":75562,"applicationId":57449,"mscId":25362,"mscName":"Belgium","decisionDate":"2025-06-12T09:25:34.89","decision":"authorized","eventType":"decision","part1Id":88682,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":75562,"applicationId":57449,"mscId":25365,"mscName":"Netherlands","decisionDate":"2025-06-12T09:25:34.89","decision":"authorized","eventType":"decision","part1Id":88682,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":true},{"id":75562,"applicationId":57449,"mscId":25363,"mscName":"Spain","decisionDate":"2025-06-12T09:25:34.89","decision":"authorized","eventType":"decision","part1Id":88682,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":75562,"applicationId":57449,"mscId":25361,"mscName":"Italy","decisionDate":"2025-06-12T09:25:34.89","decision":"authorized","eventType":"decision","part1Id":88682,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":75562,"applicationId":57449,"mscId":25364,"mscName":"France","decisionDate":"2025-06-12T09:25:34.89","decision":"authorized","eventType":"decision","part1Id":88682,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false}],"productRoleGroupDocument":[{"documentUuid":"604a77c1-11d7-4350-937a-96db3dba2827","productRoleGroupId":275898},{"documentUuid":"74a2943e-2d8e-45a3-94d3-d7e3c0d428d6","productRoleGroupId":275900},{"documentUuid":"a4791b00-5cba-4341-8540-092712bd45ad","productRoleGroupId":275901},{"documentUuid":"57385cc8-af02-4ffb-8391-723898f12bf3","productRoleGroupId":275899},{"documentUuid":"65173a79-1465-4904-b59d-e18a3d01d8aa","productRoleGroupId":275897},{"documentUuid":"7fb78087-4c44-4484-97c3-0c3b80127f08","productRoleGroupId":275896}]},{"id":59160,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2023-506686-66-01","trialStatus":"Authorised","submissionDate":"2025-07-02","partI":{"assessmentOutcome":"acceptable_conditions","assessmentOutcomeDate":"2025-08-26"},"partIIInfo":[],"decisionDate":"2025-08-27","ctMSCsByApplication":[{"id":25367,"mscName":"Poland","reportingStatusCode":"Authorised"},{"id":25366,"mscName":"Germany","reportingStatusCode":"Authorised"},{"id":25362,"mscName":"Belgium","reportingStatusCode":"Authorised"},{"id":25365,"mscName":"Netherlands","reportingStatusCode":"Authorised"},{"id":25363,"mscName":"Spain","reportingStatusCode":"Authorised"},{"id":25361,"mscName":"Italy","reportingStatusCode":"Authorised"},{"id":25364,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"SM-4","modScope":"PART_I","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":86949,"applicationId":59160,"mscId":25363,"mscName":"Spain","decisionDate":"2025-08-29T10:09:01.44","decision":"authorized_conditions","eventType":"decision","part1Id":96421,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":87035,"applicationId":59160,"mscId":25367,"mscName":"Poland","decisionDate":"2025-08-29T12:54:24.67","decision":"authorized_conditions","eventType":"decision","part1Id":96421,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":86713,"applicationId":59160,"mscId":25366,"mscName":"Germany","decisionDate":"2025-08-28T07:20:04.168","decision":"authorized_conditions","eventType":"decision","part1Id":96421,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":86719,"applicationId":59160,"mscId":25365,"mscName":"Netherlands","decisionDate":"2025-08-28T08:20:13.521","decision":"authorized_conditions","eventType":"decision","part1Id":96421,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true},{"id":86685,"applicationId":59160,"mscId":25362,"mscName":"Belgium","decisionDate":"2025-08-27T16:11:08.619","decision":"authorized_conditions","eventType":"decision","part1Id":96421,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":86739,"applicationId":59160,"mscId":25361,"mscName":"Italy","decisionDate":"2025-08-28T09:17:36.602","decision":"authorized_conditions","eventType":"decision","part1Id":96421,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":87431,"applicationId":59160,"mscId":25364,"mscName":"France","decisionDate":"2025-09-01T18:39:00.494","decision":"authorized_conditions","eventType":"decision","part1Id":96421,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false}],"productRoleGroupDocument":[{"documentUuid":"57385cc8-af02-4ffb-8391-723898f12bf3","productRoleGroupId":300332},{"documentUuid":"65173a79-1465-4904-b59d-e18a3d01d8aa","productRoleGroupId":300335},{"documentUuid":"74a2943e-2d8e-45a3-94d3-d7e3c0d428d6","productRoleGroupId":300336},{"documentUuid":"a4791b00-5cba-4341-8540-092712bd45ad","productRoleGroupId":300334},{"documentUuid":"604a77c1-11d7-4350-937a-96db3dba2827","productRoleGroupId":300333},{"documentUuid":"7fb78087-4c44-4484-97c3-0c3b80127f08","productRoleGroupId":300337}]},{"id":64016,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2023-506686-66-01","trialStatus":"Authorised","submissionDate":"2025-09-30","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-01-19"},"partIIInfo":[{"id":247878,"mscId":25367,"mscInfo":{"id":25367,"mscName":"Poland","countryOrganisationId":2031,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-11-30","decision":"authorized_conditions","decisionDate":"2024-08-12","reportingStatusCode":"Authorised","countryName":"Poland","trialStatus":"Authorised","firstDecisionDate":"2024-08-12"},"applicationStatusCode":"Authorised"},{"id":266410,"mscId":25365,"mscInfo":{"id":25365,"mscName":"Netherlands","countryOrganisationId":2029,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-01-19","decision":"authorized_conditions","decisionDate":"2024-08-12","reportingStatusCode":"Authorised","countryName":"Netherlands","trialStatus":"Authorised","firstDecisionDate":"2024-08-12"},"applicationStatusCode":"Authorised"},{"id":247873,"mscId":25362,"mscInfo":{"id":25362,"mscName":"Belgium","countryOrganisationId":2002,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-12-03","decision":"authorized_conditions","decisionDate":"2024-08-09","reportingStatusCode":"Authorised","countryName":"Belgium","trialStatus":"Authorised","firstDecisionDate":"2024-08-09"},"applicationStatusCode":"Authorised"},{"id":247874,"mscId":25363,"mscInfo":{"id":25363,"mscName":"Spain","countryOrganisationId":2027,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-11-26","decision":"authorized_conditions","decisionDate":"2024-08-09","reportingStatusCode":"Authorised","countryName":"Spain","trialStatus":"Authorised","firstDecisionDate":"2024-08-09"},"applicationStatusCode":"Authorised"},{"id":247877,"mscId":25366,"mscInfo":{"id":25366,"mscName":"Germany","countryOrganisationId":2013,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-11-03","decision":"authorized_conditions","decisionDate":"2024-08-12","reportingStatusCode":"Authorised","countryName":"Germany","trialStatus":"Authorised","firstDecisionDate":"2024-08-12"},"applicationStatusCode":"Authorised"},{"id":247872,"mscId":25361,"mscInfo":{"id":25361,"mscName":"Italy","countryOrganisationId":2018,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-10-23","decision":"authorized_conditions","decisionDate":"2024-08-13","reportingStatusCode":"Authorised","countryName":"Italy","trialStatus":"Authorised","firstDecisionDate":"2024-08-13"},"applicationStatusCode":"Authorised"},{"id":247875,"mscId":25364,"mscInfo":{"id":25364,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-11-18","decision":"authorized","decisionDate":"2024-09-13","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2024-09-13"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-01-19","ctMSCsByApplication":[{"id":25367,"mscName":"Poland","reportingStatusCode":"Authorised"},{"id":25365,"mscName":"Netherlands","reportingStatusCode":"Authorised"},{"id":25362,"mscName":"Belgium","reportingStatusCode":"Authorised"},{"id":25363,"mscName":"Spain","reportingStatusCode":"Authorised"},{"id":25366,"mscName":"Germany","reportingStatusCode":"Authorised"},{"id":25361,"mscName":"Italy","reportingStatusCode":"Authorised"},{"id":25364,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"SM-5","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":105730,"applicationId":64016,"mscId":25366,"mscName":"Germany","decisionDate":"2026-01-20T10:19:30.416","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":247877,"part1Id":103305,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":106127,"applicationId":64016,"mscId":25362,"mscName":"Belgium","decisionDate":"2026-01-22T10:45:53.032","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":247873,"part1Id":103305,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":105390,"applicationId":64016,"mscId":25365,"mscName":"Netherlands","decisionDate":"2026-01-19T08:22:53.709","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":266410,"part1Id":103305,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true},{"id":106125,"applicationId":64016,"mscId":25361,"mscName":"Italy","decisionDate":"2026-01-22T10:35:04.504","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":247872,"part1Id":103305,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":106368,"applicationId":64016,"mscId":25364,"mscName":"France","decisionDate":"2026-01-23T18:29:24.759","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":247875,"part1Id":103305,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":106306,"applicationId":64016,"mscId":25363,"mscName":"Spain","decisionDate":"2026-01-23T13:25:41.936","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":247874,"part1Id":103305,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":106435,"applicationId":64016,"mscId":25367,"mscName":"Poland","decisionDate":"2026-01-26T09:27:00.877","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":247878,"part1Id":103305,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false}],"productRoleGroupDocument":[{"documentUuid":"74a2943e-2d8e-45a3-94d3-d7e3c0d428d6","productRoleGroupId":321511},{"documentUuid":"7fb78087-4c44-4484-97c3-0c3b80127f08","productRoleGroupId":321512},{"documentUuid":"a4791b00-5cba-4341-8540-092712bd45ad","productRoleGroupId":321513},{"documentUuid":"65173a79-1465-4904-b59d-e18a3d01d8aa","productRoleGroupId":321515},{"documentUuid":"604a77c1-11d7-4350-937a-96db3dba2827","productRoleGroupId":321514},{"documentUuid":"57385cc8-af02-4ffb-8391-723898f12bf3","productRoleGroupId":321516}]},{"id":87802,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2023-506686-66-01","trialStatus":"Authorised","submissionDate":"2026-08-07","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-11-09"},"partIIInfo":[{"id":332774,"mscId":25364,"mscInfo":{"id":25364,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-14","decision":"authorized","decisionDate":"2024-09-13","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2024-09-13"},"applicationStatusCode":"Authorised"},{"id":349022,"mscId":25365,"mscInfo":{"id":25365,"mscName":"Netherlands","countryOrganisationId":2029,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-11-09","decision":"authorized_conditions","decisionDate":"2024-08-12","reportingStatusCode":"Authorised","countryName":"Netherlands","trialStatus":"Authorised","firstDecisionDate":"2024-08-12"},"applicationStatusCode":"Authorised"},{"id":332772,"mscId":25362,"mscInfo":{"id":25362,"mscName":"Belgium","countryOrganisationId":2002,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-10-14","decision":"authorized_conditions","decisionDate":"2024-08-09","reportingStatusCode":"Authorised","countryName":"Belgium","trialStatus":"Authorised","firstDecisionDate":"2024-08-09"},"applicationStatusCode":"Authorised"},{"id":332776,"mscId":25366,"mscInfo":{"id":25366,"mscName":"Germany","countryOrganisationId":2013,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-11","decision":"authorized_conditions","decisionDate":"2024-08-12","reportingStatusCode":"Authorised","countryName":"Germany","trialStatus":"Authorised","firstDecisionDate":"2024-08-12"},"applicationStatusCode":"Authorised"},{"id":332771,"mscId":25361,"mscInfo":{"id":25361,"mscName":"Italy","countryOrganisationId":2018,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-10","decision":"authorized_conditions","decisionDate":"2024-08-13","reportingStatusCode":"Authorised","countryName":"Italy","trialStatus":"Authorised","firstDecisionDate":"2024-08-13"},"applicationStatusCode":"Authorised"},{"id":332773,"mscId":25363,"mscInfo":{"id":25363,"mscName":"Spain","countryOrganisationId":2027,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-16","decision":"authorized_conditions","decisionDate":"2024-08-09","reportingStatusCode":"Authorised","countryName":"Spain","trialStatus":"Authorised","firstDecisionDate":"2024-08-09"},"applicationStatusCode":"Authorised"},{"id":332777,"mscId":25367,"mscInfo":{"id":25367,"mscName":"Poland","countryOrganisationId":2031,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-10-02","decision":"authorized_conditions","decisionDate":"2024-08-12","reportingStatusCode":"Authorised","countryName":"Poland","trialStatus":"Authorised","firstDecisionDate":"2024-08-12"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-11-09","ctMSCsByApplication":[{"id":25364,"mscName":"France","reportingStatusCode":"Authorised"},{"id":25365,"mscName":"Netherlands","reportingStatusCode":"Authorised"},{"id":25362,"mscName":"Belgium","reportingStatusCode":"Authorised"},{"id":25366,"mscName":"Germany","reportingStatusCode":"Authorised"},{"id":25361,"mscName":"Italy","reportingStatusCode":"Authorised"},{"id":25363,"mscName":"Spain","reportingStatusCode":"Authorised"},{"id":25367,"mscName":"Poland","reportingStatusCode":"Authorised"}],"businessKey":"SM-6","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":150127,"applicationId":87802,"mscId":25362,"mscName":"Belgium","decisionDate":"2026-11-09T15:59:04.73","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":332772,"part1Id":148302,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":150151,"applicationId":87802,"mscId":25364,"mscName":"France","decisionDate":"2026-11-09T16:39:51.705","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":332774,"part1Id":148302,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":151018,"applicationId":87802,"mscId":25367,"mscName":"Poland","decisionDate":"2026-11-13T20:02:37.72","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":332777,"part1Id":148302,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":150608,"applicationId":87802,"mscId":25366,"mscName":"Germany","decisionDate":"2026-11-12T10:37:46.253","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":332776,"part1Id":148302,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":150240,"applicationId":87802,"mscId":25361,"mscName":"Italy","decisionDate":"2026-11-10T10:27:15.249","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":332771,"part1Id":148302,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":150711,"applicationId":87802,"mscId":25363,"mscName":"Spain","decisionDate":"2026-11-12T13:06:53.842","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":332773,"part1Id":148302,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":150102,"applicationId":87802,"mscId":25365,"mscName":"Netherlands","decisionDate":"2026-11-09T15:15:05.502","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":349022,"part1Id":148302,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"7fb78087-4c44-4484-97c3-0c3b80127f08","productRoleGroupId":458762},{"documentUuid":"a4791b00-5cba-4341-8540-092712bd45ad","productRoleGroupId":458759},{"documentUuid":"65173a79-1465-4904-b59d-e18a3d01d8aa","productRoleGroupId":458761},{"documentUuid":"604a77c1-11d7-4350-937a-96db3dba2827","productRoleGroupId":458758},{"documentUuid":"57385cc8-af02-4ffb-8391-723898f12bf3","productRoleGroupId":458763},{"documentUuid":"74a2943e-2d8e-45a3-94d3-d7e3c0d428d6","productRoleGroupId":458760}]}],"trialGlobalEnd":[],"memberStatesConcerned":[{"mscName":"Spain","mscId":25363,"firstDecisionDate":"2024-08-09T11:58:31.318","lastDecisionDate":"2026-11-12T13:06:53.842","mscPublicStatusCode":5},{"mscName":"Italy","mscId":25361,"firstDecisionDate":"2024-08-13T11:45:49.334","lastDecisionDate":"2026-11-10T10:27:15.249","mscPublicStatusCode":5},{"mscName":"Poland","mscId":25367,"firstDecisionDate":"2024-08-12T13:10:14.873","lastDecisionDate":"2026-11-13T20:02:37.72","mscPublicStatusCode":5},{"mscName":"Germany","mscId":25366,"firstDecisionDate":"2024-08-12T14:22:56.697","lastDecisionDate":"2026-11-12T10:37:46.253","mscPublicStatusCode":5},{"mscName":"Belgium","mscId":25362,"firstDecisionDate":"2024-08-09T11:19:58.047","lastDecisionDate":"2026-11-09T15:59:04.73","mscPublicStatusCode":5},{"mscName":"France","mscId":25364,"firstDecisionDate":"2024-08-09T15:31:02.948","lastDecisionDate":"2026-11-09T16:39:51.705","mscPublicStatusCode":5},{"mscName":"Netherlands","mscId":25365,"firstDecisionDate":"2024-08-12T15:15:24.995","lastDecisionDate":"2026-11-09T15:15:05.502","mscPublicStatusCode":5}],"eudraCt":{"isTransitioned":false}},"events":{"temporaryHaltList":[],"trialEvents":[{"mscId":25361,"mscName":"Italy","events":[{"notificationType":"START_OF_TRIAL","date":"2024-10-16"},{"notificationType":"START_OF_RECRUITMENT","date":"2024-10-16"},{"notificationType":"END_OF_RECRUITMENT","date":"2026-07-15"}]},{"mscId":25362,"mscName":"Belgium","events":[{"notificationType":"START_OF_TRIAL","date":"2024-11-26"},{"notificationType":"START_OF_RECRUITMENT","date":"2024-11-26"},{"notificationType":"END_OF_RECRUITMENT","date":"2026-07-15"}]},{"mscId":25363,"mscName":"Spain","events":[{"notificationType":"START_OF_TRIAL","date":"2024-10-15"},{"notificationType":"START_OF_RECRUITMENT","date":"2024-10-16"},{"notificationType":"END_OF_RECRUITMENT","date":"2026-07-15"}]},{"mscId":25364,"mscName":"France","events":[{"notificationType":"START_OF_TRIAL","date":"2024-10-09"},{"notificationType":"START_OF_RECRUITMENT","date":"2024-10-09"},{"notificationType":"END_OF_RECRUITMENT","date":"2026-07-15"}]},{"mscId":25365,"mscName":"Netherlands","events":[{"notificationType":"START_OF_TRIAL","date":"2025-02-18"},{"notificationType":"START_OF_RECRUITMENT","date":"2025-09-16"},{"notificationType":"END_OF_RECRUITMENT","date":"2026-07-15"}]},{"mscId":25366,"mscName":"Germany","events":[{"notificationType":"START_OF_TRIAL","date":"2025-03-18"},{"notificationType":"START_OF_RECRUITMENT","date":"2025-03-18"},{"notificationType":"END_OF_RECRUITMENT","date":"2026-07-15"}]},{"mscId":25367,"mscName":"Poland","events":[{"notificationType":"START_OF_TRIAL","date":"2024-12-17"},{"notificationType":"START_OF_RECRUITMENT","date":"2025-01-28"},{"notificationType":"END_OF_RECRUITMENT","date":"2026-07-15"}]}],"unexpectedEvents":[],"seriousBreaches":[],"urgentSafetyMeasures":[]},"results":{},"documents":[{"title":"D4_Patient facing documents_QLQ-C30_English","uuid":"e026b8fb-ea96-44a8-b288-6906086f4aa5","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient Diary Crizo","uuid":"4fde15db-f9d4-45b1-b09b-dcd50b38a231","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"4.0","systemVersion":"1"},{"title":"D4_Patient Diary Crizo_DE","uuid":"b6ba8cd4-4c93-41b0-b90e-eb3801146433","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"4.0","systemVersion":"1"},{"title":"D4_Patient Diary Crizo_ES","uuid":"73d297c4-b6ac-47fa-8184-b061e08cdcc6","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"4.0","systemVersion":"1"},{"title":"D4_Patient Diary Crizo_FR","uuid":"f2a2dcf9-30d5-4546-a613-47004cd4a285","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"4.0","systemVersion":"1"},{"title":"D4_Patient Diary Crizo_IT","uuid":"9b64080f-be5b-47c5-a366-85cace485037","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"4.0","systemVersion":"1"},{"title":"D4_Patient Diary Crizo_NL","uuid":"d9e16ece-c596-4f77-b28e-fdaef63f428c","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"4.0","systemVersion":"1"},{"title":"D4_Patient Diary Crizo_PL","uuid":"73b1f725-21a9-42fd-b769-f7f21c8d72cf","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"4.0","systemVersion":"1"},{"title":"D4_Patient Diary Darovasertib_DE-DE_Redacted","uuid":"50ee50e9-f55c-4751-be39-72200669ea36","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"4.0","systemVersion":"1"},{"title":"D4_Patient Diary Darovasertib_ES-ES_Redacted","uuid":"578e54c6-7501-4b72-8203-84c21b051dec","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"4.0","systemVersion":"1"},{"title":"D4_Patient Diary Darovasertib_FR-FR_Redacted","uuid":"4412836e-3e6c-4886-9724-5e2a3e52b7a4","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"4.0","systemVersion":"1"},{"title":"D4_Patient Diary Darovasertib_IT-IT_Redacted","uuid":"e9eb9db6-a702-4d5f-82ac-fe3211248ba7","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"4.0","systemVersion":"1"},{"title":"D4_Patient Diary Darovasertib_NL-NL_Redacted","uuid":"79afd3af-71da-44ff-97a0-d351b52af9e1","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":18,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"4.0","systemVersion":"1"},{"title":"D4_Patient Diary Darovasertib_PL-PL_Redacted","uuid":"9174b275-a890-4a5e-850e-1053843c1d52","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"4.0","systemVersion":"1"},{"title":"D4_Patient facing documents_EQ-5D-5L_Paper Interviewer_EN","uuid":"aeef7456-bbfa-4c92-8c6b-28adb8a885b1","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1.7","systemVersion":"1"},{"title":"D4_Patient facing documents_EQ-5D-5L_Paper Interviewer_BEL-DE","uuid":"358fecc6-add4-40c1-a234-5103e420bfae","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":28,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1.2","systemVersion":"1"},{"title":"D4_Patient facing documents_EQ-5D-5L_Paper Interviewer_BEL-Dutch","uuid":"fadf8289-163a-44bf-9929-1284d08028c9","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":36,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1.3","systemVersion":"1"},{"title":"D4_Patient facing documents_EQ-5D-5L_Paper Interviewer_BEL-FR","uuid":"07a0048f-52bb-4662-a272-fe0075f0e788","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":33,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1.2","systemVersion":"1"},{"title":"D4_Patient facing documents_EQ-5D-5L_Paper Interviewer_DEU-DE","uuid":"94a4a879-2ec0-4421-8a62-7afe46ffb057","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":29,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1.2","systemVersion":"1"},{"title":"D4_Patient facing documents_EQ-5D-5L_Paper Interviewer_ESP","uuid":"75d4be90-1039-44e3-93be-410e61767c00","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1.0","systemVersion":"1"},{"title":"D4_Patient facing documents_EQ-5D-5L_Paper Interviewer_FRA-FR","uuid":"e0728ca3-8ad6-433d-9eb7-08917acccfd1","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1.2","systemVersion":"1"},{"title":"D4_Patient facing documents_EQ-5D-5L_Paper Interviewer_ITA","uuid":"823a34e8-f726-485e-a85f-679e031647d4","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1.2","systemVersion":"1"},{"title":"D4_Patient facing documents_EQ-5D-5L_Paper Interviewer_NLD","uuid":"9d4c0c35-cdd7-4434-b37b-e96109c50e57","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":37,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1.1","systemVersion":"1"},{"title":"D4_Patient facing documents_EQ-5D-5L_Paper Interviewer_POL","uuid":"25e13ba6-0147-4b82-b81e-57f0588c452e","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1.0","systemVersion":"1"},{"title":"D4_Patient facing documents_EQ-5D-5L_Paper Self-Complete_BEL-DE","uuid":"89727f2a-fa1a-4658-8d1f-774684ca70d3","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1.1","systemVersion":"1"},{"title":"D4_Patient facing documents_EQ-5D-5L_Paper Self-Complete_BEL-DE","uuid":"ca24623b-cda8-49f0-bb9c-3c9ed9846227","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":28,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1.1","systemVersion":"1"},{"title":"D4_Patient facing documents_EQ-5D-5L_Paper Self-Complete_BEL-Dutch","uuid":"9226119e-26b9-4962-89b0-d2baad69caa7","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":36,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1.2","systemVersion":"1"},{"title":"D4_Patient facing documents_EQ-5D-5L_Paper Self-Complete_BEL-FR","uuid":"e8000421-fe99-4324-ba4e-0d9108030b5e","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":33,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing documents_EQ-5D-5L_Paper Self-Complete_DEU-DE","uuid":"0c6ee97a-4dd9-4f9c-82cd-d85ac0ff1f47","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":29,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing documents_EQ-5D-5L_Paper Self-Complete_EN","uuid":"d1eb9cc8-7ed7-49b0-8b43-c6f0fa1e5052","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1.2","systemVersion":"1"},{"title":"D4_Patient facing documents_EQ-5D-5L_Paper Self-Complete_ESP","uuid":"48e1fb80-a8ae-4611-960f-bc44f35717ab","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing documents_EQ-5D-5L_Paper Self-Complete_FRA-FR","uuid":"ce75dbcc-7d5f-4309-83e6-21ed76336a51","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1.2","systemVersion":"1"},{"title":"D4_Patient facing documents_EQ-5D-5L_Paper Self-Complete_ITA","uuid":"29727b34-331e-4e10-9d3a-903e5256bb60","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1.1","systemVersion":"1"},{"title":"D4_Patient facing documents_EQ-5D-5L_Paper Self-Complete_NLD","uuid":"029e01ec-9df1-477c-b58e-72aaeb0e8fce","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":37,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1.1","systemVersion":"1"},{"title":"D4_Patient facing documents_EQ-5D-5L_Paper Self-Complete_POL","uuid":"e4f48b35-d61d-4d8f-9f76-8b025a109302","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient Diary Darovasertib_Redacted","uuid":"397d85a1-b1f5-45aa-ac6c-e955f00c8fd3","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1","systemVersion":"1"},{"title":"D1_Protocol_Clarification_Letter_2023-506686-66_04Jun2025_Redacted","uuid":"e8e59a98-1a8c-4877-981d-a1dbe1871c62","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1","systemVersion":"1"},{"title":"D1_Protocol_2023-506686-66-01_Summary of changes","uuid":"6e54acc7-d45f-48c6-84b1-d6a17303e5ff","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"3.0","systemVersion":"4"},{"title":"D1_Protocol_2023-506686-66-01_Redacted","uuid":"31c94b22-8ea2-4575-9d8f-616b24203881","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"3.0","systemVersion":"4"},{"title":"D4_EORTC_QLQ-C30_collection_overview_for publication","uuid":"a7c0a37f-77e3-4363-8c82-c4438aeb4bb0","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"3","systemVersion":"1"},{"title":"D4_EQ-5D-5L_collection_overview_ for publication","uuid":"65507df8-7438-4a30-8286-ae48403a8ce3","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"1.2","systemVersion":"1"},{"title":"D1_Protocol_2023-506686-66-01_v4.0-Redacted","uuid":"fad5c024-4f38-431b-9963-78921ee5ec9b","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"4.0","systemVersion":"1"},{"title":"D1_Protocol Synopsis_2023-506686-66-01_EN_Redacted","uuid":"4b8c3fe2-6ceb-4e47-9e21-55f1b4c1c360","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"3.0","systemVersion":"4"},{"title":"D1_Protocol Synopsis_2023-506686-66-01_DE-BE_Redacted","uuid":"987fc372-16c9-4266-baa1-d5934607a3ac","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":28,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"4.0","systemVersion":"5"},{"title":"D1_Protocol Synopsis_2023-506686-66-01_FR-BE_Redacted","uuid":"f0228130-bf9a-49ef-af80-2e7977d39a73","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":33,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"4.0","systemVersion":"5"},{"title":"D1_Protocol Synopsis_2023-506686-66-01_DE-DE_Redacted","uuid":"37104edc-191d-4d17-9448-496a1dbae6d1","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":29,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"4.0","systemVersion":"5"},{"title":"D1_Protocol Synopsis_2023-506686-66-01_ES-ES_Redacted","uuid":"cb26ad2c-98f2-403f-a647-a80cf51912e5","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"4.0","systemVersion":"5"},{"title":"D1_Protocol Synopsis_2023-506686-66-01_FR-FR_Redacted","uuid":"d0696e60-5682-403d-9a9b-154e0facc069","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"4.0","systemVersion":"5"},{"title":"D1_Protocol Synopsis_2023-506686-66-01_IT-IT_Redacted","uuid":"153ed5f4-1e6b-41e7-9926-a2025b55eb19","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"4.0","systemVersion":"5"},{"title":"D1_Protocol Synopsis_2023-506686-66-01_NL-NL_Redacted","uuid":"1a021d0e-bb88-4cf5-8471-499d12f36919","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":37,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"4.0","systemVersion":"5"},{"title":"D1_Protocol Synopsis_2023-506686-66-01_PL-PL_Redacted","uuid":"74e3eef5-85e4-4f46-8ba6-fe5b6d04da9c","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"4.0","systemVersion":"5"},{"title":"D1_Protocol Synopsis_2023-506686-66-01_NL-BE_Redacted","uuid":"cf210ecc-4b1c-4864-8305-65fcb66b1739","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":36,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"4.0","systemVersion":"5"},{"title":"D1_Protocol Synopsis_Layman_2023-506686-66-01_EN","uuid":"530a6da6-7cc9-40f5-b6d4-0efa81bc4632","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"5.0","systemVersion":"4"},{"title":"D1_Protocol Synopsis_Layman_2023-506686-66-01_DE-BE","uuid":"71a7dc1f-fa07-4f77-98aa-7d2ef9071ec6","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":28,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"6.0","systemVersion":"5"},{"title":"D1_Protocol Synopsis_Layman_2023-506686-66-01_DE-DE","uuid":"027f506c-0243-4e87-acad-ec28c558e197","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":29,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"6.0","systemVersion":"5"},{"title":"D1_Protocol Synopsis_Layman_2023-506686-66-01_ES-ES","uuid":"b596d226-1c0e-4f91-b08f-6690656dd2ca","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"6.0","systemVersion":"5"},{"title":"D1_Protocol Synopsis_Layman_2023-506686-66-01_FR-BE","uuid":"0dad619d-5fd3-4223-a45a-4e36d58146f2","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":33,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"6.0","systemVersion":"5"},{"title":"D1_Protocol Synopsis_Layman_2023-506686-66-01_FR-FR","uuid":"73fc39df-58f2-4ad0-9349-37a055125d60","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"6.0","systemVersion":"5"},{"title":"D1_Protocol Synopsis_Layman_2023-506686-66-01_IT-IT","uuid":"ec13b155-a6c3-4e60-94f9-f87795783e7f","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"6.0","systemVersion":"5"},{"title":"D1_Protocol Synopsis_Layman_2023-506686-66-01_NL-BE","uuid":"afd2e656-b117-4111-9432-f8c4cc4ff193","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":36,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"6.0","systemVersion":"5"},{"title":"D1_Protocol Synopsis_Layman_2023-506686-66-01_NL-NL","uuid":"592f66d8-4b3d-49d1-96e4-1cb1cb874411","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":37,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"6.0","systemVersion":"5"},{"title":"D1_Protocol Synopsis_Layman_2023-506686-66-01_PL-PL","uuid":"8982c4cc-c982-4162-be4b-20c4950fba86","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"6.0","systemVersion":"5"},{"title":"D1_Protocol Synopsis_2023-506686-66-01_v4.0-Redacted","uuid":"2215f4d3-e57a-4760-909b-14a0b70785de","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"4.0","systemVersion":"1"},{"title":"D1_Protocol Synopsis_Layman_2023-506686-66-01_EN_v6.0","uuid":"785b524b-c1e7-4ecb-98c1-780a91bf3f4b","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"6.0","systemVersion":"1"},{"title":"D1_Protocol Synopsis_Layman_2023-506686-66-01_EN_v5.0 vs v6.0_Redline","uuid":"eb910b9f-f705-4079-bf99-ce903c6feab7","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":148302,"manualVersion":"6.0","systemVersion":"1"},{"title":"G2_ SmPC_opdivo","uuid":"7fb78087-4c44-4484-97c3-0c3b80127f08","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":458762,"manualVersion":"N/A","systemVersion":"1"},{"title":"G2_ SmPC_opdivo","uuid":"a4791b00-5cba-4341-8540-092712bd45ad","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":458759,"manualVersion":"N/A","systemVersion":"2"},{"title":"G2_ SmPC_xalkori","uuid":"65173a79-1465-4904-b59d-e18a3d01d8aa","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":458761,"manualVersion":"N/A","systemVersion":"1"},{"title":"G2_ SmPC_Dacarbazine_medac","uuid":"604a77c1-11d7-4350-937a-96db3dba2827","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":458758,"manualVersion":"N/A","systemVersion":"2"},{"title":"G2_ SmPC_yervoy","uuid":"57385cc8-af02-4ffb-8391-723898f12bf3","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":458763,"manualVersion":"N/A","systemVersion":"2"},{"title":"G2_ SmPC_keytruda","uuid":"74a2943e-2d8e-45a3-94d3-d7e3c0d428d6","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":458760,"manualVersion":"N/A","systemVersion":"2"},{"title":"K1_Recruitment arrangements","uuid":"c268d8f0-add1-4028-9e76-d301c62dee1e","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":332774,"manualVersion":"2.0","systemVersion":"1"},{"title":"L3_SIS and ICF_Patient Travel Services","uuid":"df32b008-a0ed-40e3-b82a-253ec5b900d7","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":332774,"manualVersion":"1","systemVersion":"2"},{"title":"L4_Other subject information material_Patient Information Brochure","uuid":"527c8542-cec2-423b-aaec-8d51e7d0d468","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":332774,"manualVersion":"1.0","systemVersion":"1"},{"title":"L2_ SIS and ICF Pregnant Partner_Redacted","uuid":"705c7b8e-183e-4c74-b7a6-f1717644bf24","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":332774,"manualVersion":"1","systemVersion":"2"},{"title":"L5_Other subject information material_Patient Diary Darovasertib","uuid":"39617464-76a8-4ff9-b0b5-6c6838f9ec26","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":332774,"manualVersion":"3","systemVersion":"1"},{"title":"L6_Other subject information material_Patient Diary Crizo","uuid":"3d7d3b5f-5480-41cd-be36-e47a11fee0cb","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":332774,"manualVersion":"4","systemVersion":"1"},{"title":"L1_SIS and ICF_Adult Main ICF _FR_TC_Redacted","uuid":"0349bf61-828f-49a0-bd0a-0e31ccf33dff","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":332774,"manualVersion":"10","systemVersion":"3"},{"title":"L1_SIS and ICF_Adult Main ICF_FR_Clean_Redacted","uuid":"3ea73b31-3d76-479b-b14e-32f1fe31d11a","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":332774,"manualVersion":"10","systemVersion":"3"},{"title":"L2_Website Content Global_ENG","uuid":"72b13070-6b9e-4082-a9d3-65ae1477cb22","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":332774,"manualVersion":"1","systemVersion":"1"},{"title":"L2_Global Study Website_FRN","uuid":"1e350b31-b932-4fc4-a611-be18f4a5c2d6","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":332774,"manualVersion":"1","systemVersion":"1"},{"title":"K4_Recruitment material_GP Letter","uuid":"dd7b05cf-a6b4-4792-a200-fc66b5c46817","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":18,"fileType":"PDF","associatedEntityId":349022,"manualVersion":"2.0","systemVersion":"1"},{"title":"K1_Recruitment arrangements","uuid":"b3879fc7-fbda-47e1-aa08-bf1690cf6133","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":349022,"manualVersion":"3.0","systemVersion":"1"},{"title":"K2_Website Content Global_ENG","uuid":"b2a6db03-16a0-4a2c-95ab-925cc559a20d","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":349022,"manualVersion":"1","systemVersion":"1"},{"title":"K2_Global Study Website_NDL_Clean","uuid":"51a64fdc-e2a3-4f17-a9d0-55e9c1bb05da","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":37,"fileType":"PDF","associatedEntityId":349022,"manualVersion":"2","systemVersion":"1"},{"title":"K2_Global Study Website_NDL_TC","uuid":"da4102dc-dd6b-46b5-be0a-da8659645cbc","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":37,"fileType":"PDF","associatedEntityId":349022,"manualVersion":"2","systemVersion":"1"},{"title":"L3_SIS and ICF_Patient Travel Services","uuid":"2ca8081b-c6e1-4f59-a4ce-15b742bfbb50","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":18,"fileType":"PDF","associatedEntityId":349022,"manualVersion":"2.0","systemVersion":"1"},{"title":"L2_SIS and ICF_Pregnant Partner ICF","uuid":"b8e7d67b-33c9-4676-8dc7-11c2f8782b8d","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":18,"fileType":"PDF","associatedEntityId":349022,"manualVersion":"3.0","systemVersion":"1"},{"title":"L1-SIS and Adult Main ICF_NDL_Clean_Redacted","uuid":"b328c3ed-9671-43b5-8e28-8e5c40a32553","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":18,"fileType":"PDF","associatedEntityId":349022,"manualVersion":"11","systemVersion":"4"},{"title":"K1_Recruitment arrangements","uuid":"b81ab0a1-d51d-4424-80c9-22bad4c4ec62","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":332772,"manualVersion":"NA","systemVersion":"1"},{"title":"K2_Physician Referral letter","uuid":"2cf58263-4aee-481b-ac9c-294bd32b0425","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":332772,"manualVersion":"1","systemVersion":"1"},{"title":"L3_SIS and ICF_Patient Travel Services_FRA","uuid":"2626a19b-60d5-4d63-a562-436abfd9225c","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":33,"fileType":"PDF","associatedEntityId":332772,"manualVersion":"1.0","systemVersion":"1"},{"title":"L3_SIS and ICF_Patient Travel Services_GER","uuid":"12757322-b38a-43a1-a8e8-2e54bb6aeff9","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":28,"fileType":"PDF","associatedEntityId":332772,"manualVersion":"1.0","systemVersion":"1"},{"title":"L3_SIS and ICF_Patient Travel Services_NLD","uuid":"28b7b841-b8b2-4f14-b199-c7a4bcacac57","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":36,"fileType":"PDF","associatedEntityId":332772,"manualVersion":"1.0","systemVersion":"1"},{"title":"L4_Other subject information material_Patient Information Brochure_FRA","uuid":"83d11e7e-f137-4d3a-bbbd-5fbdb8e4f0dd","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":33,"fileType":"PDF","associatedEntityId":332772,"manualVersion":"1.0","systemVersion":"1"},{"title":"L4_Other subject information material_Patient Information Brochure_GER","uuid":"4985a073-9232-48c2-9539-a0722239e69f","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":28,"fileType":"PDF","associatedEntityId":332772,"manualVersion":"1.0","systemVersion":"1"},{"title":"L4_Other subject information material_Patient Information Brochure_NLD","uuid":"fe3dedcb-5f93-4fbb-bd84-92728ce86948","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":36,"fileType":"PDF","associatedEntityId":332772,"manualVersion":"1.0","systemVersion":"1"},{"title":"L2_ SIS and ICF_Pregnant Partner ICF_FRA","uuid":"ab071764-cd90-47ff-9974-a854a4266fa3","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":33,"fileType":"PDF","associatedEntityId":332772,"manualVersion":"2.0","systemVersion":"1"},{"title":"L2_ SIS and ICF_Pregnant Partner ICF_NLD","uuid":"8c364514-d822-4dbf-ba68-ad8eae88258a","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":36,"fileType":"PDF","associatedEntityId":332772,"manualVersion":"2.0","systemVersion":"1"},{"title":"L2_ SIS and ICF_Pregnant Partner ICF_GER","uuid":"0e35e6cc-4e16-4561-9dda-07155d4739bd","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":28,"fileType":"PDF","associatedEntityId":332772,"manualVersion":"2.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Adult Main ICF_DE-BE_Clean_Redacted","uuid":"5d979075-8315-4a96-a593-465707ebcd60","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":28,"fileType":"PDF","associatedEntityId":332772,"manualVersion":"8","systemVersion":"3"},{"title":"L1_SIS and ICF_Adult Main ICF_FRA_BE_Clean_Redacted","uuid":"6502da33-e4d8-4840-bcfe-97156e393232","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":33,"fileType":"PDF","associatedEntityId":332772,"manualVersion":"8","systemVersion":"3"},{"title":"L1_SIS and ICF_Adult Main ICF_NLD_BE_Clean_Redacted","uuid":"1e0cbd64-07ec-4ddf-8058-fe813d6e4ee8","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":36,"fileType":"PDF","associatedEntityId":332772,"manualVersion":"8","systemVersion":"3"},{"title":"L2_Global Study Website_FRN-BEL","uuid":"d1971224-652b-4b41-ac05-b9d49e90deeb","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":33,"fileType":"PDF","associatedEntityId":332772,"manualVersion":"1","systemVersion":"1"},{"title":"L2_Global Study Website_GER-BEL","uuid":"02646b57-854e-4c48-bf59-a8b096d033d7","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":28,"fileType":"PDF","associatedEntityId":332772,"manualVersion":"1","systemVersion":"1"},{"title":"L2_Global Study Website_NDL-BEL","uuid":"6aa4d8ba-24f5-4e55-b0f5-911399f2cd8b","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":36,"fileType":"PDF","associatedEntityId":332772,"manualVersion":"1","systemVersion":"1"},{"title":"L2_Website Content Global_ENG","uuid":"b77ba8c3-4583-48b0-80e0-f792c157ae65","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":332772,"manualVersion":"1","systemVersion":"1"},{"title":"L1_SIS and ICF_Adult Main ICF_DE-BE_tracked","uuid":"46747643-09f1-4b9c-9318-ec894d9c8bbb","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":28,"fileType":"PDF","associatedEntityId":332772,"manualVersion":"8","systemVersion":"2"},{"title":"L1_SIS and ICF_Adult Main ICF_FRA_BE_tracked","uuid":"0c7abc07-ca15-4a1d-84a8-4eedab5dbe49","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":33,"fileType":"PDF","associatedEntityId":332772,"manualVersion":"8","systemVersion":"2"},{"title":"L1_SIS and ICF_Adult Main ICF_NLD_BE_tracked","uuid":"05c6e751-0b65-41fd-bba8-073bb795e877","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":36,"fileType":"PDF","associatedEntityId":332772,"manualVersion":"8","systemVersion":"2"},{"title":"K1_ Recruitment arrangements","uuid":"dede9fd6-23f5-412f-8795-b8b44cccdf06","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":332776,"manualVersion":"NA","systemVersion":"1"},{"title":"K2_ Physician Referral letter","uuid":"435c05b6-e539-4d74-be2f-f24c2929904f","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":332776,"manualVersion":"1","systemVersion":"1"},{"title":"L4_Other subject information material_Patient information brochure","uuid":"9a7f7447-6d45-4fea-af1e-b58e4a5af7c5","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":332776,"manualVersion":"2.0","systemVersion":"1"},{"title":"L2_SIS and ICF_Pregnant Partner_Clean_Redacted","uuid":"7cc6ad04-f3ca-46f8-99e4-68c860eb309a","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":332776,"manualVersion":"4","systemVersion":"1"},{"title":"L2_SIS and ICF_Pregnant Partner_TC_Redacted","uuid":"15ef7f2f-981e-43f1-9186-e92920c98c6e","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":332776,"manualVersion":"4","systemVersion":"2"},{"title":"L3_SIS and ICF Patient Travel Services_Clean","uuid":"b5e40364-54c8-48f4-9fcc-cf14d5ccd0c5","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":332776,"manualVersion":"3","systemVersion":"1"},{"title":"L3_SIS and ICF Patient Travel Services_TC","uuid":"208465a6-b548-4221-8ad0-afde10d8ab59","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":332776,"manualVersion":"3","systemVersion":"1"},{"title":"L1_SIS and ICF_Adult Main ICF_GER_Clean_Redacted","uuid":"442bb0c0-ecf1-4ec7-a6bb-64631afa6d5f","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":332776,"manualVersion":"10","systemVersion":"3"},{"title":"L1_SIS and ICF_Adult Main ICF_GER_TC_Redacted","uuid":"dadcbedc-fd33-4b69-bf6f-6ce46af8d1bd","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":332776,"manualVersion":"10","systemVersion":"3"},{"title":"L2_Global Study Website_GER","uuid":"8f7f5348-9f6a-40e7-9ce1-e087a8d54734","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":29,"fileType":"PDF","associatedEntityId":332776,"manualVersion":"1","systemVersion":"1"},{"title":"L2_Website Content Global_ENG","uuid":"e8e9a94e-d513-42f6-935b-4beb32bb14a5","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":332776,"manualVersion":"1","systemVersion":"1"},{"title":"K1_Recruitment arrangements","uuid":"93f72c2b-8e68-42c5-b044-f8fac8f3f459","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":332771,"manualVersion":"NA","systemVersion":"1"},{"title":"K2_Recruitment Material_Physician Referral letter","uuid":"58a002ab-5eff-4edd-a883-17fccd5791e2","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":332771,"manualVersion":"1.0","systemVersion":"1"},{"title":"L3_SIS and ICF_Patient Travel Service","uuid":"3c33d03d-2c2c-4458-877e-c14c05fd4571","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":332771,"manualVersion":"1.0","systemVersion":"1"},{"title":"L4_Other subject information material_Patient Information Brochure_ITA","uuid":"3462c0f5-c7a8-4ec5-99a5-ff8d952b0ca4","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":332771,"manualVersion":"1.0","systemVersion":"1"},{"title":"L2_SIS and ICF Pregnant Partner_ITA","uuid":"26b1a90c-9a1b-4a52-95dc-bc4b28447194","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":332771,"manualVersion":"2.0","systemVersion":"1"},{"title":"L2_Global Study Website_ITA","uuid":"1b8a41b8-f9bc-48a4-8582-10932eba5d5f","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":332771,"manualVersion":"1","systemVersion":"1"},{"title":"L2_Website Content Global_ENG","uuid":"d203ca0c-626b-4abe-965b-50176e086db0","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":332771,"manualVersion":"1","systemVersion":"1"},{"title":"L1_SIS and ICF Main Adult_ITA_Clean","uuid":"b634a6e9-5e4d-415c-ab93-3789f7647e9a","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":332771,"manualVersion":"10","systemVersion":"3"},{"title":"L1_SIS and ICF Main Adult_ITA_TC","uuid":"31982c7a-9a5d-4e87-92b2-21e119687f67","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":332771,"manualVersion":"10","systemVersion":"3"},{"title":"L1_SIS and Main Adult_ENG_TC","uuid":"12ae6f05-292f-48f2-9da1-39ad87e3a4b5","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":332771,"manualVersion":"10","systemVersion":"2"},{"title":"L1_SIS and Main Adult_ENG_Clean","uuid":"57e85b94-7fa2-4dfd-8b39-f857646b33da","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":332771,"manualVersion":"10","systemVersion":"2"},{"title":"L2_Other Subject Material  EC Acknowledgment of English ICF for Italy","uuid":"dc7b3a88-5569-410f-af54-e75e32cb62df","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":332771,"manualVersion":"1","systemVersion":"1"},{"title":"K1_ Recruitment arrangements","uuid":"b72b2bd0-021c-4ee4-a625-df0883e3c3e8","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":332773,"manualVersion":"NA","systemVersion":"1"},{"title":"K2_Recruitment Material_Physician Referral letter","uuid":"06c5fed1-96b5-40e1-8189-4f6169ccfc83","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":332773,"manualVersion":"1.0","systemVersion":"1"},{"title":"L4_Other subject information material_Patient Information Brochure","uuid":"204d7410-2561-44fb-9996-b388fe535e99","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":332773,"manualVersion":"1.0","systemVersion":"1"},{"title":"L2_ SIS and ICF_Pregnant Partner ICF","uuid":"c00caad7-256d-4d21-a651-50a8ffe0e46b","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":332773,"manualVersion":"1.0","systemVersion":"1"},{"title":"L3_SIS and ICF_Patient Travel Services","uuid":"3067277f-7e1a-4671-b406-9b5f417d6226","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":332773,"manualVersion":"2.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Adult Main ICF_ESP_Clean_Redacted","uuid":"6469031f-3934-46e9-a6f1-644bbe95448d","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":332773,"manualVersion":"9","systemVersion":"3"},{"title":"L1_SIS and ICF_Adult Main ICF_ESP_TC_Redacted","uuid":"c6f78f70-6ff0-42c9-ad28-e7fc6b54f828","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":332773,"manualVersion":"9","systemVersion":"3"},{"title":"L2_Global Study Website_ESP","uuid":"aa708933-8ff5-4777-a817-142fc94fadac","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":332773,"manualVersion":"1","systemVersion":"1"},{"title":"L2_Website Content Global_ENG","uuid":"c35f0bd0-5389-41f6-bff4-5f7fb42e3526","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":332773,"manualVersion":"1","systemVersion":"1"},{"title":"K2_Recruitment material_Physician Referral letter_PL","uuid":"e2c3c57e-54fa-412d-9afc-15c76a2158e8","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":332777,"manualVersion":"1.0","systemVersion":"1"},{"title":"K1_ Recruitment arrangements_ Recruitment and Informed consent procedure_PL_Clean","uuid":"a56def2a-5162-4694-b4f2-7c6f7491fdae","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":332777,"manualVersion":"3","systemVersion":"1"},{"title":"K1_ Recruitment arrangements_ Recruitment and Informed consent procedure_PL_TC","uuid":"afcc5880-2c13-4d1c-af5b-05b37d656817","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":332777,"manualVersion":"3","systemVersion":"1"},{"title":"L3_SIS and ICF_Patient Travel Services_Data Privacy Notice and Confirmation Form","uuid":"d23892aa-ff25-455d-86a1-545e4c84f35e","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":332777,"manualVersion":"2.0","systemVersion":"1"},{"title":"L4_Other subject information material_Patient Information Brochure","uuid":"15479e14-0b7b-4e6d-a796-b4bb9c82fb3a","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":332777,"manualVersion":"1.0","systemVersion":"1"},{"title":"L2_SIS and ICF Pregnant Partner_PL_Clean","uuid":"5cfd5388-e891-4270-ada6-95e8b8019d14","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":332777,"manualVersion":"3","systemVersion":"1"},{"title":"L2_SIS and ICF Pregnant Partner_PL_TC","uuid":"b0828b89-84d6-4549-8878-64547f0b4db5","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":332777,"manualVersion":"3","systemVersion":"1"},{"title":"L1_SIS and Main ICF_PL_Clean_Redacted","uuid":"6778fc20-9d63-40bf-be0c-277a03ab730d","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":332777,"manualVersion":"11","systemVersion":"4"},{"title":"L1_SIS and Main ICF_PL_TC_Redacted","uuid":"1d2a7c0e-72bb-4102-821e-68376ea4ced6","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":332777,"manualVersion":"11","systemVersion":"4"},{"title":"L2_Global Study Website_POL","uuid":"fd99e4c1-a415-46e6-a28e-d6632b9b1709","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":332777,"manualVersion":"1","systemVersion":"1"},{"title":"L2_Website Content Global_ENG","uuid":"a6c3f36c-61f1-44e8-9b66-583123ee039b","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":332777,"manualVersion":"1","systemVersion":"1"},{"title":"L1_SIS and Main ICF_PL_Eng_TC_Redacted","uuid":"2447e581-6660-4ea3-9b35-8381b9353f48","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":332777,"manualVersion":"10","systemVersion":"2"},{"title":"L1_SIS and Main ICF_PL_Eng_Clean_Redacted","uuid":"63430aab-da12-46f0-bdf1-c53138957046","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":332777,"manualVersion":"10","systemVersion":"2"}],"trialRegion":"Both","trialRegionCode":3,"correctiveMeasures":[]}